var title_f40_55_41840="Herpes zoster OLT";
var content_f40_55_41840=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Herpes zoster",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Herpes zoster infection of the buttock and lower back in a patient who has undergone liver transplantation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jean-Fran&ccedil;ois Dufour, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_55_41840=[""].join("\n");
var outline_f40_55_41840=null;
var title_f40_55_41841="Cherry angioma2";
var content_f40_55_41841=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cherry angioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 365px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_55_41841=[""].join("\n");
var outline_f40_55_41841=null;
var title_f40_55_41842="MRI myocardial viability";
var content_f40_55_41842=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Assessment of myocardial viability by CMR",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 431px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Short-axis CMR images obtained after contrast administration are compared with corresponding short-axis 201-thallium (Tl) tomograms at rest and after redistribution (REDIST). Persistent enhancement (yellow arrow) develops in the inferolateral wall, corresponding to severe irreversible 201TI defect in same region (white arrow in REDIST image). The inferior wall also demonstrates substantial perfusion defect at rest but shows mild redistribution, indicating myocardial viability; CMR images in this area show lesser degree of enhancement than in area of irreversible injury.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     With permission from: Ramani K, Judd RM, Holly TA, et al. Circulation 1998; 98:2687.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_55_41842=[""].join("\n");
var outline_f40_55_41842=null;
var title_f40_55_41843="Multimodal MRI and PET periictal imaging";
var content_f40_55_41843=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F62082&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F62082&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Multimodal MRI and PET periictal imaging in a patient with multifocal seizures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 221px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Upper panel) 18FDG-PET images from patient described in Figure 2 obtained on day 25 showing multiple focal areas of hypermetabolism. Middle panel) FLAIR images obtained on day 28. Lower panel) Co-registration showing co-localization of areas of hypermetabolism and areas with FLAIR abnormalities. EEG recording (not shown) demonstrated a similar localization of ictal activity involving right frontal pole and left central region.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Cole, AJ. Status epilepticus and periictal imaging. Epilepsia 2004; 45 Suppl 4:72. Copyright &copy;2004 Blackwell Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_55_41843=[""].join("\n");
var outline_f40_55_41843=null;
var title_f40_55_41844="Bendamustine: Patient drug information";
var content_f40_55_41844=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Bendamustine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/20/32071?source=see_link\">",
"     see \"Bendamustine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5957167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Treanda&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F15065726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Treanda&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F15888139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700794",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause tissue damage if the drug leaks from the vein. Tell your nurse if you have any redness, burning, pain, swelling, or leaking of fluid where the drug is going into your body.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691928",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat leukemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691947",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat lymphoma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691968",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat multiple myeloma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691948",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat macroglobulinemia.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701597",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to bendamustine, mannitol, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697735",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug and for 3 months after getting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698085",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs. These include headache, weakness, fever, shakes, aches, pains, and sweating. Mild pain drugs may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698243",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation or sores. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698306",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in the arms or legs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11984 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-869C284B9E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_55_41844=[""].join("\n");
var outline_f40_55_41844=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5957167\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15065726\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15888139\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017575\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017574\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017579\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017580\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017582\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017577\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017584\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?31/20/32071?source=related_link\">",
"      Bendamustine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_55_41845="Rectal biopsy in acute GVHD";
var content_f40_55_41845=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F61225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F61225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute graft-versus-host disease (GVHD) rectal biopsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 399px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rectal biopsy in a patient with acute graft-versus-host disease (GVHD) shows crypt cell necrosis with the accumulation of degenerative material in the dead crypts.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_55_41845=[""].join("\n");
var outline_f40_55_41845=null;
var title_f40_55_41846="Acanthosis nigricans in groin";
var content_f40_55_41846=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76234&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76234&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Acanthosis nigricans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hyperpigmented, velvety plaques are present in the groin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_55_41846=[""].join("\n");
var outline_f40_55_41846=null;
var title_f40_55_41847="Psychosocial treatment of alcohol abuse and dependence";
var content_f40_55_41847=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Psychosocial treatment of alcohol abuse and dependence",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/55/41847/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/55/41847/contributors\">",
"     Mark S Gold, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/55/41847/contributors\">",
"     Mark D Aronson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/55/41847/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/55/41847/contributors\">",
"     Richard Saitz, MD, MPH, FACP, FASAM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/55/41847/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/55/41847/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/55/41847/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 2, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2004 the World Health Organization estimated that two billion people consumed alcohol annually worldwide and 76.3 million had alcohol-use disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/1\">",
"     1",
"    </a>",
"    ]. Nearly two million deaths each year and 4 percent of the total global burden of disease have been attributed to alcohol abuse and dependence. A 2002 representative survey of 43,000 US adults found the lifetime prevalence of alcohol dependence to be 12.5 percent; only 24 percent of those reporting alcohol dependence were ever treated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The post-detoxification \"rehabilitation phase\" of treatment for substance dependence is comprised of psychosocial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medication treatments. Short-term goals include: preventing alcohol withdrawal; encouraging abstinence; promoting attendance at Alcoholics Anonymous meetings or other counseling programs; and involving family, community, and employment resources, including Employee Assistance Programs. Early intervention, before an alcoholic has reached \"the bottom\" and suffers from legal or medical problems, is important. Long-term goals include restoration of self-esteem, resolution of alcohol-related social problems, improvement in physical health issues, and long-term abstinence from alcohol use.",
"   </p>",
"   <p>",
"    Psychosocial treatments can reduce alcohol intake and increase abstinence, either alone or in conjunction with pharmacologic treatment. In primary care, physicians can provide structured advice and support in brief interventions that have been shown to be efficacious [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. In mental health and substance-use specialty care, clinicians provide psychosocial interventions such as motivational interviewing and cognitive behavioral therapy, which also demonstrate efficacy in randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic addresses psychosocial treatment for alcohol abuse and dependence. Screening and brief intervention, pharmacotherapy, and withdrawal management for unhealthy alcohol use is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19209?source=see_link\">",
"     \"Pharmacotherapy for alcohol abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/61/20441?source=see_link\">",
"     \"Management of moderate and severe alcohol withdrawal syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42265?source=see_link\">",
"     \"Brief intervention for unhealthy alcohol and other drug use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25993?source=see_link\">",
"     \"Screening for unhealthy use of alcohol and other drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol is used by the majority safely and without apparent consequences. Therapeutic options for patients who drink excess alcohol depend upon the degree of abuse. The spectrum of alcohol use includes abstinence, low-risk use, high-risk use, problem drinking (alcohol-related consequences, but not meeting ICD-10 or DSM-IV criteria for dependence), alcohol abuse, and alcohol dependence, as reviewed by Saitz [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/8\">",
"     8",
"    </a>",
"    ]. Standard definitions for at-risk drinking and alcohol dependence are presented below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     At-risk drinking",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Institute on Alcohol Abuse and Alcoholism (NIAAA) defines \"at risk\" drinking (which suggests that the person is at risk for adverse consequences) as [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Greater than 14 drinks per week or four drinks per occasion for men",
"     </li>",
"     <li>",
"      Greater than seven drinks per week or three drinks per occasion for women",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A standard drink contains approximately 0.5 ounces of alcohol as defined by Department of Health and Human Services and the United States Department of Agriculture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/10\">",
"     10",
"    </a>",
"    ]. This corresponds to 12 fl oz of regular beer, 5 fl oz of wine, and 1.5 fl oz of 80-proof distilled spirit.",
"   </p>",
"   <p>",
"    Criteria for at-risk drinking may be modified by comorbidities, especially in the older population. Increased mortality risk has been demonstrated for older patients who are at-risk drinkers, as defined by the CARET (Comorbidity-Alcohol Risk Evaluation Tool) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/11\">",
"     11",
"    </a>",
"    ]. At risk drinking in patients with significant medical or psychiatric conditions, or who take medication for insomnia, seizures, allergies, indigestion, or pain is defined as two to three drinks per day on two or more days a week, or four or more drinks on any occasion. Patients with hepatitis or who have ulcer disease are considered at risk with any amount of alcohol intake.",
"   </p>",
"   <p>",
"    An important subset of at risk drinking, particularly in teenagers and young adults, is binge drinking. DSM-IV defines binge drinking as five or more standard drinks for men, and four for women, in one sitting in the past year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Total consumption is not the only factor associated with adverse consequences; binge or high intensity drinking, as an example, is linked to injuries, psychosocial problems, and negative consequences, especially in younger patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Alcohol dependence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol dependence is defined by the DSM-IV as a maladaptive pattern of use associated with three or more of the following (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25993?source=see_link\">",
"     \"Screening for unhealthy use of alcohol and other drugs\"",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tolerance",
"     </li>",
"     <li>",
"      Withdrawal",
"     </li>",
"     <li>",
"      Substance taken in larger quantity than intended",
"     </li>",
"     <li>",
"      Persistent desire to cut down or control use",
"     </li>",
"     <li>",
"      Time is spent obtaining, using, or recovering from substance",
"     </li>",
"     <li>",
"      Social, occupational, or recreational tasks are sacrificed",
"     </li>",
"     <li>",
"      Use continues despite physical and psychological problems",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT GOALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of treatment for alcohol abuse and dependence can be broadly seen as restoration of medical and social well-being by control of the alcohol problem. One consensus group has defined recovery as \"a voluntarily maintained lifestyle characterized by sobriety, personal health, and citizenship\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the addiction literature has traditionally advocated abstinence from alcohol as the goal of treatment, there is some evidence that once in recovery some patients may be able to resume normal or controlled drinking. This is an area of controversy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a classic study from the Rand Corporation, men with alcohol problems were followed for 18 months in 45 treatment centers funded nationally in the US [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/18\">",
"     18",
"    </a>",
"    ]. Non-problematic drinking (no symptoms of dependence, less than 3 ounces alcohol daily) was reported at 18 months in 22 percent of the treated men; for those with definite alcoholism at study intake, 16 percent achieved normal drinking, while 36 percent of those with fewer symptoms at intake were able to drink normally. A four-year follow-up found that 18 percent of the subjects continued moderate drinking with no problems of dependency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Advocates for harm reduction may acknowledge that abstinence is the best outcome, but that not every individual achieves this end, and that controlled drinking for some individuals is an achievable aim which reduces risk to patients. Proponents of this philosophy consider their strategy to be compassionate and pragmatic. This approach may be particularly appropriate for adolescents and young adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Moderate alcohol intake is associated with beneficial cardiovascular effects (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/33/31258?source=see_link\">",
"     \"Cardiovascular benefits and risks of moderate alcohol consumption\"",
"    </a>",
"    ). This may be cited by patients as a reason to attempt controlled drinking rather than abstinence. Controlled drinking may be a more appropriate goal for patients with at risk drinking behaviors, than for those with alcohol dependence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MOTIVATIONAL INTERVIEWING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Motivational interviewing (MI) is a counseling technique for eliciting behavior change by helping the patient explore and resolve ambivalence about change. It is patient-centered and non-confrontational, avoiding judgments about behaviors and exhortations to modify unhealthy lifestyle issues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/6\">",
"     6",
"    </a>",
"    ]. The provider aims to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Seek to understand the client's frame of reference",
"     </li>",
"     <li>",
"      Express acceptance and affirmation",
"     </li>",
"     <li>",
"      Elicit and reinforce the client's own self-motivational statements of problem recognition, concern, desire and intent to change, and ability to change",
"     </li>",
"     <li>",
"      Monitor the client's degree of readiness to change and ensure resistance is not generated by jumping ahead of the client",
"     </li>",
"     <li>",
"      Affirm the client's freedom of choice and self-regulation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Motivational enhancement therapy (MET) is a four-session, brief-contact intervention based on MI involving comprehensive assessment of drinking and related behaviors and feedback [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/21\">",
"     21",
"    </a>",
"    ]. Project MATCH demonstrated equivalent three year outcomes in a randomized trial of 1726 alcohol-abusers, comparing MET with cognitive behavioral therapy and 12 step facilitation therapy, both 12 weeks in duration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized trial of MI used at intake into community-based substance abuse programs found that the group exposed to motivational interviewing, compared to controls, had improved program retention (especially for those with alcohol abuse), although substance abuse outcomes at 84 days did not differ from controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     BRIEF INTERVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening and brief intervention are effective treatments for non-dependent, unhealthy (or at-risk) alcohol use in primary care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/24\">",
"     24",
"    </a>",
"    ]. Evidence on screening and brief intervention is either insufficient or mixed for other drug use in primary care and in other settings, including inpatient care and emergency departments. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25993?source=see_link\">",
"     \"Screening for unhealthy use of alcohol and other drugs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42265?source=see_link\">",
"     \"Brief intervention for unhealthy alcohol and other drug use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     COGNITIVE BEHAVIORAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive behavioral therapy (CBT) is a structured goal-directed form of psychotherapy in which patients learn how their thought processes contribute to their behavior. Increased cognitive awareness is combined with techniques to help patients develop new and adaptive ways of behaving, and alter their social environment, which in turn leads to change in thoughts and emotions.",
"   </p>",
"   <p>",
"    A meta-analysis of 53 trials found CBT to have a modest positive effect on outcomes for alcohol and other drug dependence. Comparable results were seen across most categories of illicit substances, including alcohol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/7\">",
"     7",
"    </a>",
"    ]. Studies have generally not found the combination of CBT and medications for alcohol dependence to improve outcomes more than either intervention individually [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19209?source=see_link\">",
"     \"Pharmacotherapy for alcohol abuse and dependence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     HOSPITALIZATION AND REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brief intervention is not useful for patients suffering from alcohol dependence. Once a diagnosis of dependence has been presented and the patient is willing to stop drinking, the physician must consider the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Options for detoxification: inpatient, residential, day treatment, or outpatient (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/61/20441?source=see_link\">",
"       \"Management of moderate and severe alcohol withdrawal syndromes\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/16/4361?source=see_link\">",
"       \"Ambulatory alcohol detoxification\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Evaluation for comorbid psychiatric disorder",
"     </li>",
"     <li>",
"      Referral to Alcoholics Anonymous or other alcohol programs",
"     </li>",
"     <li>",
"      Pharmacotherapy to help with withdrawal and prevent relapse (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19209?source=see_link\">",
"       \"Pharmacotherapy for alcohol abuse and dependence\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Inpatient versus outpatient treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with mild to moderate symptoms of alcohol withdrawal can be safely and effectively managed as outpatients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/27\">",
"     27",
"    </a>",
"    ]. Many patients, however, prefer to enter a treatment center or environment that is free of cues and relapse triggers. Some addiction providers in residential programs suggest that the \"dose\" of treatment received in these programs improves success compared to outpatient programs; this hypothesis, however, has not been tested by a randomized study.",
"   </p>",
"   <p>",
"    Symptoms of minor withdrawal include tremulousness, mild anxiety, headache, diaphoresis, palpitations, anorexia, and gastrointestinal upset (",
"    <a class=\"graphic graphic_table graphicRef75499 \" href=\"mobipreview.htm?12/5/12379\">",
"     table 1",
"    </a>",
"    ). The severity of withdrawal may also be assessed using a revised Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWA-Ar) (",
"    <a class=\"graphic graphic_table graphicRef64835 \" href=\"mobipreview.htm?20/61/21470\">",
"     table 2",
"    </a>",
"    )&nbsp;(",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?33/0/33796?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/61/20441?source=see_link\">",
"     \"Management of moderate and severe alcohol withdrawal syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Guidelines for management of withdrawal have been developed by the American Society of Addiction Medicine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/29\">",
"     29",
"    </a>",
"    ]. The CIWA-Ar scale can be helpful in identifying patients for appropriate levels of care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/30\">",
"     30",
"    </a>",
"    ]. The scale is intended for use only in patients who are able to communicate verbally and who have been recently drinking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/31\">",
"     31",
"    </a>",
"    ]. These guidelines, with scores added, include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Minimal withdrawal (CIWA-Ar score &lt;10 and no disorientation or hallucinations): Thiamine and supportive care.",
"     </li>",
"     <li>",
"      Mild withdrawal (CIWA-Ar score 10 to 15): Medication to reduce symptoms and monitoring to reduce risk of complications. Benzodiazepine therapy may be indicated.",
"     </li>",
"     <li>",
"      Moderate (CIWA-Ar score 16 to 20) and Severe (CIWA-Ar score &gt;20) withdrawal: Thiamine, supportive care, hourly monitoring, and benzodiazepine therapy until CIWA-Ar score is &lt;10. Respiratory monitoring may be indicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to moderate and severe withdrawal symptoms, indications for inpatient treatment include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History of withdrawal seizures or complications",
"     </li>",
"     <li>",
"      Depression with suicidal ideation",
"     </li>",
"     <li>",
"      The presence of severe coexisting medical or psychiatric conditions",
"     </li>",
"     <li>",
"      Extremely unstable home situation",
"     </li>",
"     <li>",
"      Failure to respond to outpatient treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Inpatient detoxification may be cost-effective in a number of other patients as well, but this is often limited by insurance coverage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Peer support groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcoholics Anonymous (AA), the best known peer support program for substance use disorders, is a voluntary program for people with problem drinking, based on fellowship and a belief in a spiritual basis for recovery. Abstinence is encouraged on a \"one day at a time\" basis. Members attend meetings (either open to all, or restricted to participants with alcoholism) in which experiences related to drinking and recovery are shared, and steps in the Twelve Steps to Recovery are discussed. The Twelve Step program entails acknowledgment that alcohol has led to loss of control, that recovery is a spiritual journey through belief in a higher power, and through personal exploration and acceptance. More information about AA can be found on their website:",
"    <a class=\"external\" href=\"file://www.alcoholics-anonymous.org/\">",
"     www.alcoholics-anonymous.org",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Referral to Alcoholics Anonymous appears to be cost-effective for alcohol-dependent patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/34\">",
"     34",
"    </a>",
"    ]. In a study of 200 patients who chose either to attend AA or to seek help from a professional outpatient alcoholism treatment provider, per-person treatment costs over three years for the AA group were 45 percent ($1826) lower than costs for the outpatient treatment group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/35\">",
"     35",
"    </a>",
"    ]. Outcomes for the two groups were similar.",
"   </p>",
"   <p>",
"    The physician can take an active role in the referral to AA by making the first call with the patient present, helping to locate meeting sites, and identifying times for the patient to attend. It is helpful to request that the patient provide feedback to the physician once they begin attending meetings.",
"   </p>",
"   <p>",
"    Some patients are uncomfortable with the AA emphasis on the role of a higher power, and alternative support programs are available, although no substantial research has been conducted on their effectiveness. One such program is SMART Recovery (Self Management and Recovery Training), which offers free treatment advice on-line as well as group meetings which stress self-reliance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/36\">",
"     36",
"    </a>",
"    ]. For those who prefer to attempt controlled drinking, self help groups are available with both group meetings and internet support [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     NUTRITION AND EXERCISE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol abusers and dependents and their children are at increased risk of developing eating disorders, especially obesity or binge or addictive overeating. The process of alcohol detoxification and abstinence is often accompanied by overeating; sometimes food becomes a replacement for alcohol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/38\">",
"     38",
"    </a>",
"    ]. As part of comprehensive treatment of alcohol abuse or dependence, patients should be encouraged to exercise and should be instructed in a healthy diet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Vitamin and mineral supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drinking may interfere with the absorption, digestion, metabolism, and utilization of nutrients, particularly vitamins; vitamins A, C, D, E, K, and the B vitamins are deficient in some alcoholics. Additionally, dietary sources for vitamins are often suboptimal in alcohol abusers. Thiamine deficiency creates a risk for the development of Wernicke's encephalopathy, and patients who are undergoing detoxification are generally treated with thiamine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/24/40328?source=see_link\">",
"     \"Overview of the chronic neurologic complications of alcohol\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest that outpatients with alcoholism, whether or not they are undergoing treatment for alcoholism, be advised to take supplemental",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    and a daily multivitamin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     FOLLOW-UP AND RELAPSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to monitor for relapse once abstinence and recovery have occurred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/40\">",
"     40",
"    </a>",
"    ]. Relapse is defined by the DSM-IV as the return to use of alcohol",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other drugs after a period of abstinence and sobriety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Relapse usually begins with a \"slip\" or \"lapse\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/41\">",
"     41",
"    </a>",
"    ]. Lapses can be considered as less serious drinking events than a full blown relapse. Examples of lapse include having a drink at a wedding, missing a planned AA meeting, or even lying about some aspects of recovery. The risk of lapsing decreases over time. Lapses are important to recognize and manage before they become full-blown relapses. Brief intervention can be helpful in addressing a lapse.",
"   </p>",
"   <p>",
"    Factors associated with higher rates of relapse include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Male gender",
"     </li>",
"     <li>",
"      Younger age",
"     </li>",
"     <li>",
"      Fewer social supports",
"     </li>",
"     <li>",
"      Greater alcohol consumption prior to treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Poor compliance with drug therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/25\">",
"       25",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Reasons for relapse include depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/43,44\">",
"     43,44",
"    </a>",
"    ], boredom, loneliness, stopping AA, and anxiety. Physicians who continue to be supportive, encourage AA participation, and treat comorbid anxiety or depression may help reduce the incidence of relapse.",
"   </p>",
"   <p>",
"    There are few data on rates of relapse once abstinence is achieved. The National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) followed 1772 individuals over age 18 who were in full remission from alcohol abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/44\">",
"     44",
"    </a>",
"    ]. Over a three year period, 26 percent developed symptoms of an Alcohol Use Disorder (AUD) while an additional 5 percent had become alcohol dependent. Of note, this survey may not be representative of all individuals in alcohol recovery, since participants agreed to participate in the longitudinal study and be interviewed in their home, and thus people at higher risk for relapse may have been excluded.",
"   </p>",
"   <p>",
"    A minority of patients who were alcohol abusers or dependent at some time in their lives eventually get back to a point where they can safely consume alcohol. In the NESARC study, abstinence, compared to low risk drinking, was associated with a lower risk for relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/44\">",
"     44",
"    </a>",
"    ]. Younger drinkers had the greatest risk of relapse, and this risk was not influenced by risk drinking behavior in remission, highlighting the vulnerability of this age group. In one case-control report comparing posttreatment alcohol-dependent patients (n = 51) who engaged in limited drinking with 51 controls who reported total abstinence, the limited drinkers were four times as likely to regress to unacceptable drinking, although most (62 percent) did not regress to the point of alcohol dependence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41847/abstract/45\">",
"     45",
"    </a>",
"    ]. It is not possible at this time to predict which patients can safely resume drinking alcohol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/28/39361?source=see_link\">",
"       \"Patient information: Alcohol use &mdash; when is drinking a problem? (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/21/44371?source=see_link\">",
"       \"Patient information: Alcohol use &mdash; when is drinking a problem? (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At risk drinking is &gt;14 drinks per week or four drinks per occasion for men, and &gt;7 drinks per week or three drinks per occasion for women. Alcohol dependence is defined by having three or more of seven criteria listed above. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with alcohol dependence, who are willing to stop drinking, may require treatment for alcohol withdrawal. Outpatient therapy is safe for most patients with mild to moderate withdrawal symptoms; inpatient therapy is indicated for patients with severe withdrawal symptoms, and for those with a history of complications from prior withdrawal, psychiatric illness, or lack of social support. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Inpatient versus outpatient treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/61/20441?source=see_link\">",
"       \"Management of moderate and severe alcohol withdrawal syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest that patients with alcohol dependence be offered a choice of medication or a psychosocial intervention, because research on combined treatment shows mixed results. For patients who do not achieve remission or an adequate reduction in heavy drinking, we recommend switching or combining modalities. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19209?source=see_link\">",
"       \"Pharmacotherapy for alcohol abuse and dependence\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest the use of motivation interviewing for patients with alcohol dependence who lack readiness to reduce intake. We suggest either brief intervention in primary care and cognitive behavioral therapy in mental health specialty care for treatment of alcohol dependence. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Motivational interviewing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Cognitive behavioral therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42265?source=see_link&amp;anchor=H603354#H603354\">",
"       \"Brief intervention for unhealthy alcohol and other drug use\", section on 'Readiness to change'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest participation in Alcoholics Anonymous for patients with alcohol problems who wish to stop drinking. For patients who are not comfortable with the Alcoholics Anonymous program approach, other alcohol support programs are available but have not been as well studied. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Peer support groups'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     World Health Organization (WHO). WHO global status report on alcohol 2004. Geneva: WHO; 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41847/abstract/2\">",
"      Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2007; 64:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41847/abstract/3\">",
"      Miller, NS, Swift, RM. Primary care medicine and psychiatry: Addictions treatment. Psychiatric Annals 1997; 27:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41847/abstract/4\">",
"      Fiellin DA, Reid MC, O'Connor PG. New therapies for alcohol problems: application to primary care. Am J Med 2000; 108:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41847/abstract/5\">",
"      Walsh DC, Hingson RW, Merrigan DM, et al. The impact of a physician's warning on recovery after alcoholism treatment. JAMA 1992; 267:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41847/abstract/6\">",
"      Rollnick, S, Miller, WR. What is motivational interviewing? Behavioural and Cognitive Psychotherapy 1995; 23:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41847/abstract/7\">",
"      Magill M, Ray LA. Cognitive-behavioral treatment with adult alcohol and illicit drug users: a meta-analysis of randomized controlled trials. J Stud Alcohol Drugs 2009; 70:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41847/abstract/8\">",
"      Saitz R. Clinical practice. Unhealthy alcohol use. N Engl J Med 2005; 352:596.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute on Alcohol Abuse and Alcoholism. The physicians' guide to helping patients with alcohol problems. Government Printing Office; Washington, DC 1995.",
"    </li>",
"    <li>",
"     U.S. Department of Health and Human Services and the U.S. Department of Agriculture (USDA). Nutrition and your Health: Dietary Guidelines for Americans. 4th ed. Home and Garden Bulletin No. 232. Washington, DC: USDA, 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41847/abstract/11\">",
"      Moore AA, Giuli L, Gould R, et al. Alcohol use, comorbidity, and mortality. J Am Geriatr Soc 2006; 54:757.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association, Diagnostic and Statistical Manual, 4th ed, APA Press, Washington, DC 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41847/abstract/13\">",
"      Smith GS, Keyl PM, Hadley JA, et al. Drinking and recreational boating fatalities: a population-based case-control study. JAMA 2001; 286:2974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41847/abstract/14\">",
"      Hingson R, Heeren T, Winter MR, Wechsler H. Early age of first drunkenness as a factor in college students' unplanned and unprotected sex attributable to drinking. Pediatrics 2003; 111:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41847/abstract/15\">",
"      Walsh JM, Flegel R, Atkins R, et al. Drug and alcohol use among drivers admitted to a Level-1 trauma center. Accid Anal Prev 2005; 37:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41847/abstract/16\">",
"      Betty Ford Institute Consensus Panel. What is recovery? A working definition from the Betty Ford Institute. J Subst Abuse Treat 2007; 33:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41847/abstract/17\">",
"      Saladin, ME, Santa Ana, EJ. Controlled drinking: more than just a controversy. Current Opinion in Psychiatry 2004; 17:175.",
"     </a>",
"    </li>",
"    <li>",
"     Armor DJ, Polich, JM, Stambul, BH. Alcoholism and Treatment. New York: Wiley; 1978, p 109.",
"    </li>",
"    <li>",
"     Polich, JM, Armor, DJ, Braiker, HB. The course of alcoholism: Four years after treatment. New York: Wiley; 1981.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41847/abstract/20\">",
"      Marlatt GA, Witkiewitz K. Harm reduction approaches to alcohol use: health promotion, prevention, and treatment. Addict Behav 2002; 27:867.",
"     </a>",
"    </li>",
"    <li>",
"     Miller, WR, Zweben, A, DiClemente, C, et al. Motivational enhancement therapy: a clinical research guide for therapists treating individuals with alcohol abuse and dependence. Project MATCH monograph 2. DHHS Publication No (ADM) 92-1894. Washington, DC: Department of Health and Human Services, 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41847/abstract/22\">",
"      Matching alcoholism treatments to client heterogeneity: Project MATCH three-year drinking outcomes. Alcohol Clin Exp Res 1998; 22:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41847/abstract/23\">",
"      Carroll KM, Ball SA, Nich C, et al. Motivational interviewing to improve treatment engagement and outcome in individuals seeking treatment for substance abuse: a multisite effectiveness study. Drug Alcohol Depend 2006; 81:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41847/abstract/24\">",
"      U.S. Preventive Services Task Force. Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: recommendation statement. Ann Intern Med 2004; 140:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41847/abstract/25\">",
"      Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006; 295:2003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41847/abstract/26\">",
"      Weiss RD, Kueppenbender KD. Combining psychosocial treatment with pharmacotherapy for alcohol dependence. J Clin Psychopharmacol 2006; 26 Suppl 1:S37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41847/abstract/27\">",
"      Hayashida M, Alterman AI, McLellan AT, et al. Comparative effectiveness and costs of inpatient and outpatient detoxification of patients with mild-to-moderate alcohol withdrawal syndrome. N Engl J Med 1989; 320:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41847/abstract/28\">",
"      Sullivan JT, Sykora K, Schneiderman J, et al. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict 1989; 84:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41847/abstract/29\">",
"      Mayo-Smith MF. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA 1997; 278:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41847/abstract/30\">",
"      Holbrook AM, Crowther R, Lotter A, et al. Diagnosis and management of acute alcohol withdrawal. CMAJ 1999; 160:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41847/abstract/31\">",
"      Hecksel KA, Bostwick JM, Jaeger TM, Cha SS. Inappropriate use of symptom-triggered therapy for alcohol withdrawal in the general hospital. Mayo Clin Proc 2008; 83:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41847/abstract/32\">",
"      Practice guideline for the treatment of patients with substance use disorders: alcohol, cocaine, opioids. American Psychiatric Association. Am J Psychiatry 1995; 152:1.",
"     </a>",
"    </li>",
"    <li>",
"     Patient placement criteria for the treatment of substance-related disorders, 2nd ed, American Society of Addiction Medicine, Chevy Chase, MD 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41847/abstract/34\">",
"      Gold MS. Neurobiology of addiction and recovery: the brain, the drive for the drug, and the 12-step fellowship. J Subst Abuse Treat 1994; 11:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41847/abstract/35\">",
"      Humphreys K, Moos RH. Reduced substance-abuse-related health care costs among voluntary participants in Alcoholics Anonymous. Psychiatr Serv 1996; 47:709.",
"     </a>",
"    </li>",
"    <li>",
"     www.smartrecovery.org (accessed April 17, 2006).",
"    </li>",
"    <li>",
"     www.moderation.org (accessed February 22, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41847/abstract/38\">",
"      Hodgkins CC, Cahill KS, Seraphine AE, et al. Adolescent drug addiction treatment and weight gain. J Addict Dis 2004; 23:55.",
"     </a>",
"    </li>",
"    <li>",
"     Kasser, C, Geller, A, Howell, E, Wartenberg, A. Detoxification: principles and protocols. American Society of Addiction Medicine. www.asam.org/publ/detoxification.htm (Accessed April 7, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41847/abstract/40\">",
"      Friedmann PD, Saitz R, Samet JH. Management of adults recovering from alcohol or other drug problems: relapse prevention in primary care. JAMA 1998; 279:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41847/abstract/41\">",
"      Witkiewitz K, Masyn KE. Drinking trajectories following an initial lapse. Psychol Addict Behav 2008; 22:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41847/abstract/42\">",
"      Dawson DA, Grant BF, Stinson FS, et al. Recovery from DSM-IV alcohol dependence: United States, 2001-2002. Addiction 2005; 100:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41847/abstract/43\">",
"      Gold, MS, Miller, N. Depression vs. craving in alcoholic relapse. Neurendocrinology Letters 1993; 15:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41847/abstract/44\">",
"      Dawson DA, Goldstein RB, Grant BF. Rates and correlates of relapse among individuals in remission from DSM-IV alcohol dependence: a 3-year follow-up. Alcohol Clin Exp Res 2007; 31:2036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41847/abstract/45\">",
"      Watson CG, Hancock M, Gearhart LP, et al. A comparative outcome study of frequent, moderate, occasional, and nonattenders of Alcoholics Anonymous. J Clin Psychol 1997; 53:209.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7810 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-C2273CD5CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_55_41847=[""].join("\n");
var outline_f40_55_41847=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      At-risk drinking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Alcohol dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT GOALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MOTIVATIONAL INTERVIEWING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      BRIEF INTERVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      COGNITIVE BEHAVIORAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HOSPITALIZATION AND REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Inpatient versus outpatient treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Peer support groups",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      NUTRITION AND EXERCISE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Vitamin and mineral supplementation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      FOLLOW-UP AND RELAPSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/7810\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/7810|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/5/12379\" title=\"table 1\">",
"      Timing of withdrawal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/61/21470\" title=\"table 2\">",
"      CIWA-Ar withdrawal scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?33/0/33796?source=related_link\" title=\"calculator 1\">",
"      Calculator: CIWA-Ar Clinical Institute Withdrawal Assessment for Alcohol scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/16/4361?source=related_link\">",
"      Ambulatory alcohol detoxification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42265?source=related_link\">",
"      Brief intervention for unhealthy alcohol and other drug use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/33/31258?source=related_link\">",
"      Cardiovascular benefits and risks of moderate alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/61/20441?source=related_link\">",
"      Management of moderate and severe alcohol withdrawal syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/24/40328?source=related_link\">",
"      Overview of the chronic neurologic complications of alcohol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/21/44371?source=related_link\">",
"      Patient information: Alcohol use &mdash; when is drinking a problem? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/28/39361?source=related_link\">",
"      Patient information: Alcohol use &mdash; when is drinking a problem? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19209?source=related_link\">",
"      Pharmacotherapy for alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25993?source=related_link\">",
"      Screening for unhealthy use of alcohol and other drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_55_41848="Congenital aganglionic megacolon (Hirschsprung disease)";
var content_f40_55_41848=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Congenital aganglionic megacolon (Hirschsprung disease)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/55/41848/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/55/41848/contributors\">",
"     David E Wesson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/55/41848/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/55/41848/contributors\">",
"     William J Klish, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/55/41848/contributors\">",
"     Jonathan I Singer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/55/41848/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/55/41848/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/55/41848/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hirschsprung disease (HD) is a motor disorder of the gut, which is caused by the failure of neural crest cells (precursors of enteric ganglion cells) to migrate completely during intestinal development. The resulting aganglionic segment of the colon fails to relax, causing a functional obstruction. In the majority of patients, the disorder affects a short segment of the distal colon, with a transition zone in the rectosigmoid colon. In other patients, the aganglionosis involves longer segments of the colon. In approximately 5 percent the entire colon is affected, and in rare cases the small bowel may also be involved.",
"   </p>",
"   <p>",
"    HD occurs in approximately 1 in 5000 live births, with an overall male:female ratio of 3:1 to 4:1; when the entire colon is involved, the gender ratio more nearly approaches 1:1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most accepted theory of the cause of HD is that there is a defect in the craniocaudal migration of neuroblasts originating from the neural crest that occurs during the first 12 weeks of gestation. However, defects in the differentiation of neuroblasts into ganglion cells and accelerated ganglion cell destruction within the intestine may also contribute to the disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least eight genetic mutations have been identified in patients with HD&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The predominant gene affected is the RET proto-oncogene. RET malfunction accounts for at least 50 percent of familial and 20 percent of sporadic cases, and is especially seen in patients with long segment disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. In one study, RET variations were found in 82 percent of patients with total colonic aganglionosis, as compared with 33 percent of those with short segment disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/7\">",
"     7",
"    </a>",
"    ]. More than 20 different mutations in the RET proto-oncogene have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. In addition, certain RET proto-oncogene polymorphisms are associated with a phenotype of HD (short or long segment disease) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/8\">",
"     8",
"    </a>",
"    ]. Mutations between the promoter region and exon 2 of the RET genomic sequence may account for many more of the sporadic cases even when RET itself is not mutated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The RET protein is a receptor tyrosine kinase that appears to transduce growth and differentiation signals in several developing tissues including those derived from the neural crest. Glial-cell-line-derived neurotrophic factor (GDNF) and neurturin have been identified as ligands for RET, and GDNF is necessary for activation of RET [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/11\">",
"     11",
"    </a>",
"    ]. Mouse models have demonstrated that RET is necessary for migration and survival of enteric neurons, and that the degree of aganglionosis is proportionate to RET dosage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to their effects on the enteric nervous system, GDNF or RET have crucial roles in the differentiation and survival of central nervous system neurons, the development of the peripheral nervous system, and the development of the kidneys and ureters. Defects in the RET proto-oncogenes have been described in multiple endocrine neoplasia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/33/41495?source=see_link\">",
"     \"Classification and genetics of multiple endocrine neoplasia type 2\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mutations in other genes have been described in only a few patients, accounting for 1 to 5 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. These genes include endothelin 3 (EDN3), endothelin receptor B (EDNRB), endothelin converting enzyme (ECE1), the gene encoding the Sry-related transcription factor SOX10 (SOX10) and the PHOX2B gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/5,12\">",
"     5,12",
"    </a>",
"    ]. A genome-wide association study also identified an association with neuregulin 1 (NRG1), a regulator of enteric ganglia precursors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/13\">",
"     13",
"    </a>",
"    ]. The genetic defect in the remainder of patients remains unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Associated syndromes and congenital anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;HD is strongly associated with trisomy 21 (Down syndrome), which is present in 2 to 3 percent of individuals with HD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/14\">",
"     14",
"    </a>",
"    ]. Conversely, trisomy 21 or another chromosomal anomaly is present in about 12 percent of individuals with HD.",
"   </p>",
"   <p>",
"    Monogenic syndromes associated with HD include the following (",
"    <a class=\"graphic graphic_table graphicRef73215 \" href=\"mobipreview.htm?35/42/36525\">",
"     table 1",
"    </a>",
"    ): &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bardet-Biedl syndrome (BBS) (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13929?source=see_link&amp;anchor=H11#H11\">",
"       \"Pathogenesis of obesity\", section on 'Bardet-Biedl syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cartilage-hair hypoplasia &ndash; This is a rare syndrome characterized by short stature, short limbs with increased carrying angle at the elbow, increased lumbar lordosis, ligamentous laxity, scoliosis, and immunodeficiency. Affected infants often present with enterocolitis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/51/7992?source=see_link&amp;anchor=H6#H6\">",
"       \"Cartilage-hair hypoplasia\", section on 'Gastrointestinal abnormalities'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Congenital central hypoventilation syndrome (CCHS) (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22520?source=see_link&amp;anchor=H5#H5\">",
"       \"Disorders of ventilatory control\", section on 'Congenital central hypoventilation syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Multiple endocrine neoplasia type 2 (MEN2) (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22794?source=see_link\">",
"       \"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mowat-Wilson syndrome (MWS) &ndash; This is caused by haploinsufficiency of the ZEB2 gene (also known as SIP01) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/15-17\">",
"       15-17",
"      </a>",
"      ]. Approximately 50 percent of individuals with MWS have HD; other features are distinctive facial characteristics, moderate to severe intellectual disability, genitourinary anomalies and heart defects. Smith-Lemli-Opitz syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/4,18-20\">",
"       4,18-20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/52/23369?source=see_link&amp;anchor=H13#H13\">",
"       \"Causes and clinical manifestations of primary adrenal insufficiency in children\", section on 'Defects in cholesterol biochemistry'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Waardenburg syndrome &ndash; This is an autosomal dominant inherited pigmentary disorder; nearly 100 percent of Waardenburg syndrome type 4 have HD. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24586?source=see_link&amp;anchor=H24#H24\">",
"       \"The genodermatoses\", section on 'Waardenburg syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For trisomy 21, CCHS, and BBS, RET acts as a modifier gene for the Hirschsprung phenotype. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/15/26874?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical features and diagnosis of Down syndrome\", section on 'Gastrointestinal abnormalities'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22520?source=see_link&amp;anchor=H5#H5\">",
"     \"Disorders of ventilatory control\", section on 'Congenital central hypoventilation syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24586?source=see_link&amp;anchor=H24#H24\">",
"     \"The genodermatoses\", section on 'Waardenburg syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 20 to 25 percent of patients with HD have associated congenital anomalies, often but not always in association with one of the syndromes described above. Anomalies of the kidney and urinary tract (CAKUT), including hydronephrosis and renal hypoplasia, are particularly common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. This association is not explained by a simple relationship with RET or GDNF, but these genes could be involved as disease modifiers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/60/22472?source=see_link\">",
"     \"Overview of congenital anomalies of the kidney and urinary tract (CAKUT)\"",
"    </a>",
"    .) Congenital heart disease is found in about 5 percent of individuals with HD (excluding those with Down syndrome) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/14\">",
"     14",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with HD are diagnosed in the neonatal period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients present with symptoms of distal intestinal obstruction: bilious emesis, abdominal distension, and failure to pass stool [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/23\">",
"     23",
"    </a>",
"    ]. The diagnosis can be suggested by a delay in passage of the first meconium (greater than 48 hours of age). This is because about 95 percent of neonates with HD fail to pass meconium within the first 48 hours of life, as compared with about 1 percent of full-term newborns without HD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. There may be an explosive expulsion of gas and stool after the digital rectal examination (squirt sign or blast sign), which may relieve the obstruction temporarily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Affected children may also present initially with enterocolitis, a potentially life threatening illness in which patients have a sepsis-like picture with fever, vomiting, diarrhea, and abdominal distension, which can progress to toxic megacolon. Patients with enterocolitis require fluid resuscitation, intravenous antibiotic therapy including coverage for anaerobic bacteria, rectal irrigations, and, in rare cases, an emergency colostomy. A rare complication of HD is volvulus, which can affect the sigmoid and less commonly the transverse colon and cecum. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/8/34950?source=see_link\">",
"     \"Emergency complications of Hirschsprung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with less severe disease may not be diagnosed until later in childhood. Such patients typically have a history of chronic constipation and failure to thrive. Although uncommon, HD can be newly diagnosed in adulthood. Patients present with symptoms of abdominal distension and a long history of refractory constipation without fecal incontinence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HD should be suspected in the clinical settings discussed above. Rectal biopsy is considered the gold standard for diagnosis, and may be supported by findings on abdominal radiographs, contrast enema, or anorectal manometry. Each of these procedures has advantages and disadvantages related to availability, technical expertise, radiation exposure, and invasiveness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/30\">",
"     30",
"    </a>",
"    ]. The diagnostic steps depend on the level of suspicion for HD, whether there is concern about Hirschsprung enterocolitis (which requires emergency management) and on the available resources and",
"    <span class=\"nowrap\">",
"     institutional/clinician",
"    </span>",
"    preference (",
"    <a class=\"graphic graphic_algorithm graphicRef51156 \" href=\"mobipreview.htm?24/32/25089\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The extent to which clinical features can help determine the likelihood of HD (and the need for rectal biopsy) is incompletely understood. One study that addresses this issue compared 50 children who presented with constipation and were diagnosed with HD to a concurrent cohort of 50 patients with idiopathic constipation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/31\">",
"     31",
"    </a>",
"    ]. Significantly more patients with HD experienced delayed passage of meconium, abdominal distension, and vomiting, and had a transition zone identified on a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema study. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Contrast enema'",
"    </a>",
"    below.) The presence of at least one of these findings was identified in every patient diagnosed with HD compared with 64 percent of patients with idiopathic constipation. Thus, the authors suggest that rectal biopsy may be avoided in children with constipation who lack all of the above clinical and radiologic features.",
"   </p>",
"   <p>",
"    Practice varies regarding the management of neonates presenting well-documented delayed passage of meconium (&gt;48 hours but &lt;72 hours) but no other symptoms (no abdominal distension, vomiting, or feeding problems). Such infants should undergo a careful physical examination and exclusion of other causes of delayed passage of meconium, including anorectal malformations (",
"    <a class=\"graphic graphic_table graphicRef82181 \" href=\"mobipreview.htm?40/31/41467\">",
"     table 2",
"    </a>",
"    )&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/63/15354?source=see_link&amp;anchor=H21#H21\">",
"     \"Constipation in children: Etiology and diagnosis\", section on 'Physical examination'",
"    </a>",
"    ). They should also be closely observed, and evaluated promptly for HD if they develop symptoms of constipation or abdominal distension. It would also be reasonable to perform a contrast enema and suction rectal biopsy even in otherwise asymptomatic infants who fail to pass meconium within the first 48 hours after birth, particularly if close observation cannot be assured. An urgent evaluation is essential if the infant develops symptoms of obstruction or enterocolitis. Any infant who fails to pass meconium within 72 hours of birth should be fully evaluated for HD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Rectal biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gold standard for diagnosis is a rectal biopsy, which can be obtained safely using a mucosal suction technique. The procedure can be done at the bedside or in an ambulatory setting without the need for general anesthesia. Adequate tissue is obtained for analysis in the majority of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Repeat suction biopsies or full-thickness biopsies under general anesthesia can be performed if the initial biopsy is nondiagnostic.",
"   </p>",
"   <p>",
"    The diagnosis is established if ganglion cells are absent, provided that the tissue sample is adequate (",
"    <a class=\"graphic graphic_picture graphicRef53381 \" href=\"mobipreview.htm?4/59/5049\">",
"     picture 1",
"    </a>",
"    ). Supportive findings include the presence of hypertrophic nerve fibers and elevated acetylcholinesterase activity, which can be seen with special stains and calretinin immunostaining [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]. Immunohistochemical staining for the RET oncoprotein increases the sensitivity of light microscopy as compared with conventional H&amp;E staining [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For children up to three years of age, rectal suction biopsy is more sensitive and specific than contrast enema and anorectal manometry for the diagnosis of HD (",
"    <a class=\"graphic graphic_table graphicRef65223 \" href=\"mobipreview.htm?27/38/28267\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/30,39\">",
"     30,39",
"    </a>",
"    ]. When the biopsy samples are obtained from the correct site and contain at least a small amount of muscularis mucosae, a negative test virtually excludes HD. However, the extent of the affected area may not be fully known until surgery, during which additional biopsies are usually obtained to define the surgical resection margins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Abdominal radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before obtaining a biopsy, the diagnosis may be suggested by an abdominal radiograph that shows signs of distal intestinal obstruction (ie, decreased or absent air in the rectum and dilated bowel loops proximal to the aganglionic region). Careful review of the plain radiographs also may reveal the transition zone even when it is not visible on the contrast enema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Contrast enema",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cone-shaped transition zone or caliber change, (usually in the rectosigmoid area) can be seen in an unprepped",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema study, although it often is not visible in newborns (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59877 \" href=\"mobipreview.htm?28/31/29183\">",
"     image 1",
"    </a>",
"    ). The transition zone, which represents the change from the normal",
"    <span class=\"nowrap\">",
"     caliber/narrowed",
"    </span>",
"    rectum (aganglionic segment) to the dilated colon proximal to the aganglionic region, is seen best in the early lateral and oblique views. In patients with total colonic involvement, the entire colon may appear normal but dilated loops of distal small bowel may be visible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/41\">",
"     41",
"    </a>",
"    ]. If a transition zone is not clearly detected, a follow-up postevacuation film at least 24 hours later may reveal residual retained barium in the colon, which is suggestive of the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/3,42\">",
"     3,42",
"    </a>",
"    ]. The recto-sigmoid index, the ratio between the diameter of the rectum and the sigmoid colon, is typically &gt;1 in children without HD. Reversal of this ratio, although less often noted than a transition zone, is a useful sign of HD in infants and older children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Contrast enema is less sensitive than rectal suction biopsy and anorectal manometry for the diagnosis of HD (",
"    <a class=\"graphic graphic_table graphicRef65223 \" href=\"mobipreview.htm?27/38/28267\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/30,39\">",
"     30,39",
"    </a>",
"    ]. A digital rectal examination within a few days of the contrast enema may dilate the rectum and cause a false negative result. Once the diagnosis of HD has been established, a contrast enema may help the surgeon to localize the transition zone and determine the length of the aganglionic segment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Anorectal manometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anorectal manometry sometimes is used to aid in the diagnosis and is especially helpful in patients with ultrashort segment disease. It is helpful as a screening test because a clearly normal study demonstrating relaxation of the internal anal sphincter with distension of the rectum excludes the diagnosis of HD. Lack of relaxation of the internal anal sphincter with balloon rectal distension is suggestive of HD. Although anal manometry has a positive predictive value that is reported to be 75 to 95 percent, it tends to be less accurate in infants younger than one month of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/11/16568?source=see_link&amp;anchor=H42686006#H42686006\">",
"     \"Motility testing: When does it help?\", section on 'Anorectal manometry'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Serum proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one report, mass spectroscopy of serum from patients with HD identified specific protein markers that may prove useful in early screening, but this technique has not been widely tested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Comparison of diagnostic procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic accuracy of rectal suction biopsy (RSB), contrast enema (CE), and anorectal manometry (ARM) were compared in a prospective study of 111 consecutive patients (age range 4 days to 12 years, median age 5.3 months) in whom HD was suspected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/30\">",
"     30",
"    </a>",
"    ]. All patients underwent RSB, CE, and ARM. Full-thickness rectal biopsy was performed in patients in whom at least two of these index tests were abnormal. In patients in whom less than two index tests were abnormal, the diagnosis of HD was excluded through clinical follow-up for at least six months. A diagnosis of HD was made in 28 patients. RSB was the most sensitive and specific (93 and 100 percent, respectively) (",
"    <a class=\"graphic graphic_table graphicRef65223 \" href=\"mobipreview.htm?27/38/28267\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstay of treatment is surgery. The goals are to resect the affected segment, bring the normal ganglionic bowel down close to the anus, and preserve sphincter function. Many surgical techniques have been developed. The choice among them usually is based upon surgeon preference since the overall complication rates and long-term results are similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The traditional abdominoperineal pull-through involved two or three stages, in which patients initially underwent a diverting colostomy (to allow the dilated bowel to decompress) with definitive repair performed later. However, most centers now perform the procedure in one stage, an approach that does not appear to increase complication rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/27,47-49\">",
"     27,47-49",
"    </a>",
"    ]. Laparoscopic assisted and transanal repairs are gaining in popularity, and are now preferred over the open procedures in many centers. The results seem to be equal to the traditional abdominoperineal pull-through with the added benefit of earlier resumption of full feeds, less pain, shorter hospitalization, and less conspicuous scars [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/50-53\">",
"     50-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of the emergency complications of HD (including acute bowel obstruction, enterocolitis and volvulus) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/8/34950?source=see_link\">",
"     \"Emergency complications of Hirschsprung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients have normal or near-normal anorectal function after definitive surgery for HD, and most enjoy an excellent quality of life, although some abnormalities of bowel function are common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/54-58\">",
"     54-58",
"    </a>",
"    ]. The most common long-term complications are fecal incontinence, constipation, and enterocolitis. Fecal incontinence has the greatest impact on quality of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Constipation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Constipation or persistent obstructive symptoms after operative repair for HD can be caused by mechanical obstruction, persistent or acquired aganglionosis, a colonic motility disorder (eg, intestinal neuronal dysplasia), increased internal anal sphincter tone, or nonspecific colonic",
"    <span class=\"nowrap\">",
"     dysmotility/stool",
"    </span>",
"    withholding behavior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/59\">",
"     59",
"    </a>",
"    ]. The diagnostic evaluation typically includes a radiographic contrast study to evaluate for stricture, rectal suction biopsy to evaluate for persistent aganglionosis, and a motility evaluation (eg, radio-opaque marker study). If increased internal anal sphincter tone is suspected, a trial of botulinum toxin injection may be helpful (",
"    <a class=\"graphic graphic_algorithm graphicRef78219 \" href=\"mobipreview.htm?40/36/41550\">",
"     algorithm 2",
"    </a>",
"    ). In many cases, obstructive symptoms improve or resolve with time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Enterocolitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite surgical repair, Hirschsprung-associated enterocolitis (HAEC) is a major cause of morbidity and occasional mortality postoperatively, with incidence rates as high as 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/60-65\">",
"     60-65",
"    </a>",
"    ]. It usually occurs within the first year after surgical repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk for HAEC appears to be increased in patients with an anastomotic stricture, suggesting that intestinal stasis may have a role in the etiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/65\">",
"     65",
"    </a>",
"    ]. The risk is also increased in patients with long-segment disease, particularly for patients with total colon aganglionosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/61,62,66\">",
"     61,62,66",
"    </a>",
"    ]; such patients also have increased risks for perianal excoriations, electrolyte imbalance, and anastomotic leak, as compared with patients with rectosigmoid disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/67\">",
"     67",
"    </a>",
"    ]. The risk for these problems tends to improve with time after surgery. The risk factors, clinical presentation, and management of HAEC are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/8/34950?source=see_link&amp;anchor=H5#H5\">",
"     \"Emergency complications of Hirschsprung disease\", section on 'Enterocolitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diarrhea and incontinence are seen commonly during the early postoperative period. Loss of water-absorptive surface area from colonic resection and anal sphincter dysfunction are likely etiologic factors. Improvement of bowel function occurs in the majority of patients with frequency of stools and continence improving with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/3,51,54,60-62,68\">",
"     3,51,54,60-62,68",
"    </a>",
"    ]. There appears to be a rapid decrease in stool frequency during the first six months postoperatively with a slower decline over the next several years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term follow-up reveals that approximately 75 to 95 percent of patients achieve a stool frequency of five or fewer stools per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/60,61,68\">",
"     60,61,68",
"    </a>",
"    ]. Some patients may have problems with constipation and fecal soiling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/60,61,68,69\">",
"     60,61,68,69",
"    </a>",
"    ]. Most patients with Down syndrome and HD have disturbances of bowel function (soiling, recurrent enterocolitis) over the long term, and some revert to a permanent colostomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/70\">",
"     70",
"    </a>",
"    ]. Those with total colon HD have more fecal soiling, but for most patients with HD, the disease-specific quality of life tends to improve as time passes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41848/abstract/56,71\">",
"     56,71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/18/20770?source=see_link\">",
"       \"Patient information: Hirschsprung disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hirschsprung disease (HD) is caused by congenital absence of ganglion cells in the distal rectum and a varying amount of the bowel. It affects the rectum and part of the sigmoid colon in approximately 75 percent of patients, but it also can involve more proximal segments, the entire colon, or (in rare cases) most of the small bowel. There is an increased risk for HD among patients with trisomy 21, several other genetic syndromes, and congenital anomalies of the kidneys and urinary tract (",
"      <a class=\"graphic graphic_table graphicRef73215 \" href=\"mobipreview.htm?35/42/36525\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Associated syndromes and congenital anomalies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of patients with HD are diagnosed in the neonatal period when they present with symptoms of distal intestinal obstruction, including bilious emesis, abdominal distension, and failure to pass stool. Patients with less severe disease may not be diagnosed until later in infancy or childhood. Such patients typically have a history of chronic constipation and failure to thrive. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rarely, affected infants may present with enterocolitis, a potentially life threatening illness in which patients have a sepsis-like picture with fever, vomiting, diarrhea, and abdominal distension, which can progress to toxic megacolon. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/8/34950?source=see_link\">",
"       \"Emergency complications of Hirschsprung disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Definitive diagnosis of HD is made by rectal biopsy, which may be supported by findings on abdominal radiographs, contrast enema, or anorectal manometry. The diagnostic steps depend on the level of suspicion for HD, whether there is concern about Hirschsprung-associated enterocolitis (which requires emergency management), and on the available resources and",
"      <span class=\"nowrap\">",
"       institutional/clinician",
"      </span>",
"      preference (",
"      <a class=\"graphic graphic_algorithm graphicRef51156 \" href=\"mobipreview.htm?24/32/25089\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment for HD is surgical resection of the aganglionic segment of bowel. The normal ganglionic bowel is brought down and anastomosed to the anus, and sphincter function is generally preserved. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients have normal or near-normal anorectal function after definitive surgery for HD, and most enjoy an excellent quality of life, although some abnormalities of bowel function are common. The most common long-term complications are fecal incontinence and constipation. Postoperative enterocolitis may also occur, and is a medical emergency. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Outcome'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/8/34950?source=see_link\">",
"       \"Emergency complications of Hirschsprung disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/1\">",
"      Kleinhaus S, Boley SJ, Sheran M, Sieber WK. Hirschsprung's disease -- a survey of the members of the Surgical Section of the American Academy of Pediatrics. J Pediatr Surg 1979; 14:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/2\">",
"      Suita S, Taguchi T, Ieiri S, Nakatsuji T. Hirschsprung's disease in Japan: analysis of 3852 patients based on a nationwide survey in 30 years. J Pediatr Surg 2005; 40:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/3\">",
"      Kays DW. Surgical conditions of the neonatal intestinal tract. Clin Perinatol 1996; 23:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/4\">",
"      Parisi MA, Kapur RP. Genetics of Hirschsprung disease. Curr Opin Pediatr 2000; 12:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/5\">",
"      Martucciello G, Ceccherini I, Lerone M, Jasonni V. Pathogenesis of Hirschsprung's disease. J Pediatr Surg 2000; 35:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/6\">",
"      Uesaka T, Nagashimada M, Yonemura S, Enomoto H. Diminished Ret expression compromises neuronal survival in the colon and causes intestinal aganglionosis in mice. J Clin Invest 2008; 118:1890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/7\">",
"      Moore SW, Zaahl M. Clinical and genetic differences in total colonic aganglionosis in Hirschsprung's disease. J Pediatr Surg 2009; 44:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/8\">",
"      Fitze G, Cramer J, Ziegler A, et al. Association between c135G/A genotype and RET proto-oncogene germline mutations and phenotype of Hirschsprung's disease. Lancet 2002; 359:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/9\">",
"      Kim JH, Yoon KO, Kim JK, et al. Novel mutations of RET gene in Korean patients with sporadic Hirschsprung's disease. J Pediatr Surg 2006; 41:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/10\">",
"      Burzynski GM, Nolte IM, Osinga J, et al. Localizing a putative mutation as the major contributor to the development of sporadic Hirschsprung disease to the RET genomic sequence between the promoter region and exon 2. Eur J Hum Genet 2004; 12:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/11\">",
"      Uesaka T, Jain S, Yonemura S, et al. Conditional ablation of GFRalpha1 in postmigratory enteric neurons triggers unconventional neuronal death in the colon and causes a Hirschsprung's disease phenotype. Development 2007; 134:2171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/12\">",
"      Bajaj R, Smith J, Trochet D, et al. Congenital central hypoventilation syndrome and Hirschsprung's disease in an extremely preterm infant. Pediatrics 2005; 115:e737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/13\">",
"      Garcia-Barcelo MM, Tang CS, Ngan ES, et al. Genome-wide association study identifies NRG1 as a susceptibility locus for Hirschsprung's disease. Proc Natl Acad Sci U S A 2009; 106:2694.",
"     </a>",
"    </li>",
"    <li>",
"     Parisi MA. Hirschsprung disease overview. GeneReviews [Internet] 2002 (revised 2011). Available at: file://www.ncbi.nlm.nih.gov/books/NBK1439/ (Accessed on December 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/15\">",
"      Bonnard A, Zeidan S, Degas V, et al. Outcomes of Hirschsprung's disease associated with Mowat-Wilson syndrome. J Pediatr Surg 2009; 44:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/16\">",
"      Saunders CJ, Zhao W, Ardinger HH. Comprehensive ZEB2 gene analysis for Mowat-Wilson syndrome in a North American cohort: a suggested approach to molecular diagnostics. Am J Med Genet A 2009; 149A:2527.",
"     </a>",
"    </li>",
"    <li>",
"     Adam MP, Bean LJH, Miller VR. Mowat-Wilson Syndrome (Hirschprung disease-mental retardation syndrome). Gene Reviews 2008. Available at: file://www.ncbi.nlm.nih.gov/books/NBK1412/.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/18\">",
"      Flori E, Girodon E, Samama B, et al. Trisomy 7 mosaicism, maternal uniparental heterodisomy 7 and Hirschsprung's disease in a child with Silver-Russell syndrome. Eur J Hum Genet 2005; 13:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/19\">",
"      Mueller C, Patel S, Irons M, et al. Normal cognition and behavior in a Smith-Lemli-Opitz syndrome patient who presented with Hirschsprung disease. Am J Med Genet A 2003; 123A:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/20\">",
"      de Pontual L, Pelet A, Clement-Ziza M, et al. Epistatic interactions with a common hypomorphic RET allele in syndromic Hirschsprung disease. Hum Mutat 2007; 28:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/21\">",
"      Sarioglu A, Tanyel FC, B&uuml;y&uuml;kpamuk&ccedil;u N, Hi&ccedil;s&ouml;nmez A. Hirschsprung-associated congenital anomalies. Eur J Pediatr Surg 1997; 7:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/22\">",
"      Pini Prato A, Musso M, Ceccherini I, et al. Hirschsprung disease and congenital anomalies of the kidney and urinary tract (CAKUT): a novel syndromic association. Medicine (Baltimore) 2009; 88:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/23\">",
"      Khan AR, Vujanic GM, Huddart S. The constipated child: how likely is Hirschsprung's disease? Pediatr Surg Int 2003; 19:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/24\">",
"      Swenson O, Sherman JO, Fisher JH. Diagnosis of congenital megacolon: an analysis of 501 patients. J Pediatr Surg 1973; 8:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/25\">",
"      SHERRY SN, KRAMER I. The time of passage of the first stool and first urine by the newborn infant. J Pediatr 1955; 46:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/26\">",
"      Clark DA. Times of first void and first stool in 500 newborns. Pediatrics 1977; 60:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/27\">",
"      Lall A, Gupta DK, Bajpai M. Neonatal Hirschsprung's disease. Indian J Pediatr 2000; 67:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/28\">",
"      Wheatley MJ, Wesley JR, Coran AG, Polley TZ Jr. Hirschsprung's disease in adolescents and adults. Dis Colon Rectum 1990; 33:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/29\">",
"      Crocker NL, Messmer JM. Adult Hirschsprung's disease. Clin Radiol 1991; 44:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/30\">",
"      De Lorijn F, Reitsma JB, Voskuijl WP, et al. Diagnosis of Hirschsprung's disease: a prospective, comparative accuracy study of common tests. J Pediatr 2005; 146:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/31\">",
"      Lewis NA, Levitt MA, Zallen GS, et al. Diagnosing Hirschsprung's disease: increasing the odds of a positive rectal biopsy result. J Pediatr Surg 2003; 38:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/32\">",
"      Alizai NK, Batcup G, Dixon MF, Stringer MD. Rectal biopsy for Hirschsprung's disease: what is the optimum method? Pediatr Surg Int 1998; 13:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/33\">",
"      Kapur RP. Practical pathology and genetics of Hirschsprung's disease. Semin Pediatr Surg 2009; 18:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/34\">",
"      Schofield DE, Devine W, Yunis EJ. Acetylcholinesterase-stained suction rectal biopsies in the diagnosis of Hirschsprung's disease. J Pediatr Gastroenterol Nutr 1990; 11:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/35\">",
"      Kapur RP. Hirschsprung disease and other enteric dysganglionoses. Crit Rev Clin Lab Sci 1999; 36:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/36\">",
"      Lake BD, Puri P, Nixon HH, Claireaux AE. Hirschsprung's disease: an appraisal of histochemically demonstrated acetylcholinesterase activity in suction rectal biopsy specimens as an aid to diagnosis. Arch Pathol Lab Med 1978; 102:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/37\">",
"      Barshack I, Fridman E, Goldberg I, et al. The loss of calretinin expression indicates aganglionosis in Hirschsprung's disease. J Clin Pathol 2004; 57:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/38\">",
"      Karim S, Hession C, Marconi S, et al. The identification of ganglion cells in Hirschsprung disease by the immunohistochemical detection of ret oncoprotein. Am J Clin Pathol 2006; 126:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/39\">",
"      de Lorijn F, Kremer LC, Reitsma JB, Benninga MA. Diagnostic tests in Hirschsprung disease: a systematic review. J Pediatr Gastroenterol Nutr 2006; 42:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/40\">",
"      Pratap A, Gupta DK, Tiwari A, et al. Application of a plain abdominal radiograph transition zone (PARTZ) in Hirschsprung's disease. BMC Pediatr 2007; 7:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/41\">",
"      Stranzinger E, DiPietro MA, Teitelbaum DH, Strouse PJ. Imaging of total colonic Hirschsprung disease. Pediatr Radiol 2008; 38:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/42\">",
"      Doig CM. Hirschsprung's disease and mimicking conditions. Dig Dis 1994; 12:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/43\">",
"      Garcia R, Arcement C, Hormaza L, et al. Use of the recto-sigmoid index to diagnose Hirschsprung's disease. Clin Pediatr (Phila) 2007; 46:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/44\">",
"      Osatakul S, Patrapinyokul S, Osatakul N. The diagnostic value of anorectal manometry as a screening test for Hirschsprung's disease. J Med Assoc Thai 1999; 82:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/45\">",
"      Meunier P, Marechal JM, Mollard P. Accuracy of the manometric diagnosis of Hirschsprung's disease. J Pediatr Surg 1978; 13:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/46\">",
"      Wang, JX, Qin, P, Liu, QL, et al. Detection and significance of serum protein marker of Hirschsprung disease. Pediatrics 2007; 120:e56. Erratum in: Pediatrics 2007; 120:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/47\">",
"      Teitelbaum DH, Cilley RE, Sherman NJ, et al. A decade of experience with the primary pull-through for hirschsprung disease in the newborn period: a multicenter analysis of outcomes. Ann Surg 2000; 232:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/48\">",
"      So HB, Becker JM, Schwartz DL, Kutin ND. Eighteen years' experience with neonatal Hirschsprung's disease treated by endorectal pull-through without colostomy. J Pediatr Surg 1998; 33:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/49\">",
"      Ramesh JC, Ramanujam TM, Yik YI, Goh DW. Management of Hirschsprung's disease with reference to one-stage pull-through without colostomy. J Pediatr Surg 1999; 34:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/50\">",
"      Bonnard A, de Lagausie P, Leclair MD, et al. Definitive treatment of extended Hirschsprung's disease or total colonic form. Surg Endosc 2001; 15:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/51\">",
"      Coran AG, Teitelbaum DH. Recent advances in the management of Hirschsprung's disease. Am J Surg 2000; 180:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/52\">",
"      Langer JC, Durrant AC, de la Torre L, et al. One-stage transanal Soave pullthrough for Hirschsprung disease: a multicenter experience with 141 children. Ann Surg 2003; 238:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/53\">",
"      Travassos DV, Bax NM, Van der Zee DC. Duhamel procedure: a comparative retrospective study between an open and a laparoscopic technique. Surg Endosc 2007; 21:2163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/54\">",
"      Yanchar NL, Soucy P. Long-term outcome after Hirschsprung's disease: patients' perspectives. J Pediatr Surg 1999; 34:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/55\">",
"      Bai Y, Chen H, Hao J, et al. Long-term outcome and quality of life after the Swenson procedure for Hirschsprung's disease. J Pediatr Surg 2002; 37:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/56\">",
"      Ludman L, Spitz L, Tsuji H, Pierro A. Hirschsprung's disease: functional and psychological follow up comparing total colonic and rectosigmoid aganglionosis. Arch Dis Child 2002; 86:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/57\">",
"      Dasgupta R, Langer JC. Evaluation and management of persistent problems after surgery for Hirschsprung disease in a child. J Pediatr Gastroenterol Nutr 2008; 46:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/58\">",
"      Chumpitazi BP, Nurko S. Defecation disorders in children after surgery for Hirschsprung disease. J Pediatr Gastroenterol Nutr 2011; 53:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/59\">",
"      Langer JC. Persistent obstructive symptoms after surgery for Hirschsprung's disease: development of a diagnostic and therapeutic algorithm. J Pediatr Surg 2004; 39:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/60\">",
"      Moore SW, Albertyn R, Cywes S. Clinical outcome and long-term quality of life after surgical correction of Hirschsprung's disease. J Pediatr Surg 1996; 31:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/61\">",
"      Marty TL, Seo T, Matlak ME, et al. Gastrointestinal function after surgical correction of Hirschsprung's disease: long-term follow-up in 135 patients. J Pediatr Surg 1995; 30:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/62\">",
"      Reding R, de Ville de Goyet J, Gosseye S, et al. Hirschsprung's disease: a 20-year experience. J Pediatr Surg 1997; 32:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/63\">",
"      Agarwala S, Bhatnagar V, Mitra DK. Long-term follow-up of Hirschsprung's disease: review of early and late complications. Indian Pediatr 1996; 33:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/64\">",
"      Sariolu A, Senocak M, Hi&ccedil;s&ouml;nmez A, B&uuml;y&uuml;kpamuk&ccedil;u N. Management of uncommon complications of definitive operations of Hirschsprung's disease. Eur J Pediatr Surg 1996; 6:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/65\">",
"      Hackam DJ, Filler RM, Pearl RH. Enterocolitis after the surgical treatment of Hirschsprung's disease: risk factors and financial impact. J Pediatr Surg 1998; 33:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/66\">",
"      Pini Prato A, Gentilino V, Giunta C, et al. Hirschsprung disease: do risk factors of poor surgical outcome exist? J Pediatr Surg 2008; 43:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/67\">",
"      Anupama B, Zheng S, Xiao X. Ten-year experience in the management of total colonic aganglionosis. J Pediatr Surg 2007; 42:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/68\">",
"      Sherman JO, Snyder ME, Weitzman JJ, et al. A 40-year multinational retrospective study of 880 Swenson procedures. J Pediatr Surg 1989; 24:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/69\">",
"      Ieiri S, Nakatsuji T, Akiyoshi J, et al. Long-term outcomes and the quality of life of Hirschsprung disease in adolescents who have reached 18 years or older--a 47-year single-institute experience. J Pediatr Surg 2010; 45:2398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/70\">",
"      Menezes M, Puri P. Long-term outcome of patients with enterocolitis complicating Hirschsprung's disease. Pediatr Surg Int 2006; 22:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41848/abstract/71\">",
"      Hartman EE, Oort FJ, Aronson DC, et al. Explaining change in quality of life of children and adolescents with anorectal malformations or Hirschsprung disease. Pediatrics 2007; 119:e374.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5903 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-593C6D74E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_55_41848=[""].join("\n");
var outline_f40_55_41848=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Genes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Associated syndromes and congenital anomalies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Rectal biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Abdominal radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Contrast enema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Anorectal manometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Serum proteins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Comparison of diagnostic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Constipation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Enterocolitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5903\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5903|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?24/32/25089\" title=\"algorithm 1\">",
"      Hirschsprung diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?40/36/41550\" title=\"algorithm 2\">",
"      Obstruction post HS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5903|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?28/31/29183\" title=\"diagnostic image 1\">",
"      Hirschsprung dz barium enema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5903|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/59/5049\" title=\"picture 1\">",
"      Hirschsprung histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5903|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/42/36525\" title=\"table 1\">",
"      Hirschspr assoc syndr",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/31/41467\" title=\"table 2\">",
"      Causes of delayed passage of meconium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/38/28267\" title=\"table 3\">",
"      Comparison Dx tests Hirschsprun",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/51/7992?source=related_link\">",
"      Cartilage-hair hypoplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/52/23369?source=related_link\">",
"      Causes and clinical manifestations of primary adrenal insufficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/33/41495?source=related_link\">",
"      Classification and genetics of multiple endocrine neoplasia type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/15/26874?source=related_link\">",
"      Clinical features and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22794?source=related_link\">",
"      Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/63/15354?source=related_link\">",
"      Constipation in children: Etiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22520?source=related_link\">",
"      Disorders of ventilatory control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/8/34950?source=related_link\">",
"      Emergency complications of Hirschsprung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/11/16568?source=related_link\">",
"      Motility testing: When does it help?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/60/22472?source=related_link\">",
"      Overview of congenital anomalies of the kidney and urinary tract (CAKUT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13929?source=related_link\">",
"      Pathogenesis of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/18/20770?source=related_link\">",
"      Patient information: Hirschsprung disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24586?source=related_link\">",
"      The genodermatoses",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_55_41849="Screening for and diagnosis of chronic hepatitis C virus infection";
var content_f40_55_41849=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Screening for and diagnosis of chronic hepatitis C virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/55/41849/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/55/41849/contributors\">",
"     Norah A Terrault, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/55/41849/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/55/41849/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/55/41849/contributors\">",
"     Adrian M Di Bisceglie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/55/41849/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/55/41849/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/55/41849/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic tests for hepatitis C virus (HCV) can be divided into two broad categories:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serologic assays that detect antibodies to hepatitis C",
"     </li>",
"     <li>",
"      Molecular assays that detect or quantify HCV RNA",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other investigations such as genotype testing, serum fibrosis panels and liver biopsy may help to predict the response to treatment and prognosis.",
"   </p>",
"   <p>",
"    This topic will review recommendations regarding screening for HCV infection and approaches to the diagnosis of HCV infection. Other issues related to HCV infection are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2169?source=see_link\">",
"     \"Epidemiology and transmission of hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/50/31530?source=see_link\">",
"     \"Clinical manifestations and natural history of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/45/43735?source=see_link\">",
"     \"Overview of the management of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     WHO SHOULD BE TESTED",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several organizations have provided guidelines for who should be tested. Despite having reviewed similar data and including experts, the various guidelines do not all agree. All of the guidelines recommend screening patients at increased risk for HCV (eg, those with a history of injection drug use). In addition, starting in 2012, the Centers for Disease Control and Prevention (CDC) recommended birth cohort screening for all persons in the United States born between 1945 and 1965 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At least two studies suggest that screening patients in the United States who were born between 1945 and 1965 or 1946 and 1970, respectively, would be cost-effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The studies estimated that if patients found to be HCV positive were treated with peginterferon,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , and direct acting antiviral therapy (for patients with genotype 1), it would cost $35,700 to $37,700 per quality-adjusted life-year. However, birth-cohort screening may not be cost-effective in countries where the prevalence of HCV is lower [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/30/26087?source=see_link\">",
"     \"A short primer on cost-effectiveness analysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, because 12 to 35 percent of adult prison inmates in the United States have chronic HCV, some have argued for routine screening in this population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H147402142\">",
"    <span class=\"h2\">",
"     Authors' recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our general approach is consistent with the guidelines issued by the CDC and the American Association for the Study of Liver Diseases (AASLD). We screen the following patients for HCV:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anyone in the United States born between 1945 and 1965",
"     </li>",
"     <li>",
"      Those with a history of illicit injection drug use or intranasal cocaine use, even if only used once",
"     </li>",
"     <li>",
"      Those who received clotting factors made before 1987",
"     </li>",
"     <li>",
"      Those who received",
"      <span class=\"nowrap\">",
"       blood/organs",
"      </span>",
"      before July 1992",
"     </li>",
"     <li>",
"      Those who have been informed that they received blood from a donor who later tested positive for HCV",
"     </li>",
"     <li>",
"      Those who were ever on chronic hemodialysis",
"     </li>",
"     <li>",
"      Those with evidence of liver disease (persistently elevated alanine aminotransferase [ALT] level)",
"     </li>",
"     <li>",
"      Those infected with HIV",
"     </li>",
"     <li>",
"      Children born to HCV-infected mothers",
"     </li>",
"     <li>",
"      Those with a needle stick injury or mucosal exposure to HCV-positive blood",
"     </li>",
"     <li>",
"      Those who are a current sexual partner of an HCV-infected person",
"     </li>",
"     <li>",
"      Incarcerated individuals",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Notably, the presence of an abnormal serum ALT level, any history of injection drug use, or a history of blood transfusion before 1992 identified 85 percent of HCV RNA positive participants between the ages 20 to 59 in the most recent National Health and Nutrition Examination Survey in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/8\">",
"     8",
"    </a>",
"    ]. While an elevated ALT level is an indication for HCV testing, it is not required for testing to be performed, and patients meeting other criteria for HCV screening should undergo antibody testing regardless of their ALT level. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Testing approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H147402317\">",
"    <span class=\"h2\">",
"     Recommendations from groups in the United States",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Centers for Disease Control and Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;In",
"    <a class=\"external\" href=\"file://www.cdc.gov/mmwr/pdf/rr/rr5203.pdf\">",
"     2003",
"    </a>",
"    and",
"    <a class=\"external\" href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5912a1.htm\">",
"     2010",
"    </a>",
"    guidelines, the CDC recommends that testing for HCV should be routine in patients at increased risk for infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In addition, in a guideline issued in",
"    <a class=\"external\" href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/rr6104a1.htm\">",
"     2012",
"    </a>",
"    , the CDC also recommended screening for all patients born in the United States between 1945 and 1965 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specifically, the guidelines recommend screening for those who:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Were born in the United States between 1945 and 1965",
"     </li>",
"     <li>",
"      Ever injected illegal drugs",
"     </li>",
"     <li>",
"      Received clotting factors made before 1987",
"     </li>",
"     <li>",
"      Received",
"      <span class=\"nowrap\">",
"       blood/organs",
"      </span>",
"      before July 1992",
"     </li>",
"     <li>",
"      Were ever on chronic hemodialysis",
"     </li>",
"     <li>",
"      Have evidence of liver disease (elevated alanine aminotransferase [ALT] level)",
"     </li>",
"     <li>",
"      Are infected with HIV",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Testing should also be performed based upon the need for exposure management including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Healthcare, emergency, and public safety workers after needle",
"      <span class=\"nowrap\">",
"       stick/mucosal",
"      </span>",
"      exposure to HCV-positive blood",
"     </li>",
"     <li>",
"      Children born to HCV-positive women",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Routine testing is not recommended (unless an additional risk factor is identified) in:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Healthcare, emergency medical, and public safety workers",
"     </li>",
"     <li>",
"      Pregnant women",
"     </li>",
"     <li>",
"      Household (non-sexual) contacts of HCV-positive persons",
"     </li>",
"     <li>",
"      The general population",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The need for testing is uncertain in the following groups:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recipients of transplanted tissue after 1992",
"     </li>",
"     <li>",
"      Intranasal cocaine or other non-injecting illicit drug users",
"     </li>",
"     <li>",
"      Those with a history of tattooing, body piercing",
"     </li>",
"     <li>",
"      Those with a history of sexually transmitted diseases or multiple sex partners",
"     </li>",
"     <li>",
"      Long-term steady sexual partners of HCV-positive persons",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     American Association for the Study of Liver Diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;A",
"    <a class=\"external\" href=\"file://www.aasld.org/practiceguidelines/Documents/Bookmarked Practice Guidelines/Diagnosis_of_HEP_C_Update.Aug _09pdf.pdf\">",
"     2009 practice guideline",
"    </a>",
"    issued by the AASLD recommends testing for the following groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Those who have injected illicit drugs in the recent and remote past, including those who injected only once and do not consider themselves to be drug users.",
"     </li>",
"     <li>",
"      Those with conditions associated with a high prevalence of HCV including patients with HIV infection, those with hemophilia who received clotting factor concentrates before 1987, persons who were ever on hemodialysis, and those with unexplained abnormal aminotransferase levels.",
"     </li>",
"     <li>",
"      Prior recipients of transfusions or organ transplants before July 1992, including those who were notified that they received blood from a donor who later tested positive for HCV infection.",
"     </li>",
"     <li>",
"      Children born to HCV-infected mothers.",
"     </li>",
"     <li>",
"      Healthcare, emergency and public safety workers after a needle stick injury or mucosal exposure to HCV-positive blood.",
"     </li>",
"     <li>",
"      Current sexual partners of HCV-infected persons.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H147402266\">",
"    <span class=\"h3\">",
"     United States Preventive Services Task Force",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"external\" href=\"file://www.uspreventiveservicestaskforce.org/uspstf/uspshepc.htm\">",
"     United States Preventive Services Task Force",
"    </a>",
"    (USPSTF) recommends against routine screening for hepatitis C virus (HCV) infection in asymptomatic adults who are not at increased risk for infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition, they found insufficient evidence to make a recommendation for or against routine screening in adults at high risk for HCV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/13\">",
"     13",
"    </a>",
"    ]. In making this recommendation, the USPSTF notes potential harms of screening and treatment, including labeling of the patient, adverse treatment effects, and unnecessary liver biopsies.",
"   </p>",
"   <p>",
"    This recommendation should be interpreted as suggesting the need for additional research [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/14\">",
"     14",
"    </a>",
"    ]. A response from the Centers for Disease Control and Prevention to the USPSTF recommendation emphasizes that medical and public health professionals should continue the practice of screening persons for risk factors and offering testing to those at increased risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H147402228\">",
"    <span class=\"h3\">",
"     National Institutes of Health",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"external\" href=\"file://consensus.nih.gov/2002/2002HepatitisC2002116html.htm\">",
"     National Institutes of Health (NIH) consensus guidelines",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/16,17\">",
"     16,17",
"    </a>",
"    ] are similar to those of the CDC. In addition to the CDC guidelines, the NIH guidelines recommended screening individuals who:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Received a blood transfusion or organ transplantation prior to 1990 (rather than 1992)",
"     </li>",
"     <li>",
"      Have had multiple sexual partners",
"     </li>",
"     <li>",
"      Are spouses or household contacts of HCV-infected patients",
"     </li>",
"     <li>",
"      Share instruments for intranasal cocaine use",
"     </li>",
"     <li>",
"      Incarcerated individuals",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H256798872\">",
"    <span class=\"h2\">",
"     Recommendations from groups outside of the United States",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommendations from several European countries are similar to those from the United States. As examples, guidelines have been issued by:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The",
"      <a class=\"external\" href=\"file://www.easl.eu/assets/application/files/4a7bd873f9cccbf_file.pdf\">",
"       European Association for the Study of the Liver (EASL)",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The",
"      <a class=\"external\" href=\"file://www.nhs.uk/Livewell/hepatitisc/Documents/Information-for-professionals-19.05.061for-web-15600.pdf\">",
"       National Health Service",
"      </a>",
"      in Britain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The",
"      <a class=\"external\" href=\"file://www.snfge.asso.fr/01-Bibliotheque/0D-Pratiques-cliniques/HAS/depistage_vhc_2001_rapport.pdf\">",
"       Agence Nationale d&rsquo;Accr&eacute;ditation et d&rsquo;&Eacute;valuation en Sant&eacute; (ANES)",
"      </a>",
"      in France [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/20\">",
"       20",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ANTIBODY TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two types of hepatitis C virus (HCV) antibody tests are available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Screening assays designed to detect antibody to HCV (anti-HCV) with high sensitivity.",
"     </li>",
"     <li>",
"      Supplemental assays designed to help identify false positive screening tests. These assays are infrequently used in clinical practice.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Screening assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;The commonly available screening test for anti-HCV is an enzyme immunoassay (EIA, also called enzyme-linked immunosorbent assay or ELISA) that detects HCV antibodies. The hepatitis C virus is a small 40 to 60 nm virus with a lipid envelope and a single-stranded RNA viral genome comprising approximately 9500 nucleotides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/22\">",
"     22",
"    </a>",
"    ]. The N-terminus encodes the basic nucleocapsid (C) followed by two glycoprotein domains, the envelope (E1), and second",
"    <span class=\"nowrap\">",
"     envelope/nonstructural-1",
"    </span>",
"    <span class=\"nowrap\">",
"     (E2/NS1)",
"    </span>",
"    regions. Downstream to this region are the genes encoding nonstructural proteins NS2, NS3, NS4, and NS5, respectively. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/5/29780?source=see_link\">",
"     \"Characteristics of the hepatitis C virus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The EIA test has many advantages in the diagnostic setting, including ease of use, low variability, ease of automation, and relatively low expense. The second generation version of the test, EIA-2, is the most commonly used screening test in the United States. This assay detects antibodies to recombinant antigens from the core (C22) and nonstructural regions 3 (C33) and 4 (C100) of the HCV.",
"   </p>",
"   <p>",
"    EIA-2 is more sensitive and specific than the earlier assay, EIA-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/23\">",
"     23",
"    </a>",
"    ]. As an example, in a population in which hepatitis is highly prevalent, such as injection drug users or patients in a liver clinic, the sensitivity is as high as 95 percent (versus 70 to 80 percent for the previous assay), and the positive predictive value is 88 to 95 percent (versus 70 to 85 percent for the previous assay) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/24\">",
"     24",
"    </a>",
"    ]. The positive predictive value is lower (50 to 61 percent) in lower prevalence populations such as blood donors. EIA-2 also shortened the average \"window period\" for detection of seroconversion; the mean time to seroconversion after blood transfusion is 10 weeks, versus 16 weeks for the earlier assay. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/50/31530?source=see_link\">",
"     \"Clinical manifestations and natural history of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Overall, EIA-2 testing allows detection of anti-HCV in about 95 percent of individuals with HCV as confirmed by highly sensitive molecular tests such as the polymerase chain reaction (PCR) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/25\">",
"     25",
"    </a>",
"    ] or transcription-mediated amplification (TMA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A third version of the anti-HCV screening test (EIA-3) has been approved for screening blood products in the United States and has been introduced into the diagnostic setting at some institutions. EIA-3 adds an additional antigen from the nonstructural region (NS5). EIA-3 appears to have increased sensitivity in the high prevalence setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/27\">",
"     27",
"    </a>",
"    ] and slightly better specificity in the blood donor population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/24,28\">",
"     24,28",
"    </a>",
"    ]. In addition, the mean time to detection of seroconversion is shortened by two to three weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/41/40601?source=see_link\">",
"     \"Laboratory testing of donated blood\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For immunocompromised individuals, including those with HIV infection, patients on dialysis, and transplant recipients, anti-HCV may not be detectable despite the presence of HCV infection. For patients at risk for HCV infection or in whom HCV is suspected (such as those with an elevated serum ALT level), HCV RNA testing should be considered even if anti-HCV tests are negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An over-the-counter antibody testing kit (\"Hepatitis C Check\" [Home Access Health Corp.]) has been approved by the FDA. A sample is sent to the laboratory and results are returned within 4 to 10 business days. Data presented to the FDA suggest that the accuracy of the test is comparable to hospital laboratory-based antibody testing. The manufacturer provides a telemedicine service offering education, counseling, and clinician referral.",
"   </p>",
"   <p>",
"    A rapid test for HCV antibodies (OraQuick HCV Rapid Antibody Test, OraSure Technologies, Inc, Bethlehem, PA) has also been approved by the FDA. The results of the test are available in about 20 minutes. The test can be run on venous blood, finger stick blood, serum, plasma, and oral fluid. The test is designed for point-of-care testing to provide increased opportunities for HCV testing outside of traditional clinical settings. The tests run on venous blood and finger stick blood have been approved for use in facilities that can perform Clinical Laboratory Improvement Amendments of 1988 (CLIA)-waived tests, such as outreach clinics, community-based organizations, and clinician offices. Data suggest that the sensitivity and specificity of the test are equivalent to EIA testing. The test is performed on a test strip and does not require additional equipment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two other rapid tests, the Multiplo Rapid",
"    <span class=\"nowrap\">",
"     HIV/HCV",
"    </span>",
"    Antibody Test (MedMira, Inc, Halifax, Nova Scotia) and the Chembio Dual Path Platform (DPP) HCV Test (Chembio Diagnostic Systems, Inc, Medford, NY) have been developed, but are not FDA approved. These three rapid tests were compared in a study that used 1100 specimens from patients with a history of injection drug use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/34\">",
"     34",
"    </a>",
"    ]. The differences in sensitivities between the OraQuick (98 to 99 percent), Multiplo (87 to 88 percent), and Chembio (96 to 98 percent) tests were all statistically significant. There were no differences among the three tests with regard to specificity (all were greater than 99 percent specific).",
"   </p>",
"   <p>",
"    In a meta-analysis that included 18 trials, point-of-care tests had sensitivities of 98 to 99 percent and specificities of 98 to 100 percent for diagnosing HCV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CONFIRMATORY ASSAYS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Confirmatory assays were developed to aid clinicians in interpreting positive anti-HCV results, particularly in low prevalence situations when risk factors for hepatitis C are not evident. In other words, the tests are usually used to identify false positive EIA test results.",
"   </p>",
"   <p>",
"    These confirmatory assays have been supplanted by tests which directly detect HCV RNA. However, for individuals who are anti-HCV positive by screening tests (EIA) and negative for HCV RNA by sensitive molecular tests, the supplemental antibody tests, called RIBA-2 and RIBA-3 (meaning recombinant immunoblot assay, second version and third versions), can be used to distinguish a false positive antibody result from a case of past (but resolved) HCV infection. In the former, the RIBA test will be negative and in the latter the RIBA test will be positive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Recombinant immunoblot assay",
"    </span>",
"    &nbsp;&mdash;&nbsp;RIBA-2 contains the same HCV antigens as EIA-2 in immunoblot format. Thus, the test is not more sensitive, but it does confer increased specificity over the screening EIA assay. Patients who react to two or more HCV antigens by RIBA-2 are considered to have a positive result, while those who react to one antigen are considered to have an indeterminate test. RIBA-3 replaced the recombinant antigens C22-3 and C100-3 with synthetic peptides and added the NS5 protein. The RIBA-3 test is more sensitive than RIBA-2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/36\">",
"     36",
"    </a>",
"    ]. Results are reported as positive, negative, or indeterminate.",
"   </p>",
"   <p>",
"    RIBA should not be used as a screening test. It should only be performed on specimens with a positive EIA. A positive RIBA indicates past or current infection. Patients who have recovered from HCV infection may remain anti-HCV positive by EIA and RIBA for years.",
"   </p>",
"   <p>",
"    A negative RIBA indicates a false positive antibody test in the vast majority of individuals. The exceptions are those in the acute early phase of infection in whom antibodies may be absent but infection present, and in some immunocompromised populations such as transplant recipients or dialysis patients, who fail to make antibody. An indeterminate RIBA result indicates the EIA result cannot be interpreted and additional confirmatory testing is needed. Individuals with positive or indeterminate RIBA results require HCV RNA testing using a sensitive PCR or TMA method.",
"   </p>",
"   <p>",
"    The Centers for Disease Control and Prevention provides guidance to laboratories on the use of antibody and HCV RNA tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/9\">",
"     9",
"    </a>",
"    ]. These recommendations can also be applied to clinical practice.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No further testing is needed if EIA antibody results are negative.",
"     </li>",
"     <li>",
"      Positive EIA results require confirmatory testing using RIBA or sensitive HCV RNA tests. If supplemental RIBA testing is used, positive or indeterminant samples require HCV RNA testing. If HCV RNA tests are used, HCV RNA negative results require RIBA testing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In clinical practice, we recommend EIA be used to screen for HCV infection. In those testing positive by EIA, determination of HCV RNA should be performed using PCR or TMA. RIBA use should be reserved for patients who are HCV RNA negative, to distinguish past and resolved HCV infections (EIA and RIBA positive) versus a false positive result (EIA positive and negative RIBA).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     HCV RNA assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCV RNA detection and quantification are essential tools in the management of individuals with chronic HCV infection. As discussed above, HCV RNA tests are used to confirm the presence or absence of infection and to quantify the amount of HCV RNA present at specific time points during therapy to guide decisions regarding duration of treatment.",
"   </p>",
"   <p>",
"    All HCV RNA assays are calibrated using the World Health Organization HCV international unit standard to provide better accuracy and comparability of results across different assays. The standard is based upon the quantitative analysis of HCV RNA genotype 1. Results can vary between assays, especially for some non-1 HCV genotype specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. As a result, serial measurements of HCV RNA during treatment are ideally performed using the same assay throughout.",
"   </p>",
"   <p>",
"    Nucleic acid tests (NAT) for detection of HCV RNA have been traditionally divided into two categories: qualitative and quantitative assays.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1987503\">",
"    <span class=\"h3\">",
"     Qualitative tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Qualitative tests provide results as positive or negative and must have a lower limit of detection of &lt;50 international",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    HCV RNA. Examples of qualitative HCV RNA assays are Amplicor PCR assay (Roche Diagnostics) and Versant TMA assay (Siemens Healthcare Diagnostics). These tests differ in the method of amplifying HCV RNA, with the Amplicor assay using reverse transcription polymerase chain reaction (PCR) and the Versant assay using transcription-mediated amplification (TMA). These tests are capable of detecting low levels of HCV RNA and are used for confirming the diagnosis of HCV infection and assessing sustained virologic responses (SVR) to antiviral therapy.",
"   </p>",
"   <p>",
"    PCR-based methods, called target amplification, involve extraction of nucleic acid from the virus. The nucleic acid is then hybridized to short nucleotide primers, which are complementary to the virus sequence and amplified through controlled, repeated cycles of replication of the hybridized sequence until a quantity of DNA sufficient for detection is reached.",
"   </p>",
"   <p>",
"    TMA-based methods, like PCR, amplify target HCV RNA. The TMA-based method captures the extracted virus using magnetic microbeads and the subsequent amplification of DNA by reverse transcription occurs in an isothermal, autocatalytic fashion rather than the cycling conditions used for PCR. Like PCR, the amplified DNA is labeled with a detection probe and the amplified amount of virus determined by comparison to internal negative controls.",
"   </p>",
"   <p>",
"    The most sensitive standard PCR assays detect HCV RNA at concentrations of approximately 50 international",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    of patient serum and TMA methods detect HCV RNA at concentrations of approximately 10 international",
"    <span class=\"nowrap\">",
"     units/mL.",
"    </span>",
"    Real-time PCR methods are rapidly replacing standard PCR methods in clinical laboratories. These assays have greater sensitivity with lower detection limits of approximately 15 international",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    and a wide linear dynamic range (7 to 8 log(10) international",
"    <span class=\"nowrap\">",
"     units/mL).",
"    </span>",
"    In addition, since real-time PCR methods do not require specimen predilution, the risk of carryover contamination (which may lead to false positive HCV RNA results) is eliminated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1987511\">",
"    <span class=\"h3\">",
"     Quantitative tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quantitative assays assess the quantity of HCV RNA in international",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    and vary in their limits of detection and dynamic range. In the past, these assays were less sensitive than qualitative assays and were therefore not used for detection of infection or confirmation of viral clearance. More recently, real-time PCR methods have become commercially available. These assays are more sensitive than prior quantitative assays (limits of detection of approximately 10 to 15 international units",
"    <span class=\"nowrap\">",
"     /mL)",
"    </span>",
"    and have a wide dynamic range (7 to 8 log(10) international",
"    <span class=\"nowrap\">",
"     units/mL).",
"    </span>",
"    Thus, the real-time PCR assays offer the combined diagnostic capabilities of qualitative and quantitative assays. PCR-based methods use target amplification (see above) and bDNA methods use signal amplification.",
"   </p>",
"   <p>",
"    Signal amplification technologies such as bDNA do not amplify the viral nucleic acid, but rather hybridize it to specific probes that are more easily amplified for detection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/39\">",
"     39",
"    </a>",
"    ]. The bDNA assay is technically easier, less variable, and has a lower chance of cross-contamination. However, signal amplification currently lacks the sensitivity of PCR-based methods, with a lower limit of detection of 615 international",
"    <span class=\"nowrap\">",
"     units/mL.",
"    </span>",
"   </p>",
"   <p>",
"    Quantitative assays are used before treatment to measure baseline HCV viral load and during treatment to assess on-treatment response and to guide therapy (eg, stopping therapy in a patient who does not have an appropriate decline in HCV RNA during treatment). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=see_link&amp;anchor=H148833684#H148833684\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\", section on 'Monitoring viral load during therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/600?source=see_link&amp;anchor=H488641848#H488641848\">",
"     \"Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4\", section on 'Monitoring viral load during therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27990?source=see_link\">",
"     \"Response-guided therapy for chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Qualitative assays should be used for detection or exclusion of infection. Quantitative assays should be obtained prior to and during treatment to monitor the response to treatment. Once an assay has been selected, the same assay should be consistently used for monitoring the treatment response. A qualitative test is used to define an SVR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     HCV GENOTYPE TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis C virus (HCV) is an extremely heterogeneous family of viruses; at least six genotypes and numerous subtypes have been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/40\">",
"     40",
"    </a>",
"    ]. A variety of methods are available to identify genotypes. HCV genotyping is essential before treatment, since the genotype defines the duration of therapy and dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    . In addition, the genotype is an important predictor of the likelihood of obtaining a sustained virologic response. The commonly used method of genotyping is the line probe assay (INNO-LiPA HCV II, Siemens Healthcare Diagnostics), which provides genotype and subtype. Currently, only genotype (not subtype) is used in making clinical decisions regarding treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14474?source=see_link&amp;anchor=H16092652#H16092652\">",
"     \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\", section on 'Viral factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/5/29780?source=see_link&amp;anchor=H5#H5\">",
"     \"Characteristics of the hepatitis C virus\", section on 'Genotypes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     LIVER BIOPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A liver biopsy is not necessary for the diagnosis of hepatitis C virus (HCV) infection. However, many patients undergo liver biopsy prior to treatment of chronic HCV infection, although the utility of a routine biopsy continues to be debated. Despite these concerns, a liver biopsy has many practical advantages in the care of patients with HCV in whom treatment is being considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Liver histology is useful for determining the stage of disease, excluding other causes of liver test elevation, and guiding decisions regarding treatment (including treatment duration) and surveillance. Patients with cirrhosis, for example, should undergo periodic screening for hepatocellular carcinoma and upper endoscopy to evaluate for varices. In addition, patients with cirrhosis who are being treated for HCV may benefit from longer courses of therapy. Sampling variability on liver biopsy, however, may lead to the underdiagnosis of as many as 15 percent of patients with cirrhosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/41,42\">",
"       41,42",
"      </a>",
"      ]. A minimal length of 25 mm and more than 10 portal triads are desirable to evaluate fibrosis accurately [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/42,43\">",
"       42,43",
"      </a>",
"      ]. Smaller biopsies with fewer portal tracts tend to underestimate the stage of fibrosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/58/29608?source=see_link\">",
"       \"Percutaneous, fine-needle aspiration, and laparoscopic liver biopsy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/30/39398?source=see_link\">",
"       \"Histologic scoring systems for chronic liver disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients on treatment, the baseline liver histology can assist in decisions regarding medication adjustment in patients who experience adverse effects. As an example, the threshold to discontinue therapy may be relatively high in patients who have an advanced fibrosis stage.",
"     </li>",
"     <li>",
"      A liver biopsy can establish the presence of concomitant diseases (such as iron overload or fatty liver disease) and the degree to which these conditions contribute to the liver disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A 2009 guideline from the American Association for the Study of Liver Diseases recommends that a liver biopsy be considered in patients with chronic HCV if the patient and provider wish information regarding fibrosis stage for prognostic purposes or to make a decision regarding treatment. The guideline also notes that the noninvasive tests are useful for defining the presence or absence of advanced fibrosis but should not replace a liver biopsy in routine practice. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/59/30650?source=see_link\">",
"     \"Noninvasive assessment of hepatic fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     NONINVASIVE MEASURES OF FIBROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a liver biopsy is regarded as the gold standard for assessing the severity of chronic hepatitis C, a number of noninvasive tests have been developed for determining the degree of fibrosis. None of the noninvasive markers is used routinely in the United States, but they will likely have an evolving role in the diagnostic approach to chronic infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/59/30650?source=see_link\">",
"     \"Noninvasive assessment of hepatic fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TESTING APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sequence of diagnostic testing in an individual patient depends upon the clinical setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/11\">",
"     11",
"    </a>",
"    ]. Initial evaluation typically begins with an EIA-2. False negative results on EIA-2 are uncommon except in transplant patients, those on hemodialysis, and patients with advanced HIV infection. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Screening assays'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H21\">",
"     'Immunocompromised patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients suspected of having chronic hepatitis C virus (HCV) infection or with risk factors for HCV should be tested for HCV antibodies using EIA-2 or EIA-3.",
"     </li>",
"     <li>",
"      HCV RNA testing should be performed in those with a positive antibody test to confirm infection. In those with a negative HCV RNA test, RIBA testing should be obtained to determine if the initial positive EIA test was a false positive or whether the individual was exposed to HCV but has resolved infection. In those with unexplained liver disease whose anti-HCV test is negative and who are immunocompromised or suspected of having acute HCV infection, HCV RNA testing using qualitative or real-time PCR assay is recommended.",
"     </li>",
"     <li>",
"      HCV RNA quantitation (viral load) should be obtained in patients being considered for treatment. Outside of the context of treatment, serial HCV RNA measurements in those with chronic infection are not needed since the viral load does not have prognostic value. Both quantitative and qualitative tests are used during treatment to assess response.",
"     </li>",
"     <li>",
"      HCV genotype should be determined in all infected persons prior to treatment to determine the duration of therapy, dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      , and the likelihood of response.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Patients with a low pretest probability of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients without risk factors for HCV infection who have a positive EIA-2 (such as blood donors) require confirmatory testing, particularly if they have no biochemical evidence of chronic liver disease. Only 30 to 40 percent of EIA-2 positive patients with a normal serum ALT (such as blood donors) are RIBA positive (compared with 80 to 90 percent of those with chronic liver disease); another 20 to 40 percent are RIBA indeterminate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. HCV RNA is detectable by PCR in 70 to 90 percent of RIBA-positive individuals, compared with 2 to 40 percent of those with an indeterminate RIBA, and none of those with a negative RIBA. Overall, HCV RNA is detectable in 35 to 45 percent of these individuals; thus, confirmatory testing should",
"    <strong>",
"     always",
"    </strong>",
"    be performed in EIA-2 positive patients with a normal serum ALT and in others without established risk factors for infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/30/15847?source=see_link\">",
"     \"Approach to patients with chronic hepatitis C virus infection and normal serum aminotransferases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One approach is to test all such EIA-2 positive patients with HCV RNA using a sensitive assay (qualitative or real-time PCR) and reserve RIBA testing for those who are HCV RNA negative.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A positive HCV RNA result is evidence of HCV infection; further evaluation is indicated including consideration of liver biopsy to assess the extent of liver disease prior to therapy. Those who are candidates for treatment will require HCV RNA quantitation and HCV genotype testing.",
"     </li>",
"     <li>",
"      Patients with a negative HCV RNA test should be tested with RIBA. A positive RIBA in such patients is consistent with past infection. If the RIBA is negative or indeterminate, it most likely suggests a false positive antibody result (no prior infection).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Patients with a high pretest probability of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, over 90 percent of patients with biochemical or clinical evidence of chronic liver disease and a positive EIA-2 have chronic HCV infection, particularly if they have risk factors for HCV infection such as a history of transfusion, injection drug use, nasal cocaine use, or other percutaneous exposures. Such patients should undergo quantitative HCV RNA determination rather than qualitative HCV RNA testing, since the likelihood of chronic infection is high and the additional information provided by the quantitative assay can be used for management. In addition, genotyping and often a liver biopsy are undertaken before treatment.",
"   </p>",
"   <p>",
"    Patients who are HCV RNA negative should be retested in several months since some will be false negatives. Other causes of chronic liver disease should be sought in those who are repeatedly HCV RNA negative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Anti-HCV in the absence of HCV RNA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detection of anti-HCV does not necessarily imply the presence of HCV RNA in the serum. Absence of HCV RNA despite anti-HCV antibodies may be seen in a number of circumstances. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2169?source=see_link\">",
"     \"Epidemiology and transmission of hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibody to HCV may persist after the viral RNA has disappeared, representing patients who had been infected in the past but no longer harbor the virus. The estimated rate of spontaneous clearance of virus after infection is 20 to 45 percent depending upon the age and immune status of the individual at the time of infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/47\">",
"       47",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/50/31530?source=see_link\">",
"       \"Clinical manifestations and natural history of chronic hepatitis C virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      False positive results on antibody tests due to technical reasons.",
"     </li>",
"     <li>",
"      Detection of anti-HCV antibodies that have been passively acquired from blood transfusions. In this situation, anti-HCV disappears over the next few weeks in keeping with the half-life of IgG. This is now extremely unusual because of improved testing of the blood supply. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2169?source=see_link\">",
"       \"Epidemiology and transmission of hepatitis C virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Detection of maternal anti-HCV antibodies in babies. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26936?source=see_link\">",
"       \"Vertical transmission of hepatitis C virus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Viremia may be intermittent, with HCV RNA not being present in the serum at the time of testing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/48\">",
"       48",
"      </a>",
"      ]; this may be a less frequent occurrence than initially suspected [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The amount of HCV RNA may be below the limit of detection of the assay or there may be other technical problems with the test. This is less of an issue with current sensitive qualitative (TMA) and quantitative (real-time PCR) assays.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56252584\">",
"    <span class=\"h2\">",
"     HCV RNA in the absence of anti-HCV",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCV RNA may be positive in some patients who lack anti-HCV antibodies. This can be seen in immunocompromised patients or in the setting of acute HCV infection. In patients who are immunocompromised and in whom exclusion of HCV desired, HCV RNA testing should be obtained if antibody testing is negative. In patients suspected of having acute HCV, HCV RNA should be checked along with antibody testing. The HCV RNA test will be positive earlier after exposure than the antibody test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Immunocompromised patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients on hemodialysis, transplant recipients, and those with advanced HIV infection have a much higher rate of false negative EIAs than immunocompetent patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/31,50\">",
"     31,50",
"    </a>",
"    ]. Thus, HCV RNA testing should be performed in all patients who are immunocompromised and EIA-2 negative if there is clinical suspicion of infection. EIA-3 may be more sensitive than EIA-2 in hemodialysis patients, although more data are necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Acute hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;EIA-2 is positive in 50 percent of patients with acute HCV infection at the time of presentation, and in 90 percent at some time during the acute illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/52\">",
"     52",
"    </a>",
"    ]. Testing for HCV RNA by a quantitative assay allows earlier diagnosis, which may be important since early therapy can decrease the incidence of chronic infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18554?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of acute hepatitis C in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     AASLD GUIDELINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2009 guideline from the American Association for the Study of Liver Diseases recommends the following approach to diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41849/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients suspected of having acute or chronic HCV infection should first be tested for anti-HCV.",
"     </li>",
"     <li>",
"      HCV RNA testing should be performed in patients with a positive anti-HCV test, patients for whom antiviral treatment is being considered (using a sensitive quantitative assay), patients with unexplained liver disease whose anti-HCV test is negative and who are immunocompromised or suspected of having acute HCV infection.",
"     </li>",
"     <li>",
"      HCV genotyping should be performed in all HCV-infected persons being considered for treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97408565\">",
"    <span class=\"h1\">",
"     TESTING FOR HIV AND HEPATITIS B",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients diagnosed with HCV should also be tested for HIV and hepatitis B due to the common modes of transmission. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/34/10793?source=see_link\">",
"     \"Serologic screening for HIV infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42279?source=see_link\">",
"     \"Serologic diagnosis of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/39/32370?source=see_link\">",
"       \"Patient information: Hepatitis C (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/4/17478?source=see_link\">",
"       \"Patient information: Hepatitis C (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several organizations have provided guidelines for who should be tested for hepatitis C virus (HCV) infection. Despite having reviewed similar data and including experts, the various guidelines do not all agree. Our approach is similar to those of the Centers for Disease Control and Prevention and the American Association for the Study of Liver Disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Who should be tested'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H147402142\">",
"       'Authors' recommendations'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      We screen the following patients for HCV:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Anyone born in the United States between 1945 and 1965",
"     </li>",
"     <li>",
"      Those with a history of illicit injection drug use or intranasal cocaine use, even if only used once",
"     </li>",
"     <li>",
"      Those who received clotting factors made before 1987",
"     </li>",
"     <li>",
"      Those who received",
"      <span class=\"nowrap\">",
"       blood/organs",
"      </span>",
"      before July 1992",
"     </li>",
"     <li>",
"      Those who have been informed that they received blood from a donor who later tested positive for HCV",
"     </li>",
"     <li>",
"      Those who were ever on chronic hemodialysis",
"     </li>",
"     <li>",
"      Those with evidence of liver disease (persistently elevated alanine aminotransferase [ALT] level)",
"     </li>",
"     <li>",
"      Those infected with HIV",
"     </li>",
"     <li>",
"      Children born to HCV-infected mothers",
"     </li>",
"     <li>",
"      Those with a needle stick injury or mucosal exposure to HCV-positive blood",
"     </li>",
"     <li>",
"      Those who are a current sexual partner of an HCV-infected person",
"     </li>",
"     <li>",
"      Incarcerated individuals",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The actual sequence of diagnostic testing in an individual patient depends upon the clinical setting. Initial evaluation typically begins with an antibody test (EIA-2 or EIA-3). Subsequent testing depends upon the clinical setting. False negative results on EIA-2 or EIA-3 are uncommon except in patients who are immunocompromised. HCV RNA testing should be performed in all patients who are immunocompromised and EIA-2 negative if there is clinical suspicion of infection. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Testing approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Immunocompromised patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients without risk factors for HCV infection who have a positive EIA-2 (such as blood donors) require confirmatory testing, particularly if they have no biochemical evidence of chronic liver disease. Our approach is to test all such patients for HCV RNA with a molecular assay. Testing with RIBA is used in those who are HCV RNA negative to distinguish between false positive anti-HCV and recovered HCV infection. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Confirmatory assays'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Patients with a low pretest probability of infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with risk factors for HCV infection such as a history of transfusion, injection drug use, nasal cocaine use, or other percutaneous exposures may not need confirmatory testing but generally undergo quantitative HCV RNA determination, genotyping, and often a liver biopsy prior to treatment. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Patients with a high pretest probability of infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Absence of HCV RNA despite anti-HCV antibodies may be seen in a number of special circumstances. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Anti-HCV in the absence of HCV RNA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A diagnostic approach to suspected acute hepatitis C is presented separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18554?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of acute hepatitis C in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/1\">",
"      Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/2\">",
"      Rein DB, Smith BD, Wittenborn JS, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 2012; 156:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/3\">",
"      McGarry LJ, Pawar VS, Panchmatia HR, et al. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology 2012; 55:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/4\">",
"      Duncan CJ, Stewart E, Fox R. Improving targeted screening for hepatitis C in the UK. BMJ 2012; 345:e6525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/5\">",
"      Sroczynski G, Esteban E, Conrads-Frank A, et al. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection. Eur J Public Health 2009; 19:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/6\">",
"      Weinbaum C, Lyerla R, Margolis HS, Centers for Disease Control and Prevention. Prevention and control of infections with hepatitis viruses in correctional settings. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/7\">",
"      Spaulding AC, Thomas DL. Screening for HCV infection in jails. JAMA 2012; 307:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/8\">",
"      Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/9\">",
"      Alter MJ, Kuhnert WL, Finelli L, Centers for Disease Control and Prevention. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/10\">",
"      Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/11\">",
"      Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/12\">",
"      U.S. Preventive Services Task Force. Screening for hepatitis C virus infection in adults: recommendation statement. Ann Intern Med 2004; 140:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/13\">",
"      Chou R, Cottrell EB, Wasson N, et al. Screening for hepatitis C virus infection in adults: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2013; 158:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/14\">",
"      Calonge N, Randhawa G, U.S. Preventive Services Task Force. The meaning of the U.S. Preventive Services Task Force grade I recommendation: screening for hepatitis C virus infection. Ann Intern Med 2004; 141:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/15\">",
"      Alter MJ, Seeff LB, Bacon BR, et al. Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. Ann Intern Med 2004; 141:715.",
"     </a>",
"    </li>",
"    <li>",
"     file://consensus.nih.gov/1997/1997HepatitisC105html.htm (Accessed on August 20, 2012).",
"    </li>",
"    <li>",
"     file://consensus.nih.gov/2002/2002hepatitisc2002116html.htm (Accessed on August 20, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/18\">",
"      European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55:245.",
"     </a>",
"    </li>",
"    <li>",
"     www.nhs.uk/Livewell/hepatitisc/Documents/Information-for-professionals-19.05.061for-web-15600.pdf (Accessed on August 20, 2012).",
"    </li>",
"    <li>",
"     www.snfge.asso.fr/01-Bibliotheque/0D-Pratiques-cliniques/HAS/depistage_vhc_2001_rapport.pdf (Accessed on August 20, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/21\">",
"      Younossi Z, McHutchison J. Serological tests for HCV infection. Viral Hepatitis Reviews 1996; 2:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/22\">",
"      Houghton M, Weiner A, Han J, et al. Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease. Hepatology 1991; 14:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/23\">",
"      Alter HJ. New kit on the block: evaluation of second-generation assays for detection of antibody to the hepatitis C virus. Hepatology 1992; 15:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/24\">",
"      Gretch DR. Diagnostic tests for hepatitis C. Hepatology 1997; 26:43S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/25\">",
"      Gretch D, Lee W, Corey L. Use of aminotransferase, hepatitis C antibody, and hepatitis C polymerase chain reaction RNA assays to establish the diagnosis of hepatitis C virus infection in a diagnostic virology laboratory. J Clin Microbiol 1992; 30:2145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/26\">",
"      Gorrin G, Friesenhahn M, Lin P, et al. Performance evaluation of the VERSANT HCV RNA qualitative assay by using transcription-mediated amplification. J Clin Microbiol 2003; 41:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/27\">",
"      Kao JH, Lai MY, Hwang YT, et al. Chronic hepatitis C without anti-hepatitis C antibodies by second-generation assay. A clinicopathologic study and demonstration of the usefulness of a third-generation assay. Dig Dis Sci 1996; 41:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/28\">",
"      Busch MP, Tobler LH, Tegtmeier G, et al. Use of third-generation hepatitis C virus (HCV) enzyme immunoassay (EIA) to resolve second-generation HCV EIA-reactive and second-generation recombinant immunoblot assay-indeterminate blood samples: data to support current Food and Drug Administration guidance on HCV lookback. Transfusion 2000; 40:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/29\">",
"      Uyttendaele S, Claeys H, Mertens W, et al. Evaluation of third-generation screening and confirmatory assays for HCV antibodies. Vox Sang 1994; 66:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/30\">",
"      Lok AS, Chien D, Choo QL, et al. Antibody response to core, envelope and nonstructural hepatitis C virus antigens: comparison of immunocompetent and immunosuppressed patients. Hepatology 1993; 18:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/31\">",
"      Pereira BJ, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997; 51:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/32\">",
"      Pereira BJ, Milford EL, Kirkman RL, et al. Prevalence of hepatitis C virus RNA in organ donors positive for hepatitis C antibody and in the recipients of their organs. N Engl J Med 1992; 327:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/33\">",
"      Lee SR, Yearwood GD, Guillon GB, et al. Evaluation of a rapid, point-of-care test device for the diagnosis of hepatitis C infection. J Clin Virol 2010; 48:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/34\">",
"      Smith BD, Drobeniuc J, Jewett A, et al. Evaluation of three rapid screening assays for detection of antibodies to hepatitis C virus. J Infect Dis 2011; 204:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/35\">",
"      Shivkumar S, Peeling R, Jafari Y, et al. Accuracy of rapid and point-of-care screening tests for hepatitis C: a systematic review and meta-analysis. Ann Intern Med 2012; 157:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/36\">",
"      Tobler LH, Lee SR, Stramer SL, et al. Performance of second- and third-generation RIBAs for confirmation of third-generation HCV EIA-reactive blood donations. Retrovirus Epidemiology Donor Study. Transfusion 2000; 40:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/37\">",
"      Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology 2007; 46:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/38\">",
"      Vermehren J, Kau A, G&auml;rtner BC, et al. Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification. J Clin Microbiol 2008; 46:3880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/39\">",
"      Martinot-Peignoux M, Marcellin P, Gournay J, et al. Detection and quantitation of serum HCV-RNA by branched DNA amplification in anti-HCV positive blood donors. J Hepatol 1994; 20:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/40\">",
"      Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995; 15:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/41\">",
"      Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97:2614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/42\">",
"      Bedossa P, Darg&egrave;re D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/43\">",
"      Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003; 39:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/44\">",
"      Lok AS, Gunaratnam NT. Diagnosis of hepatitis C. Hepatology 1997; 26:48S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/45\">",
"      Salmer&oacute;n FJ, Palacios A, P&eacute;rez-Ruiz M, et al. Epidemiology, serological markers, and hepatic disease of anti-HCV ELISA-2-positive blood donors. Dig Dis Sci 1996; 41:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/46\">",
"      Prieto M, Olaso V, Verd&uacute; C, et al. Does the healthy hepatitis C virus carrier state really exist? An analysis using polymerase chain reaction. Hepatology 1995; 22:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/47\">",
"      Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36:S35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/48\">",
"      Page K, Osburn W, Evans J, et al. Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection. Clin Infect Dis 2013; 56:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/49\">",
"      Nguyen TT, Sedghi-Vaziri A, Wilkes LB, et al. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. J Viral Hepat 1996; 3:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/50\">",
"      Lau JY, Davis GL, Brunson ME, et al. Hepatitis C virus infection in kidney transplant recipients. Hepatology 1993; 18:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/51\">",
"      Soffredini R, Rumi M, Lampertico P, et al. Increased detection of antibody to hepatitis C virus in renal transplant patients by third-generation assays. Am J Kidney Dis 1996; 28:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41849/abstract/52\">",
"      Barrera JM, Bruguera M, Ercilla MG, et al. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 1995; 21:639.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3674 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-CBA3D06F7A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_55_41849=[""].join("\n");
var outline_f40_55_41849=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      WHO SHOULD BE TESTED",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H147402142\">",
"      Authors' recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H147402317\">",
"      Recommendations from groups in the United States",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Centers for Disease Control and Prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - American Association for the Study of Liver Diseases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H147402266\">",
"      - United States Preventive Services Task Force",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H147402228\">",
"      - National Institutes of Health",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H256798872\">",
"      Recommendations from groups outside of the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ANTIBODY TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Screening assays",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CONFIRMATORY ASSAYS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Recombinant immunoblot assay",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      HCV RNA assays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1987503\">",
"      - Qualitative tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1987511\">",
"      - Quantitative tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Recommendation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      HCV GENOTYPE TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      LIVER BIOPSY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      NONINVASIVE MEASURES OF FIBROSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TESTING APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Patients with a low pretest probability of infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Patients with a high pretest probability of infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Anti-HCV in the absence of HCV RNA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56252584\">",
"      HCV RNA in the absence of anti-HCV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Immunocompromised patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Acute hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      AASLD GUIDELINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H97408565\">",
"      TESTING FOR HIV AND HEPATITIS B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/30/26087?source=related_link\">",
"      A short primer on cost-effectiveness analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/30/15847?source=related_link\">",
"      Approach to patients with chronic hepatitis C virus infection and normal serum aminotransferases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/5/29780?source=related_link\">",
"      Characteristics of the hepatitis C virus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/50/31530?source=related_link\">",
"      Clinical manifestations and natural history of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18554?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of acute hepatitis C in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2169?source=related_link\">",
"      Epidemiology and transmission of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/30/39398?source=related_link\">",
"      Histologic scoring systems for chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/41/40601?source=related_link\">",
"      Laboratory testing of donated blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/59/30650?source=related_link\">",
"      Noninvasive assessment of hepatic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/45/43735?source=related_link\">",
"      Overview of the management of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/4/17478?source=related_link\">",
"      Patient information: Hepatitis C (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/39/32370?source=related_link\">",
"      Patient information: Hepatitis C (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/58/29608?source=related_link\">",
"      Percutaneous, fine-needle aspiration, and laparoscopic liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14474?source=related_link\">",
"      Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27990?source=related_link\">",
"      Response-guided therapy for chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42279?source=related_link\">",
"      Serologic diagnosis of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/34/10793?source=related_link\">",
"      Serologic screening for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/600?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26936?source=related_link\">",
"      Vertical transmission of hepatitis C virus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_55_41850="Management of potentially resectable colorectal cancer liver metastases";
var content_f40_55_41850=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of potentially resectable colorectal cancer liver metastases",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/55/41850/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/55/41850/contributors\">",
"     Alan P Venook, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/55/41850/contributors\">",
"     Steven A Curley, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/55/41850/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/55/41850/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/55/41850/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/55/41850/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/55/41850/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 142,820 Americans are diagnosed with colon or rectal cancer annually, and 52,390 will die from this disease, most with metastatic tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/1\">",
"     1",
"    </a>",
"    ]. Global, country-specific data on incidence and mortality are available from the World Health Organization",
"    <a class=\"external\" href=\"file://globocan.iarc.fr/\">",
"     GLOBOCAN database",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Hepatic metastatic disease from colorectal cancer (CRC) is a significant clinical problem. The liver is the dominant metastatic site for patients with CRC, and although two-thirds of affected patients have extrahepatic spread, some have disease that is isolated to the liver. For patients with isolated liver metastases, regional treatment approaches may be considered as an alternative to systemic chemotherapy.",
"   </p>",
"   <p>",
"    The available regional treatments for hepatic metastases from CRC include surgical resection, local tumor ablation (ie, instillation of alcohol or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    directly into the metastatic lesions, radiofrequency ablation [RFA]), regional hepatic intraarterial chemotherapy or chemoembolization, and radiation therapy (RT). Among these treatments, only surgery is associated with a survival plateau.",
"   </p>",
"   <p>",
"    Although hepatic resection used to be reserved for patients with a maximum of three lesions in the same lobe if it was possible to achieve 1 cm margins and those without portal lymph node metastases, all of these \"rules\" have been challenged in the modern era, particularly with advancements in both surgical technique and systemic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/2\">",
"     2",
"    </a>",
"    ]. Profound improvements in the outcomes of patients with metastatic CRC over the past 15 years have been attributed to increased use of hepatic resection in selected patients and more effective chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result, the criteria for defining which patients are suited for surgical therapy have evolved, and many surgeons take an aggressive stance in the management of hepatic metastases.",
"   </p>",
"   <p>",
"    This topic review will focus on resection and the role of systemic chemotherapy. Methods and results for local ablation, regional chemotherapy into the hepatic artery, radiation therapy, and management of the primary tumor in patients who present with stage IV disease are addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/36/28234?source=see_link\">",
"     \"Nonsurgical local treatment strategies for colorectal cancer liver metastases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/29/19930?source=see_link\">",
"     \"Locoregional methods for management and palliation in patients who present with stage IV colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BIOPSY CONFIRMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A biopsy may be indicated to confirm the diagnosis, depending upon the clinical picture. The risk of tract seeding from percutaneous fine needle aspiration (FNA) biopsy appears small (only a handful of case reports are described in journals listed in Medline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/4-10\">",
"     4-10",
"    </a>",
"    ]), although this complication was described in five of 51 cases of biopsy-proven hepatic colorectal metastases in one series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/11\">",
"     11",
"    </a>",
"    ]. Needle tract seeding more often complicates FNA biopsy of primary liver tumors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/10/34986?source=see_link&amp;anchor=H27#H27\">",
"     \"Clinical features and diagnosis of primary hepatocellular carcinoma\", section on 'Histopathology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SURGICAL RESECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resection offers the greatest likelihood of cure for patients with liver-isolated CRC. In surgical case series, five-year survival rates after resection range from 24 to 58 percent, averaging 40 percent (",
"    <a class=\"graphic graphic_table graphicRef74509 \" href=\"mobipreview.htm?23/60/24524\">",
"     table 1",
"    </a>",
"    ), and surgical mortality rates are generally &lt;5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/4-6,8-19\">",
"     4-6,8-19",
"    </a>",
"    ]. Subgroups with advanced age, comorbid disease, and synchronous hepatic and colon resection may have higher procedure-related mortality and worse long-term outcomes. As an example, five-year survival rate was only 25 percent in a population-based retrospective report of 3957 US Medicare enrollees undergoing hepatic resection for colorectal cancer liver metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/20\">",
"     20",
"    </a>",
"    ]. Even so, five-year survival rates with the most active systemic chemotherapy regimens are only 10 to 11 percent, only about one-fifth of whom have a sustained disease remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/20/21833?source=see_link&amp;anchor=H183911606#H183911606\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: General principles\", section on 'Chemotherapy versus supportive care'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately one-third of five-year survivors suffer a cancer-related death, while those who survive 10 years appear to be cured [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/22\">",
"     22",
"    </a>",
"    ]. In an analysis of 612 consecutive patients who underwent resection of CRC liver metastases and were followed for at least 10 years, there were 102 actual 10-year survivors (17 percent), and only one patient experienced a disease-specific death after 10 years of survival.",
"   </p>",
"   <p>",
"    Because of its clear survival impact, surgical resection is the treatment of choice when feasible. Unfortunately, no more than 20 percent of patients with isolated hepatic metastases are amenable to potentially curative resection. Most are not surgical candidates because of tumor size, location, multifocality, or inadequate hepatic reserve.",
"   </p>",
"   <p>",
"    Some patients with initially unresectable disease may become resectable after induction chemotherapy, although the frequency with which this occurs depends on many factors, including the subjective assessment of resectability by the liver surgeon and is probably on the order of 5 to 15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/23\">",
"     23",
"    </a>",
"    ] for a patient who has truly unresectable disease. Updated guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    suggest that patients who appear to have initially unresectable metastatic colorectal cancer be categorized as potentially convertible or unconvertible. Patients whose disease is felt to be unconvertible should be referred for alternative treatment (most often palliative chemotherapy), while induction chemotherapy is appropriate for those whose disease is potentially convertible. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Neoadjuvant chemotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal selection of patients for hepatic resection is evolving, and the criteria for resectability differ among individual liver surgeons regarding borderline cases, from center to center and from country to country. One consensus statement defined absolute unresectability as nontreatable extrahepatic disease, unfitness for surgery, or involvement of more than 70 percent of the liver or six segments (",
"    <a class=\"graphic graphic_figure graphicRef81897 \" href=\"mobipreview.htm?13/35/13878\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Conversion therapy for initially unresectable metastases'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Risk scoring systems (such as the clinical risk score [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/12\">",
"     12",
"    </a>",
"    ] and others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/8,25,26\">",
"     8,25,26",
"    </a>",
"    ]) to predict which patients with metastatic CRC are most likely to benefit from resection are of limited clinical utility, particularly among patients undergoing neoadjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Whether changes in the clinical risk score after treatment translates into improved outcomes after resection is unknown. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Conversion therapy for initially unresectable metastases'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Modern multidisciplinary consensus defines resectable CRC liver metastases simply as tumors that can be resected completely, leaving an adequate liver remnant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/30\">",
"     30",
"    </a>",
"    ]. For resection to be considered, most surgeons would require that there be no radiographic evidence of involvement of the hepatic artery, major bile ducts, main portal vein, or",
"    <span class=\"nowrap\">",
"     celiac/paraaortic",
"    </span>",
"    lymph nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/31\">",
"     31",
"    </a>",
"    ], and adequate predicted functional hepatic reserve postresection. Preoperative liver MRI and intraoperative ultrasound offer the optimal assessment of the number, size, and proximity of tumors to key vascular and biliary structures. Complete resection must be feasible. There should be no unresectable extrahepatic sites of disease, and the primary tumor should have been resected for cure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concurrent resection of hepatic and extrahepatic disease in well-selected patients is associated with a possibility of long-term survival, particularly if the extrahepatic disease is surgically resectable lung or ovarian metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13560?source=see_link\">",
"     \"Surgical resection of pulmonary metastases: Outcomes by histology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/29/19930?source=see_link\">",
"     \"Locoregional methods for management and palliation in patients who present with stage IV colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The modern approach to resection of CRC liver metastases is outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef52622 \" href=\"mobipreview.htm?5/39/5756\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14008291\">",
"    <span class=\"h3\">",
"     Number and location of metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contrast-enhanced magnetic resonance imaging (MRI) of the liver identifies more hepatic lesions than are visualized by CT, and is the preferred first-line imaging study for evaluating colorectal cancer liver metastases in patients who have not previously undergone therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/33/17946?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical manifestations, diagnosis, and staging of colorectal cancer\", section on 'Liver MRI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted above, the optimal selection of patients who are candidates for resection is evolving. In the past, contraindications to liver resection were defined by retrospective series and recapitulated in a large multi-institutional review of 856 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/10\">",
"     10",
"    </a>",
"    ]. Based upon these analyses, surgeons have been reluctant to offer resection to patients with more than three lesions, those with bilobar distribution (ie, tumor involving any segments of the left and right hemi-liver), those in whom it was not possible to achieve 1 cm margins, patients with portal lymph node or other extrahepatic metastases, and those with liver metastases from cancers other than colorectal tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, these relative contraindications have been challenged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With safer surgery and better chemotherapy, hepatic resection is playing an increasing role in patients with multiple, even bilobar tumors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/35-42\">",
"       35-42",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Neoadjuvant chemotherapy'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H19\">",
"       'Therapy after resection of liver metastases'",
"      </a>",
"      below.) As an example, in a report of 484 patients with multiple metastases (136 with &ge;4, 36 with &ge;8) five-and ten-year survival was 47 and 29 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/37\">",
"       37",
"      </a>",
"      ]. Even patients with &ge;8 metastases had a five-year survival rate of 24 percent.",
"      <br/>",
"      <br/>",
"      A two-stage approach to hepatic resection may be needed in the presence of multiple bilobar metastases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/38,42,43\">",
"       38,42,43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The importance of achieving wide margins was addressed in a multicenter report of 557 patients who underwent resection for CRC liver metastases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/44\">",
"       44",
"      </a>",
"      ]. There was no difference in five-year overall survival rate or in the rate of tumor recurrence in the liver whether the tumor-free margin was 1 to 4, 5 to 9, or &gt;10 mm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/44\">",
"       44",
"      </a>",
"      ]. Only patients with a positive margin had worse survival and a higher intrahepatic recurrence rate. Similar results have been noted by others [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/41,45\">",
"       41,45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One of the classic contraindications to hepatectomy is the presence of portal lymph node metastases, thought to indicate systemic disease that could not be successfully treated surgically. This view has been challenged [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/31,46-49\">",
"       31,46-49",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A major problem is the prediction of metastatic lymph nodes in the hepatic pedicle in patients with CRC liver metastases. In one analysis, the positive predictive value (PPV) of preoperative CT was only 56 percent, and even intraoperative evaluation had a PPV of only 43 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/50\">",
"       50",
"      </a>",
"      ]. Accurate oncologic assessment requires systematic pedicular lymph node clearance, although this maneuver is not known to be of any therapeutic value.",
"      <br/>",
"      <br/>",
"      The presence of portal node metastases is not inevitably associated with distant metastases. Jaeck et al reported outcomes of complete hepatic pedicle lymphadenectomy in patients with CRC liver metastases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/46\">",
"       46",
"      </a>",
"      ]. Nineteen percent of patients survived three years despite portal node metastases. Outcome was more favorable if nodal involvement was limited to the porta as compared to along the common hepatic artery (three-year survival 38 versus 0 percent, respectively). An important caveat is that this was a retrospective review of highly selected patients who did not have enlarged portal nodes detected preoperatively. Whether this principle can be extrapolated to patients with grossly enlarged nodes is unclear.",
"     </li>",
"     <li>",
"      Similarly, the presence of other sites of limited extrahepatic metastases (particularly lung) should not be considered a contraindication to resection as long as the disease is amenable to complete extirpation. However, outcomes in this group are not as favorable, particularly when there are &gt;6 liver metastases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/51\">",
"       51",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13560?source=see_link&amp;anchor=H4#H4\">",
"       \"Surgical resection of pulmonary metastases: Outcomes by histology\", section on 'Significance of synchronous or metachronous liver metastases'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     PET scans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whole body PET scans can identify radiographically occult extrahepatic disease and optimize the selection of appropriate candidates for hepatic resection, mainly by reducing nontherapeutic laparotomy rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/4,52-54\">",
"     4,52-54",
"    </a>",
"    ]. The benefits of PET can be illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The superiority of PET over CT for detection of extrahepatic disease was suggested in a systematic overview of retrospective data which utilized a scoring system to weigh the individual studies according to the quality of the data and the clinical impact of the radiographic findings [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/52\">",
"       52",
"      </a>",
"      ]. For the six articles judged to be of the highest quality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/55-60\">",
"       55-60",
"      </a>",
"      ], the pooled sensitivity and specificity for PET were 80 and 92 percent, respectively, for hepatic disease, and 91 and 98 percent, respectively, for extrahepatic disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/52\">",
"       52",
"      </a>",
"      ]. The corresponding values for CT were 83 and 84 percent, respectively, for hepatic metastases, and 61 and 91 percent, respectively, for extrahepatic metastases. The percent change in clinical management from the performance of PET ranged from 20 to 32 percent (average 25 percent).",
"     </li>",
"     <li>",
"      The benefit of adding PET to the staging strategy was subsequently shown in a randomized trial in which 150 patients with CRC liver metastases selected for hepatic resection by CT were randomly assigned to triple-phase contrast-enhanced CT imaging only or CT plus a separate PET scan [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/53\">",
"       53",
"      </a>",
"      ]. The primary outcome measure was the number of futile laparotomies (any laparotomy that did not result in complete tumor treatment or that did not result in a disease-free survival period of at least six months). In a preliminary report, the addition of PET significantly reduced the number of futile surgeries (28 versus 45 percent) and prevented unnecessary surgery in one of every six patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two caveats must be considered when interpreting these results. First, this study used separate contrast-enhanced CT and PET images and not the increasingly popular integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    imaging, in which both PET and CT are performed sequentially during a single visit on a hybrid",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scanner. The CT component of integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    imaging is performed in most institutions without the use of intravenous contrast material, which compromises the detection of small metastases both within and outside of the liver. At some institutions,",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    is carried out with intravenous contrast, but this practice is not widespread.",
"   </p>",
"   <p>",
"    Secondly, the results of restaging PET scans (particularly if negative) must be interpreted in the context of recent therapy. Chemotherapy may reduce the sensitivity of PET for the detection of liver metastases, thought due to decreased cellular metabolic activity following chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. In one study, the false-negative rate for hepatic metastases of a PET scan performed within four weeks of chemotherapy was 87 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/62\">",
"     62",
"    </a>",
"    ]. Surgical decisions should not be based on PET scan results.",
"   </p>",
"   <p>",
"    Guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    recommend a staging PET scan for patients with potentially surgically curable metastatic colorectal cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14008586\">",
"    <span class=\"h3\">",
"     Selecting patients for diagnostic laparoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although diagnostic laparoscopy can identify occult intraperitoneal metastases, thereby preventing unnecessary laparotomy, it is not necessary in all patients. Laparoscopy is usually reserved for those thought to be at the highest risk for occult metastatic disease.",
"   </p>",
"   <p>",
"    Some data suggest that these patients can be identified using a clinical risk score, derived from five preoperative criteria (nodal positivity, relapse free interval &lt;12 months, more than one hepatic tumor, CEA level &gt;200",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    within one month of surgery, and size of largest hepatic tumor &gt;5 cm), which were significant predictors of outcome from hepatic resection in multivariate analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/12,64\">",
"     12,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the clinical risk score is not used by the vast majority of hepatobiliary surgeons, mainly because it was derived from a database of patients treated in the",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    era, before chemotherapy was routinely administered prior to liver resection, and before resection of numerous liver lesions became commonplace. In modern treatment paradigms, laparoscopy is infrequently performed, particularly since many patients have undergone surgical exploration of the peritoneum at the time of resection of a synchronous primary tumor.",
"   </p>",
"   <p>",
"    We use diagnostic laparoscopy in patients with a suspicion of small volume carcinomatosis on radiographic imaging studies (ie, CT, MRI, or PET) and for selected other cases at high risk (eg, a metachronous presentation with several liver metastases that do not respond to chemotherapy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     NEOADJUVANT CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The availability of increasingly effective systemic chemotherapy has prompted interest in preoperative or neoadjuvant systemic chemotherapy prior to liver resection. While initial systemic chemotherapy is often undertaken as a means of assessing the natural history of metastatic disease prior to embarking on metastasectomy (particularly in patients with a synchronous presentation of metastatic disease), it may also be considered as a means of \"downsizing\" liver metastases prior to resection to lessen the complexity of hepatic metastasectomy or for initially unresectable metastatic disease. Preoperative hepatic intraarterial chemotherapy is discussed below. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Role of hepatic intraarterial (HIA) chemotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5842613\">",
"    <span class=\"h2\">",
"     Chemotherapy-related liver toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enthusiasm for systemic chemotherapy prior to hepatic resection has been tempered by reports of steatosis (chemotherapy-associated steatohepatitis, CASH), vascular injury, and nodular regenerative hyperplasia in the livers of patients treated with preoperative",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -containing chemotherapy regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/65-76\">",
"     65-76",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"     \"Treatment protocols for colorectal cancer\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatic sinusoidal abnormalities (termed sinusoidal obstruction syndrome) have been described that are similar to those that characterize veno-occlusive disease, predominantly in patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      prior to hepatic metastasectomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/69,72,73,75-80\">",
"       69,72,73,75-80",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/4/40009?source=see_link\">",
"       \"Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In one study, such changes were present in 44 (51 percent) of 87 hepatic specimens from patients who had received preoperative chemotherapy, 77 percent oxaliplatin-containing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/69\">",
"       69",
"      </a>",
"      ]. None of these changes were seen in the 66 patients undergoing liver resection who had not received preoperative chemotherapy.",
"     </li>",
"     <li>",
"      In addition to vascular changes, nodular regenerative hyperplasia (precluding subsequent resection) has been reported in three patients treated with neoadjuvant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      plus 5-FU for liver metastases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/74\">",
"       74",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/14/37095?source=see_link\">",
"       \"Nodular regenerative hyperplasia of the liver\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       Irinotecan",
"      </a>",
"      -containing regimens are more often been associated with steatosis and steatohepatitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/68,72,76,80\">",
"       68,72,76,80",
"      </a>",
"      ]. One report compared outcomes from hepatic metastasectomy in 325 patients with steatosis and 160 patients without steatosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/68\">",
"       68",
"      </a>",
"      ]. Of the patients with markedly steatotic livers, 66 percent had received preoperative chemotherapy with a fluoropyrimidine,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      ,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      irinotecan. Although mortality was not significantly worse in patients with steatotic as compared to nonsteatotic livers, marked steatosis was an independent predictor of perioperative infectious complications.",
"      <br/>",
"      <br/>",
"      Steatohepatitis has been observed more frequently after chemotherapy in patients with a higher body mass index, which may explain why this complication is reported more frequently in US studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/70\">",
"       70",
"      </a>",
"      ], while vascular lesions are seen more commonly in Europeans [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/66,68,69,73,75,77,78\">",
"       66,68,69,73,75,77,78",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are conflicting data as to whether sinusoidal damage or steatohepatitis increase the risk of perioperative",
"    <span class=\"nowrap\">",
"     morbidity/mortality",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/72,77,81,82\">",
"     72,77,81,82",
"    </a>",
"    ]. In one study, patients with steatohepatitis had a significantly higher 90-day mortality rate as compared to those without steatohepatitis (15 versus 2 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/72\">",
"     72",
"    </a>",
"    ]. Others suggest that risk depends on the duration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    timing of preoperative therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/73,83,84\">",
"     73,83,84",
"    </a>",
"    ]. In one report, administration of more than 12 weeks of chemotherapy, or an interval of four or fewer weeks between stopping chemotherapy and resection predisposed patients to more postsurgical complications, higher rates of reoperation, and longer hospital stay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Emerging data suggest utility for superparamagnetic iron oxide-enhanced MRI in the preoperative detection of sinusoidal damage in patients who have received neoadjuvant chemotherapy. In one report, 24 of 60 patients treated with neoadjuvant chemotherapy (mostly 12 or more weeks of an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based regimen) were suspected of having moderate to severe sinusoidal obstruction by MRI, and 23 cases were confirmed at surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/75\">",
"     75",
"    </a>",
"    ]. The sensitivity, specificity, positive predictive value, and negative predictive value of MRI were 87, 89, 83, and 92 percent, respectively. This MRI technique is not widely available.",
"   </p>",
"   <p>",
"    Furthermore, whether patients who are identified noninvasively as having this pattern of liver damage after neoadjuvant chemotherapy can be more safely resected after a delay and how much of a delay is needed is uncertain.",
"   </p>",
"   <p>",
"    Others suggest that increases in spleen size during",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    therapy represent a biomarker for hepatic sinusoidal injury and resultant portal hypertension, and could serve as a simple method for identifying patients at risk for this complication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/85\">",
"     85",
"    </a>",
"    ]. In our experience, this is rarely clinically helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5842661\">",
"    <span class=\"h2\">",
"     Issues related to bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;The addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    to an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    - or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -based regimen results in a modestly higher frequency of tumor regression compared to regimens that do not include bevacizumab. However, these benefits have come at the cost of significant treatment-related toxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H516273937#H516273937\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'First-line use'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20653035\">",
"    <span class=\"h3\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    is associated with major complications that could interfere with metastasectomy, such as stroke and arterial thromboembolic events (approximately 2 percent), bowel perforation (2 percent), and bleeding (2 percent grade 3 to 4). Furthermore, concerns about impaired wound healing and possibly impaired hepatic regeneration may affect the safety of metastasectomy, particularly if performed too soon after bevacizumab administration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The safety of metastasectomy in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    prior to resection has been addressed in multiple retrospective series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/86-93\">",
"     86-93",
"    </a>",
"    ], none of which suggest excess problems with bleeding, wound healing, or functional recovery. Whether bevacizumab impairs hepatic regeneration after portal vein embolization (which increases resectability by increasing the volume of the future hepatic remnant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/94\">",
"     94",
"    </a>",
"    ]) is unclear; the available data are conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/95-97\">",
"     95-97",
"    </a>",
"    ]. The rationale and technique for portal vein embolization in patients undergoing liver resection is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/63/24569?source=see_link&amp;anchor=H1124057405#H1124057405\">",
"     \"Hepatic resection\", section on 'Preoperative portal vein embolization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the long half-life of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    (20 days), it is commonly recommended that at least 28 days, but preferably six to eight weeks should elapse between the last dose of bevacizumab and elective hepatic resection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H91044850#H91044850\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Hepatic metastasectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the available data correlating the incidence of postoperative complications and the time since the last",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    dose are conflicting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At least some data suggest that the interval between",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      and surgery can be shortened to 5 weeks without an increase in perioperative complications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/86\">",
"       86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a report from the community-based BRiTE observational cohort of 521 patients who had surgery after",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      , the incidence of serious wound complications in patients who had their last dose les than 2 weeks, 2 to 4 weeks, 4 to 6 weeks, 6 to 8 weeks, or &ge;8 weeks before surgery was 10, 3, 3, 6, and 2 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/98\">",
"       98",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Others have found no association between postoperative complications and days from last",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      dose (&le;60 versus &gt;60 days) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/90\">",
"       90",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    to a neoadjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based regimen",
"    <strong>",
"     may",
"    </strong>",
"    reduce the incidence and severity of oxaliplatin-related liver injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/80,93,99,100\">",
"     80,93,99,100",
"    </a>",
"    ]. However, this finding has not been prospectively validated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5842675\">",
"    <span class=\"h2\">",
"     Response evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard criteria such as RECIST (Response Evaluation Criteria in Solid Tumors, (",
"    <a class=\"graphic graphic_table graphicRef74693 \" href=\"mobipreview.htm?41/48/42764\">",
"     table 3",
"    </a>",
"    )) are used to evaluate tumor response to cytotoxic agents; they may not be applicable to biologic agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , which have a cytostatic mechanism of action. Novel CT-based morphologic criteria have been proposed which may more closely predict pathologic response and prolonged survival in patients receiving preoperative chemotherapy, both with and without bevacizumab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. However, these require external confirmation and validation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5842004\">",
"    <span class=\"h2\">",
"     Initially resectable disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with initially resectable liver metastases, a common sequence (particularly for patients with a synchronous presentation of metastatic disease) is initial systemic chemotherapy to allow early aggressive disease progression to become manifest, followed by reevaluation for surgery. If there is widespread disease progression, resection will likely provide no specific benefit. If, on the other hand, the disease has responded or is stable, resection of both the primary tumor and the metastatic disease could be attempted. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Timing of hepatectomy in patients presenting with metastases'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Upfront surgery is an appropriate option for patients with metachronous presentation of hepatic metastases. The question of whether perioperative chemotherapy improves survival in patients undergoing hepatic metastasectomy was addressed in an EORTC trial in which 364 patients with up to four metastases without prior exposure to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    were randomly assigned to liver resection with or without FOLFOX4 chemotherapy (",
"    <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/103\">",
"     103",
"    </a>",
"    ]. Six cycles (12 weeks) of chemotherapy were administered prior to surgery and six cycles were administered postoperatively. The key findings were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sixty-seven of the 182 patients assigned to chemotherapy had an objective response (four complete), while 11 progressed, eight of whom were no longer considered resectable. Overall, 83 percent of patients were successfully resected, similar to the number who were successfully resected in the surgery alone group (84 percent). Thus, the fear that initial chemotherapy would cause resectable liver metastases to become unresectable was not realized in this study. Furthermore, initial chemotherapy improved patient selection for hepatic resection. Among those undergoing upfront surgery, 18 of 170 (11 percent) had a nontherapeutic laparotomy, compared with only 8 of 159 (5 percent) in the initial chemotherapy group.",
"     </li>",
"     <li>",
"      The postoperative complication rate was significantly higher in the chemotherapy group (25 versus 16 percent). Patients receiving perioperative chemotherapy had higher rates of hepatic failure (7 versus 5 percent), biliary fistulas (8 versus 4 percent), and intraabdominal infection (7 versus 2 percent). However, the postoperative mortality rate was not higher than with surgery alone (1 versus 2 deaths).",
"     </li>",
"     <li>",
"      In a preliminary report of the latest update, at a median follow-up of 8.5 years, there was a nonstatistically significant trend in five-year progression-free survival favoring the chemotherapy group (35 versus 28 percent, hazard ratio [HR] 0.79, p = 0.058) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/104\">",
"       104",
"      </a>",
"      ]. When ineligible patients were excluded from the analysis, the difference was statistically significant.",
"      <br/>",
"      <br/>",
"      Five-year overall survival was not significantly better in the chemotherapy group (52 versus 48 percent, HR for death 0.88, 95% CI 0.68-1.14); there was also no difference when the analysis was restricted to colorectal cancer deaths. The implications of these findings on the decision to pursue chemotherapy after resection are discussed below. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Therapy after resection of liver metastases'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, whether there is a net benefit for upfront chemotherapy as compared to initial resection for patients with a metachronous presentation of potentially resectable CRC liver metastases remains uncertain. We generally prefer immediate resection rather than upfront chemotherapy. However, these decisions must often be made on a case-by case basis, with consideration of the following issues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Are there sufficient risks or suggestions of possible poor tumor biology such that the addition of one additional factor (ie, progression on chemotherapy) would be sufficient to not offer resection?",
"     </li>",
"     <li>",
"      Does the patient have diabetes, obesity, or other factors that compromise liver health, such that any degree of liver injury from preoperative chemotherapy might be significantly deleterious?",
"     </li>",
"     <li>",
"      Are the tumors resectable at present, but just a minor response would make the operation significantly less difficult (eg, allow the surgeon to more easily achieve a margin-free resection, more easily avoid a critical hepatic vein, or convert from an open to a laparoscopic resection)?",
"     </li>",
"     <li>",
"      Did the patient complete adjuvant FOLFOX previously, and if so, how long ago?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5844162\">",
"    <span class=\"h3\">",
"     Choice of regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal regimen to be used in the neoadjuvant setting for patients with initially resectable hepatic metastases is not established.",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    guidelines suggest FOLFOX or FOLFIRI or XELOX with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    or FOLFIRI with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    (if K-ras wild type) or FOLFIRI or FOLFOX with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    (if K-ras wild type), or FOLFOXIRI (",
"    <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"     table 4",
"    </a>",
"    ). Any of these regimens is an acceptable option, although we do not use bevacizumab in this setting, given the marginal benefits and risk for major complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"     \"Treatment protocols for colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Conversion therapy for initially unresectable metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"conversion therapy\" has been proposed to designate the use of induction chemotherapy in patients with isolated but initially unresectable CRC liver metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/105\">",
"     105",
"    </a>",
"    ]. It is reported that between 12 and 33 percent of patients with &ldquo;initially unresectable&rdquo; hepatic metastases have a sufficient objective response to permit a subsequent complete (R0) resection (",
"    <a class=\"graphic graphic_table graphicRef62458 \" href=\"mobipreview.htm?19/38/20077\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/65,106-112\">",
"     65,106-112",
"    </a>",
"    ]. Five-year survival rates average 30 to 35 percent, results that are substantially better than expected using chemotherapy alone (10 to 11 percent five-year survival, even with the most active regimens). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/20/21833?source=see_link&amp;anchor=H183911606#H183911606\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: General principles\", section on 'Chemotherapy versus supportive care'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the definition of &ldquo;initially unresectable&rdquo; in these reports is subjective and based in part on the aggressiveness of the liver surgeon. In our own experience, the frequency of converting a patient with truly unresectable disease to the point of resectability through the use of neoadjuvant chemotherapy is fairly low (on the order of 5 to 15 percent, even in the hands of aggressive surgeons).",
"   </p>",
"   <p>",
"    Even with the most effective regimens, the complete pathologic response rate after neoadjuvant chemotherapy is only 4 to 9 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/65,113,114\">",
"     65,113,114",
"    </a>",
"    ]. The majority of radiographic completely responding lesions (83 percent in one series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/115\">",
"     115",
"    </a>",
"    ]) contain viable tumor. Thus, even in the setting of a complete clinical response, resection is still needed. Issues surrounding the accuracy of PET scans in patients who undergo chemotherapy are discussed above. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'PET scans'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Choice of regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal regimen to be used in the neoadjuvant setting is not established, but a regimen with a high objective response rate is typically chosen, given the strong correlation between response rate and subsequent resection rate in patients with initially unresectable metastatic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/116\">",
"     116",
"    </a>",
"    ] . Tumor response is usually quantified using the RECIST (Response Evaluation Criteria In Solid Tumors) criteria (",
"    <a class=\"graphic graphic_table graphicRef74693 \" href=\"mobipreview.htm?41/48/42764\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/117,118\">",
"     117,118",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=see_link\">",
"     \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/20/21833?source=see_link&amp;anchor=H183911707#H183911707\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: General principles\", section on 'Assessment during therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is said, although not proven, that the addition of a biologic agent (ie,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    [for individuals with K-ras wild-type tumors] or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ) to a chemotherapy backbone containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    may increase the number of patients potentially eligible for resection and improve outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/113,119-123\">",
"     113,119-123",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=see_link&amp;anchor=H21096055#H21096055\">",
"     \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\", section on 'K-ras'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"     \"Treatment protocols for colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following represents the available data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/124\">",
"     124",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The benefit of agents targeting the epidermal growth factor receptor (EGFR) is modest, at best. The randomized phase II CELIM trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      in combination with either an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      -based regimen showed a high resectability rate of 34 percent, but the absence of a control group not receiving cetuximab precludes assessment of the contribution of cetuximab [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/122\">",
"       122",
"      </a>",
"      ]. Two randomized trials, the CRYSTAL and OPUS trials, showed modestly improved resection rates from 3.7 to 7 percent, and from 2.4 to 4.7 percent, respectively with the addition of cetuximab to an irinotecan or oxaliplatin-based regimen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/120,123\">",
"       120,123",
"      </a>",
"      ]. In the OPUS trial, when the analysis was limited to patients with wild-type K-ras mutation status, resectability was increased from 4 to 10 percent, but these data are based on very small numbers (3 of 73 with FOLFOX versus 6 of 61 for FOLFOX plus cetuximab).",
"      <br/>",
"      <br/>",
"      Nevertheless, largely based upon these data, the FDA has approved cetuximab, in combination with FOLFIRI, for first-line therapy of K-ras wild-type, EGFR-expressing mCRC. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=see_link&amp;anchor=H32#H32\">",
"       \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\", section on 'Cetuximab or panitumumab as a component of initial therapy'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      On the other hand, the benefit of cetuximab in combination with first-line oxaliplatin-based chemotherapy has been called into question in two other trials. In another trial, the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"       panitumumab",
"      </a>",
"      to oxaliplatin did not improve resectability [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/125\">",
"       125",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H59#H59\">",
"       \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Plus oxaliplatin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Similarly,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      only moderately improved resectability rates when added to XELOX or FOLFOX in a large randomized trial (8.4 versus 6,1 percent with chemotherapy alone) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/121\">",
"       121",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The addition of dual antibody therapy to cytotoxic regimens failed to provide any benefit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/126,127\">",
"       126,127",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The modest benefits of adding a biologic agent to the chemotherapy backbone must be counterbalanced by the high cost and potential for added toxicity, particularly with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H5842661\">",
"     'Issues related to bevacizumab'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Regardless of the regimen that is used, the number of preoperative cycles should be limited because of the potential for liver toxicity. (See",
"    <a class=\"local\" href=\"#H5842613\">",
"     'Chemotherapy-related liver toxicity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    suggest any of the following regimens are appropriate (",
"    <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"     table 4",
"    </a>",
"    ) (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"     \"Treatment protocols for colorectal cancer\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      FOLFOX or CAPOX or FOLFIRI with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      or",
"     </li>",
"     <li>",
"      FOLFOX or CAPOX or FOLFIRI plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"       panitumumab",
"      </a>",
"      (wild-type K-ras only)",
"     </li>",
"     <li>",
"      FOLFOXIRI",
"     </li>",
"     <li>",
"      For patients with metachronous metastases who have received adjuvant FOLFOX in the preceding 12 months, FOLFIRI with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      , or FOLFIRI with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"       panitumumab",
"      </a>",
"      (for wild-type K-ras only)",
"     </li>",
"     <li>",
"      Guidelines from the",
"      <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"       NCCN",
"      </a>",
"      further recommend that patients be reevaluated for conversion to resectable disease every two months if resectability is a reasonable goal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We consider the following regimens to be reasonable choices: FOLFOX alone (",
"    <a class=\"graphic graphic_table graphicRef50132 \" href=\"mobipreview.htm?16/53/17246\">",
"     table 6",
"    </a>",
"    ), FOLFOXIRI (",
"    <a class=\"graphic graphic_table graphicRef70559 \" href=\"mobipreview.htm?3/32/3599\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/110,111\">",
"     110,111",
"    </a>",
"    ], or FOLFIRI plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"     table 4",
"    </a>",
"    ) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    (for patients whose tumors lack K-ras mutations). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"     \"Treatment protocols for colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Role of hepatic intraarterial (HIA) chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for administering chemotherapy into the hepatic artery is discussed in detail below. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Regional therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The benefit of regional rather than (or in addition to) systemic therapy to downstage hepatic metastases is unclear:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A combined approach of HIA",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/21/39253?source=see_link\">",
"       floxuridine",
"      </a>",
"      plus systemic chemotherapy (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      ) was explored in a single institution study of 49 patients with initially unresectable CRC liver metastases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/128\">",
"       128",
"      </a>",
"      ]. Overall, 92 percent had either a complete or partial response rate to chemotherapy, and 23 (43 percent) were able to undergo a later resection, 19 with negative margins. The median overall survival from pump placement for the entire cohort was 40 months.",
"     </li>",
"     <li>",
"      HIA",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      was combined with systemic 5-FU and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      in a series of 87 patients, most of whom had initially unresectable but isolated hepatic CRC metastases with failure of prior systemic chemotherapy to render them potentially resectable [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/129\">",
"       129",
"      </a>",
"      ]. The median number of HIA courses was eight. A total of 23 patients underwent surgery, and resection was performed in 14. Among all patients undergoing surgery, the five-year survival was 56 percent (versus zero in those who did not get surgery), but only one patient remained recurrence-free.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While these results seem promising, this approach is not used by many clinicians outside of New York City. The only way to assess the contribution of HIA chemotherapy to neoadjuvant systemic chemotherapy is with a randomized controlled trial. Until such trials are completed, when neoadjuvant therapy is required, systemic rather than regional therapy is indicated.",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    guidelines do not include hepatic artery infusional therapy as a neoadjuvant chemotherapy option for patients with initially unresectable disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neoadjuvant systemic chemotherapy has the potential to convert some patients with initially unresectable large or critically located liver metastases to resectable disease, although the true frequency with which this occurs is probably low. The optimal selection criteria, specific regimen and duration of neoadjuvant chemotherapy, and the best way in which chemotherapy should be interdigitated with surgery in patients who present with synchronous metastatic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/130\">",
"     130",
"    </a>",
"    ] have not been defined.",
"   </p>",
"   <p>",
"    The growing number of reports describing liver toxicity and higher rates of perioperative morbidity in patients undergoing resection after receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -based neoadjuvant chemotherapy has somewhat tempered enthusiasm for this approach, particularly in patients with a small number of initially resectable liver metastases.",
"   </p>",
"   <p>",
"    We recommend the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For low-risk (medically fit, four or fewer lesions), potentially resectable patients, initial surgery rather than neoadjuvant chemotherapy should be chosen, followed by postoperative chemotherapy.",
"     </li>",
"     <li>",
"      For patients who have higher risk, borderline resectable or unresectable disease, neoadjuvant chemotherapy is the preferred approach.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The optimal regimen has not been established. Guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    suggest any of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      FOLFOX or CAPOX or FOLFIRI with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      or",
"     </li>",
"     <li>",
"      FOLFOX or CAPOX or FOLFIRI plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      (wild-type K-ras only) or",
"     </li>",
"     <li>",
"      FOLFOXIRI",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We consider the following combinations to represent reasonable choices: FOLFOX (",
"    <a class=\"graphic graphic_table graphicRef50132 \" href=\"mobipreview.htm?16/53/17246\">",
"     table 6",
"    </a>",
"    ), FOLFOXIRI (",
"    <a class=\"graphic graphic_table graphicRef70559 \" href=\"mobipreview.htm?3/32/3599\">",
"     table 7",
"    </a>",
"    ), or FOLFIRI plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"     table 4",
"    </a>",
"    ) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    (for patients whose tumors lack K-ras mutations). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"     \"Treatment protocols for colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regardless of the specific regimen chosen, the duration of neoadjuvant chemotherapy should be limited, radiographic response assessment performed at approximately six-week intervals, and surgery undertaken as soon as the metastases become clearly resectable. Liver resection should be delayed at least four weeks after completion of chemotherapy, six to eight weeks if",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    was a component of therapy. (See",
"    <a class=\"local\" href=\"#H5842613\">",
"     'Chemotherapy-related liver toxicity'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     LOCAL OPTIONS FOR INCOMPLETELY RESECTED METASTATIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiofrequency ablation (RFA) or cryosurgery is sometimes applied following macroscopically incomplete resection of CRC liver metastases or if there are incidentally found small lesions that are surgically inaccessible. This subject is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/36/28234?source=see_link&amp;anchor=H3#H3\">",
"     \"Nonsurgical local treatment strategies for colorectal cancer liver metastases\", section on 'Tumor ablation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with a macroscopically complete resection in whom a tumor-free resection margin cannot be obtained because of vascular proximity or multinodularity, further locoregional therapy may not be necessary, particularly if an ultrasonic dissector is used for the hepatic resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/44\">",
"     44",
"    </a>",
"    ]. This was shown in a collective series of 436 patients undergoing macroscopically complete, potentially curative resection for CRC liver metastases at three institutions; 234 were microscopically complete (R0), while 202 had microscopically positive margins (R1 resection) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/131\">",
"     131",
"    </a>",
"    ]. Further locoregional therapy was not given to those with an R1 resection (with the exception of argon beam or bipolar coagulation of the cut resection margin), but the majority (88 percent) had postoperative chemotherapy (as did 78 percent of the patients who underwent R0 resection).",
"   </p>",
"   <p>",
"    At a median follow-up of 40 months, there were more intrahepatic recurrences among the patients who had an R1 resection, but the rate of recurrence at the surgical margin was not higher in this group. Furthermore, five- and ten-year overall survival rates were not dissimilar between the two groups (61 and 43 percent in the R0 group, versus 57 and 37 percent in the R1 group). In multivariate analysis, preoperative CEA level and major hepatectomy (&ge;3 segments) but not R1 resection were independent predictors of poor outcome.",
"   </p>",
"   <p>",
"    These data support the view that the inability to obtain clear resection margins is not necessarily a strict contraindication to resection of liver metastases (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Patient selection'",
"    </a>",
"    above). However, a complete (R0) resection must always be the goal of any resection. Current data do not support planning for surgical resection with foreknowledge that residual disease will be left behind.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TIMING OF HEPATECTOMY IN PATIENTS PRESENTING WITH METASTASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A controversial issue is the timing of hepatic resection in patients who have liver metastases at initial presentation. Some reports indicate a poor prognosis in such patients, at least in part attributable to the failure to resect clinically occult micrometastatic liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/5,132\">",
"     5,132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In theory, delaying hepatic surgery by three to six months would permit the biological behavior of the metastatic disease to become evident, thus improving the selection of patients for whom hepatic metastasectomy might be curative. Delayed resection does not seem to increase the risk of patients becoming unresectable due to growth of the initial metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/133\">",
"     133",
"    </a>",
"    ], although if patients are untreated during this interval, it can increase the volume of resected liver, a significant predictor of postoperative complications.",
"   </p>",
"   <p>",
"    One potential solution is to perform percutaneous RFA during the interval between diagnosis and hepatic metastasectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/134\">",
"     134",
"    </a>",
"    ]. Another is to administer chemotherapy during this period, an approach that might also allow some patients with initially unresectable or borderline resectable liver metastases to undergo successful later hepatic resection. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Neoadjuvant chemotherapy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/36/28234?source=see_link\">",
"     \"Nonsurgical local treatment strategies for colorectal cancer liver metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Simultaneous resection of the primary and metastatic disease is clearly preferable from the patient's perspective, and several surgical case series have failed to confirm inferior survival or greater morbidity for patients who undergo a one-stage procedure as compared to delayed (staged) hepatic resection, unless major hepatic resection (three or more segments) is needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/133,135-141\">",
"     133,135-141",
"    </a>",
"    ]. One-stage surgery is probably a reasonable option for patients who present with low-volume (four or fewer, or all in the same lobe) resectable hepatic metastases. Because of the incidence of synchronous second primary colorectal cancers (approximately 3 to 5 percent), complete colonoscopy prior to surgical resection should be undertaken, if feasible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28634?source=see_link&amp;anchor=H21#H21\">",
"     \"Surveillance after colorectal cancer resection\", section on 'Diagnosing second cancers and polyps'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, if there are five or more simultaneous potentially resectable hepatic metastases (unless all are located in one lobe), bilobar involvement, or if disease is borderline resectable due to location, initial chemotherapy followed by reassessment and delayed resection is probably a better strategy. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Neoadjuvant chemotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     THERAPY AFTER RESECTION OF LIVER METASTASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted previously, there is a clear survival benefit from resection in patients with limited hepatic metastases from colorectal cancer (CRC). The role of systemic or regional therapy following metastasectomy is far less certain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Systemic chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A limited number of studies have explored the benefit of systemic 5-FU-based chemotherapy following resection of hepatic metastases; clear evidence of a survival benefit compared to observation alone has not yet emerged.",
"   </p>",
"   <p>",
"    Two randomized trials of similar design were initiated in the early 1990s (the French FFCD 9002 and",
"    <span class=\"nowrap\">",
"     EORTC/NCIC",
"    </span>",
"    trials), but both were closed prematurely because of slow accrual [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/142,143\">",
"     142,143",
"    </a>",
"    ]. The FFCD trial randomly assigned 173 of a planned 200 patients to six months of postoperative systemic 5-FU and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (with both drugs administered for five consecutive days once per month for six months) versus observation alone following hepatic resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/143\">",
"     143",
"    </a>",
"    ]. At five years, patients receiving chemotherapy had a significantly better disease-free survival, which was the primary endpoint (34 versus 27 percent at five years), but only a trend toward better survival (51 versus 41 percent).",
"   </p>",
"   <p>",
"    The EORTC trial used the same chemotherapy regimen, but the results have not been published separately. In a combined analysis of both trials (totaling 278 patients), the differences in median progression-free survival (28 versus 19 months, p = 0.058) and overall survival (62 versus 47 months), while potentially clinical meaningful, were not statistically significant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/142\">",
"     142",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data provide a proof of principle of the benefit of postresection adjuvant chemotherapy in this population. However, the chemotherapy used in these trials is considered inferior by modern standards. For patients with unresectable metastatic CRC, the introduction of newer drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    has been accompanied by a marked improvement in median survival from six to seven months to 20 to 24 months. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are limited data available from randomized trials on the benefits of these modern chemotherapy regimens following resection of colorectal cancer liver metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/103,144\">",
"     103,144",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial from the EORTC evaluating perioperative FOLFOX chemotherapy (six cycles preoperatively, six postoperatively) versus observation alone in patients with initially resectable liver metastases showed that chemotherapy was associated with a trend toward improved three-year progression-free survival relative to surgical resection alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/103\">",
"       103",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Therapy after resection of liver metastases'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      However, in the latest update of this trial, five-year overall survival was not significantly better in the chemotherapy group (52 versus 48 percent, HR for death 0.88, 95% CI 0.68-1.14); there was also no difference when the analysis was restricted to colorectal cancer deaths [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/104\">",
"       104",
"      </a>",
"      ]. However, these results cannot be used to conclude that there is a lack of benefit for adjuvant chemotherapy after resection of CRC liver metastases. The trial was not powered for overall survival as an endpoint. (See",
"      <a class=\"local\" href=\"#H5842004\">",
"       'Initially resectable disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The benefit of adding",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      to 5-FU and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      was tested in a multicenter trial in which 321 patients undergoing complete surgical resection for liver-isolated metastatic disease were randomly assigned to short-term infusional 5-FU plus leucovorin every other week for 24 weeks without or with irinotecan (180",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every other week) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/144\">",
"       144",
"      </a>",
"      ]. At a median follow-up of 42 months, there was no significant disease-free survival advantage for adding irinotecan (median 25 versus 22 months).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of note, at least two trials of adjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    plus short-term infusional 5-FU have failed to demonstrate a progression-free survival benefit over 5-FU plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    alone in patients with resected stage II or III disease. Thus, administration of postoperative irinotecan-containing chemotherapy should not be considered a standard approach following resection of liver-isolated metastatic disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=see_link&amp;anchor=H19#H19\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on 'Irinotecan'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     NCCN recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the paucity of data, updated guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    recommend a total of six months of perioperative therapy with an active systemic chemotherapy regimen for patients who have undergone resection of hepatic metastases from colorectal cancer. Acceptable options include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      FOLFOX or CAPOX or FOLFIRI with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      or",
"     </li>",
"     <li>",
"      FOLFOX or CAPOX or FOLFIRI plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      (wild-type K-ras only)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In view of the newly available data regarding the lack of benefit from adjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    plus 5-FU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/144\">",
"     144",
"    </a>",
"    ], we would consider most of these regimens to represent acceptable options except FOLFIRI. However, based on indirect evidence, we and others consider FOLFOX alone (",
"    <a class=\"graphic graphic_table graphicRef50132 \" href=\"mobipreview.htm?16/53/17246\">",
"     table 6",
"    </a>",
"    ) to be the reference regimen for this group of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/145\">",
"     145",
"    </a>",
"    ]. We generally do not use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    in this setting, given the marginal benefits and risk for major complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Regional therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The liver is the dominant site of recurrence in over one-half of patients undergoing potentially curative resection. This observation, coupled with the proven efficacy of adjuvant systemic 5-FU-based chemotherapy in patients with node-positive colon cancer, led to the study of regional treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Hepatic intraarterial chemotherapy alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fact that liver metastases derive their blood supply predominantly from the hepatic artery provides the rationale to apply regional intrahepatic arterial (HIA) chemotherapy following metastasectomy.",
"   </p>",
"   <p>",
"    Despite initially encouraging data from small randomized studies conducted in fewer than 40 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/146,147\">",
"     146,147",
"    </a>",
"    ], larger randomized controlled trials were disappointing. In one American Cooperative Group study that randomized patients to resection only versus resection plus HIA FUDR for a solitary or multiple resectable liver metastases, patient accrual was inadequate to address the utility of adjuvant therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/148\">",
"     148",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A later German trial was closed prematurely when interim analysis suggested a worse outcome from HIA therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/149\">",
"     149",
"    </a>",
"    ]. In this randomized study comparing HIA 5-FU plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    versus no treatment following hepatic resection of colorectal metastases in 226 patients, the treated patients had a worse median survival (35 versus 41 months), and similar median time to tumor progression (14.2 versus 13.7 months) compared to those undergoing surgery alone.",
"   </p>",
"   <p>",
"    The observation that many of these patients were failing outside of the liver led to efforts combining regional and systemic 5-FU-based chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     HIA plus systemic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of combined systemic and intrahepatic arterial chemotherapy was evaluated in an Intergroup study that randomly assigned completely resected patients to observation versus a combination of HIA FUDR and infusional 5-FU following resection. Unfortunately, only 109 patients were accrued during nine years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/150\">",
"     150",
"    </a>",
"    ]. In the final analysis, which was limited to 75 eligible patients (45 controls and 30 chemotherapy-treated patients), combined systemic and regional therapy was associated with significantly longer time to recurrence, a better four-year hepatic recurrence-free survival (67 versus 43 percent), and overall recurrence-free survival (46 versus 25 percent). However, there was no benefit in terms of median overall survival.",
"   </p>",
"   <p>",
"    A slightly different approach was employed in a study of 156 patients with metastatic CRC who were randomly assigned to receive either six months of systemic therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    -modulated 5-FU or six cycles of combination HIA with FUDR plus systemic chemotherapy with 5-FU and leucovorin following surgical resection of liver metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/151\">",
"     151",
"    </a>",
"    ]. Combination therapy was associated with a significantly better two-year survival rate (86 versus 72 percent) and two-year freedom from tumor recurrence in the liver (90 versus 60 percent).",
"   </p>",
"   <p>",
"    A later report of this series with over 10 years of follow-up suggested that benefit might be limited to the subgroup of patients with the highest risk for recurrence following resection alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/152\">",
"     152",
"    </a>",
"    ]. Using a clinical risk score as defined by Fong et al (assigning one point for each of the following: node-positive primary, disease-free interval from primary to metastases &lt;12 months, more than one hepatic metastasis, largest hepatic tumor &gt;5 cm, and CEA level &gt;200",
"    <span class=\"nowrap\">",
"     ng/ml",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/12\">",
"     12",
"    </a>",
"    ]), outcomes were not significantly different with combined therapy versus surgery alone for those with a clinical risk score of 0 to 2 (median survival 83 months in both groups). However, outcomes were significantly better with combined therapy in those with a clinical risk score of 3 to 5 (median survival 60 versus 38 months, 10-year survival 39 versus 16 percent). This series demonstrates how well some patients can do with resection that is done in a center with substantial experience, and that regional therapy can improve the rate of hepatic tumor control.",
"   </p>",
"   <p>",
"    More recent studies are exploring regimens that combine HIA chemotherapy and intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/153,154\">",
"     153,154",
"    </a>",
"    ]. Although treatment is tolerable and early results are promising, the ultimate proof of benefit will require a randomized controlled trial. Such a trial, NSABP C-09, is underway, comparing systemic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    plus oxaliplatin alone or with alternating HAI FUDR after resection of colorectal cancer liver metastases.",
"   </p>",
"   <p>",
"    Routine use of HIA chemotherapy after liver resection has not gained widespread acceptance. Placement of the HIA pump increases the complexity of the operation, and in one series, only 19 percent of the patients randomized to receive regional plus systemic chemotherapy completed the prescribed course of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/151\">",
"     151",
"    </a>",
"    ]. Concerns about hepatobiliary toxicity of FUDR delivered by HIA combined with high response rates with modern systemic chemotherapy regimens will limit the use of HIA chemotherapy after hepatic resection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44074?source=see_link&amp;anchor=H20#H20\">",
"     \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\", section on 'Floxuridine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nevertheless, updated guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    indicate that hepatic arterial infusion with or without systemic 5-FU and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    is a reasonable approach after liver resection at institutions with experience in both the surgical and medical aspects of this therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     HIA plus other local approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other investigators are exploring the role of HIA FUDR-based chemotherapy in conjunction with partial debulking of liver metastases, either via surgical resection or with cryosurgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/155\">",
"     155",
"    </a>",
"    ]. Until the results are known from such pilot studies, the use of HIA chemotherapy in that setting should be considered investigational.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Portal vein infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because HIA FUDR carries a risk for biliary sclerosis, administration into the portal vein has been explored as an alternative. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/36/28234?source=see_link&amp;anchor=H15#H15\">",
"     \"Nonsurgical local treatment strategies for colorectal cancer liver metastases\", section on 'Optimizing chemotherapy'",
"    </a>",
"    .) The rationale is based upon the observation that in contrast to clinically detectable metastases, which derive 90 percent of their blood supply from the hepatic artery, hepatic micrometastases (as well as the biliary tree) are primarily dependent on the portal vein for their blood supply. Like HIA infusion, portal vein infusion (PVI) carries with it a significant regional exposure advantage.",
"   </p>",
"   <p>",
"    The potential benefit of adjuvant PVI with FUDR after resection or ablation of isolated hepatic metastases was evaluated in two trials conducted at the City of Hope Medical Center [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/156\">",
"     156",
"    </a>",
"    ]. Systemic administration of 5-FU and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    was given in conjunction with PVI FUDR, which was administered for 14 days on and 14 days off at a dose approximately twofold higher than that used with HIA FUDR. Although there was a low incidence of hepatic drug-induced toxicity, overall and disease-free survival (at three years 42 and 19 percent, respectively) were somewhat lower than has been reported with HIA FUDR and systemic 5-FU plus leucovorin following resection of hepatic metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/150,151\">",
"     150,151",
"    </a>",
"    ]. Thus, the role for this approach appears to be limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Hepatic radiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of external beam radiotherapy and internal application of radiation therapy through the use of yttrium-labeled microspheres is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/36/28234?source=see_link\">",
"     \"Nonsurgical local treatment strategies for colorectal cancer liver metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H650939148\">",
"    <span class=\"h1\">",
"     SURVEILLANCE AFTER METASTASECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posttreatment surveillance is recommended following resection of a primary colorectal cancer; the goal is identification of those patients who might potentially be cured by further surgical intervention, and to screen for second primary cancers and polyps. Although evidence regarding the optimal follow-up strategy after liver resection for metastatic CRC is limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/157,158\">",
"     157,158",
"    </a>",
"    ], consensus-based guidelines addressing the surveillance strategy and frequency of follow-up for CRC, including advanced disease, are available from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef58912 \" href=\"mobipreview.htm?20/53/21341\">",
"     table 8",
"    </a>",
"    ). In addition, for resected stage IV disease, CT is recommended every three to six months for two years then every 6 to 12 months for a total of five years. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28634?source=see_link\">",
"     \"Surveillance after colorectal cancer resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of patients with resected isolated liver metastases from CRC will develop recurrences in liver and lung, which could be potentially treated with further resection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13560?source=see_link\">",
"     \"Surgical resection of pulmonary metastases: Outcomes by histology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13560?source=see_link&amp;anchor=H3#H3\">",
"     \"Surgical resection of pulmonary metastases: Outcomes by histology\", section on 'Colorectal cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The liver is the only site of recurrence in approximately 35 to 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/10,159,160\">",
"     10,159,160",
"    </a>",
"    ]. Five-year survival rates up to 43 percent are reported following repeat liver resection for a second recurrence, with acceptable morbidity and perioperative mortality. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Repeat resection for recurrent metastases'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    The impact of CT-based follow-up for the detection of resectable disease recurrence has been addressed in the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One review included 705 patients who underwent resection of isolated colorectal cancer liver metastases at a single institution over a 14-year period [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/160\">",
"       160",
"      </a>",
"      ]. All were followed with a similar surveillance protocol, which included outpatient clinical examinations at 3, 6, 12, 18, and 24 months, and annually thereafter, with measurement of CEA and CA 19-9 levels at each visit. In addition, all patients had CT of the thorax, abdomen and pelvis every three months for the first two years, at six monthly intervals for three more years, then annually from year six to ten.",
"      <br/>",
"      <br/>",
"      Of the 444 patients with a recurrence diagnosed on a surveillance CT, 404 were detected within two years. The site of recurrent disease was liver only in 36 percent, extrahepatic only in 38 percent, and both hepatic and extrahepatic sites in 26 percent. The authors did not report how many recurrences were detected by serum tumor markers versus CT scans.",
"      <br/>",
"      <br/>",
"      In total, recurrent disease was treated surgically in 124 patients. At every time point (within one year of original surgery, one to two years, beyond two years), those patients treated by liver",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lung resection had significantly better median survival than did those who received palliative chemotherapy alone. The mean number of scans performed per resectable recurrence was 35.3, and the cost per life-year gained was &pound;2883, a value that compares favorably to other cost-effectiveness ratios that are considered acceptable in the US and elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/30/26087?source=see_link&amp;anchor=H10#H10\">",
"       \"A short primer on cost-effectiveness analysis\", section on 'Interpretation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Another series addressing the detection of recurrences after liver surgery for CRC metastases reported that recurrences were detected in 23 percent through a CEA increase without positive findings on routine imaging, in 46 percent through a CEA rise concurrent with positive imaging, and in 31 percent through positive imaging alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/158\">",
"       158",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Consensus-based guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    recommend the following surveillance strategy for patients with stage IV disease who are rendered surgically NED (no evidence of disease):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CEA every three months for two years, then every six months for three to five years",
"     </li>",
"     <li>",
"      CT of the",
"      <span class=\"nowrap\">",
"       chest/abdomen",
"      </span>",
"      and pelvis every three to six months for two years, then every 6 to 12 months up to a total of five years",
"     </li>",
"     <li>",
"      Colonoscopy in one year; if no advanced adenoma repeat in three years, then every five years; if advanced adenoma is found, repeat in one year",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     REPEAT RESECTION FOR RECURRENT METASTASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although randomized trials have not been conducted to prove benefit, repeat hepatic resection may be considered in selected patients who recur in the liver with no evidence of extrahepatic disease, and a good performance status. In several reported series, perioperative mortality rates were less than 5 percent, and relapse-free survival rates ranged from 20 to 43 percent at two to five years (",
"    <a class=\"graphic graphic_table graphicRef67710 \" href=\"mobipreview.htm?32/49/33564\">",
"     table 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/16,47,161-173\">",
"     16,47,161-173",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with a relapse-free interval of longer than one year appear to have a more favorable outcome from reresection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/160,163\">",
"     160,163",
"    </a>",
"    ]. Other factors associated with a poor outcome include synchronous resection for the first liver metastases, and the presence of multiple lesions at second hepatectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/164,165,169\">",
"     164,165,169",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/27/19890?source=see_link\">",
"       \"Patient information: Colon and rectal cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/0/6148?source=see_link\">",
"       \"Patient information: Colon and rectal cancer (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/22/40293?source=see_link\">",
"       \"Patient information: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgical resection is the only potentially curative option for patients with liver-isolated metastatic colorectal cancer. For appropriately selected patients with four or fewer metastases, five-year relapse-free survival rates average 30 percent; in at least four contemporary series, five-year overall survival rates are approximately 58 percent. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Surgical resection'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The optimal selection of patients for resection is evolving. Since the criteria for potential liver directed therapies have been expanded, hepatic surgical consultation should be obtained for surgically-fit patients with apparently isolated liver metastases unless they fall into one of the following categories (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Patient selection'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Radiographic evidence of involvement of the common hepatic artery, common hepatic or common bile duct, or main portal vein",
"     </li>",
"     <li>",
"      Extensive liver involvement (&gt;70 percent, more than six segments (",
"      <a class=\"graphic graphic_figure graphicRef81897 \" href=\"mobipreview.htm?13/35/13878\">",
"       figure 1",
"      </a>",
"      ), or involvement of all three hepatic veins)",
"     </li>",
"     <li>",
"      Inadequate predicted postresection functional hepatic reserve",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest not using a clinical risk score to select patients for diagnostic laparoscopy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We perform an initial diagnostic laparoscopy only in patients with a suspicion of low-volume carcinomatosis based on preoperative radiographic imaging and for selected other cases at high risk for intraperitoneal metastatic disease (eg, a patient with a metachronous presentation of the primary and metastases who has several liver metastases that are not responding to chemotherapy). (See",
"      <a class=\"local\" href=\"#H14008586\">",
"       'Selecting patients for diagnostic laparoscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the hepatic metastases are potentially resectable, we suggest immediate surgical resection rather than initial chemotherapy for medically fit patients with four or fewer metastases, unless a response to chemotherapy is anticipated to allow for a significantly less complex resection (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For patients with a good performance status who have more than four metastases (unless all are localized to a single lobe), radiographic suspicion for portal node involvement, or bilobar disease (ie, tumor involving any segments of the left and right hemi-liver), we suggest initial systemic chemotherapy followed by surgical reevaluation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5842004\">",
"       'Initially resectable disease'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Others disagree, instead recommending two to three courses of preoperative chemotherapy in all patients with potentially resectable liver metastases, in part to select those patients who are most likely to benefit from resection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/55/41850/abstract/174\">",
"       174",
"      </a>",
"      ]. However, if preoperative chemotherapy is selected, the number of courses should be minimized. Radiographic response assessment should be performed at six week intervals, and surgery undertaken as soon as the metastases are clearly resectable. (See",
"      <a class=\"local\" href=\"#H5842613\">",
"       'Chemotherapy-related liver toxicity'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The optimal chemotherapy regimen is not established. We consider the following combinations to represent reasonable choices: FOLFOX (",
"      <a class=\"graphic graphic_table graphicRef50132 \" href=\"mobipreview.htm?16/53/17246\">",
"       table 6",
"      </a>",
"      ), FOLFOXIRI (",
"      <a class=\"graphic graphic_table graphicRef70559 \" href=\"mobipreview.htm?3/32/3599\">",
"       table 7",
"      </a>",
"      ), or FOLFIRI plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"       table 4",
"      </a>",
"      ) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"       panitumumab",
"      </a>",
"      (for patients whose tumors lack K-ras mutations). (See",
"      <a class=\"local\" href=\"#H5844162\">",
"       'Choice of regimen'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"       \"Treatment protocols for colorectal cancer\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Upfront chemotherapy is an appropriate option for patients with initially unresectable liver metastases; however, the likelihood of downstaging a patient with truly unresectable disease to the point of resectability is only 10 to 15 percent. Furthermore, longer durations of preoperative chemotherapy increase the potential for liver toxicity and postoperative complications.",
"      <br/>",
"      <br/>",
"      If it is attempted, the optimal regimen for conversion therapy in this setting is not established. Given the potential for treatment-related toxicity with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      and the modest improvement in overall response rate when this agent is added to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      , we prefer an oxaliplatin-based systemic combination regimen without bevacizumab, or FOLFOXIRI (for young healthy patients who are able to tolerate it). For patients with metachronous metastases who have received adjuvant FOLFOX in the preceding 12 months, FOLFIRI with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"       panitumumab",
"      </a>",
"      (for wild-type K-ras only) is a reasonable option. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Choice of regimen'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"       \"Treatment protocols for colorectal cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who have hepatic metastases at initial presentation, the optimal timing of liver resection is uncertain. We suggest one-stage surgery, if feasible (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If not feasible, resection of liver metastases can follow six to eight weeks after resection of the primary tumor. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Timing of hepatectomy in patients presenting with metastases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following complete resection of liver metastases, the best postoperative strategy is uncertain. In the absence of published randomized trials to guide clinical practice following metastasectomy, we suggest completion of a full six month course of systemic chemotherapy containing",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We recommend against the use of an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      -based regimen in this setting (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Therapy after resection of liver metastases'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The relative benefit and indications for hepatic intraarterial chemotherapy in patients with hepatic metastases from CRC remains uncertain. We suggest that this approach be restricted to institutions with expertise in both the medical and surgical oncologic aspects of this procedure. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'HIA plus systemic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are rendered free of disease, posttreatment surveillance is warranted if they would be considered candidates for a second potentially curative surgical procedure. Consensus-based guidelines for the posttreatment surveillance strategy are available from the",
"      <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"       NCCN",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H650939148\">",
"       'Surveillance after metastasectomy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/2\">",
"      Khatri VP, Petrelli NJ, Belghiti J. Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? J Clin Oncol 2005; 23:8490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/3\">",
"      Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009; 27:3677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/4\">",
"      Fernandez FG, Drebin JA, Linehan DC, et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004; 240:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/5\">",
"      Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995; 19:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/6\">",
"      Steele G Jr, Bleday R, Mayer RJ, et al. A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group Protocol 6584. J Clin Oncol 1991; 9:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/7\">",
"      Wanebo HJ, Chu QD, Vezeridis MP, Soderberg C. Patient selection for hepatic resection of colorectal metastases. Arch Surg 1996; 131:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/8\">",
"      Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Fran&ccedil;aise de Chirurgie. Cancer 1996; 77:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/9\">",
"      Yoon SS, Tanabe KK. Multidisciplinary management of metastatic colorectal cancer. Surg Oncol 1998; 7:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/10\">",
"      Hughes KS, Simon R, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery 1986; 100:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/11\">",
"      Jamison RL, Donohue JH, Nagorney DM, et al. Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg 1997; 132:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/12\">",
"      Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/13\">",
"      Iwatsuki S, Dvorchik I, Madariaga JR, et al. Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 1999; 189:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/14\">",
"      Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004; 239:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/15\">",
"      Wei AC, Greig PD, Grant D, et al. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol 2006; 13:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/16\">",
"      Simmonds PC, Primrose JN, Colquitt JL, et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 2006; 94:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/17\">",
"      Cummings LC, Payes JD, Cooper GS. Survival after hepatic resection in metastatic colorectal cancer: a population-based study. Cancer 2007; 109:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/18\">",
"      Rees M, Tekkis PP, Welsh FK, et al. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 2008; 247:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/19\">",
"      Morris EJ, Forman D, Thomas JD, et al. Surgical management and outcomes of colorectal cancer liver metastases. Br J Surg 2010; 97:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/20\">",
"      Robertson DJ, Stukel TA, Gottlieb DJ, et al. Survival after hepatic resection of colorectal cancer metastases: a national experience. Cancer 2009; 115:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/21\">",
"      Ferrarotto R, Pathak P, Maru D, et al. Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone. Clin Colorectal Cancer 2011; 10:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/22\">",
"      Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007; 25:4575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/23\">",
"      Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/24\">",
"      Poston GJ, Adam R, Alberts S, et al. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol 2005; 23:7125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/25\">",
"      Konopke R, Kersting S, Distler M, et al. Prognostic factors and evaluation of a clinical score for predicting survival after resection of colorectal liver metastases. Liver Int 2009; 29:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/26\">",
"      Nagashima I, Takada T, Matsuda K, et al. A new scoring system to classify patients with colorectal liver metastases: proposal of criteria to select candidates for hepatic resection. J Hepatobiliary Pancreat Surg 2004; 11:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/27\">",
"      Zakaria S, Donohue JH, Que FG, et al. Hepatic resection for colorectal metastases: value for risk scoring systems? Ann Surg 2007; 246:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/28\">",
"      Small RM, Lubezky N, Shmueli E, et al. Response to chemotherapy predicts survival following resection of hepatic colo-rectal metastases in patients treated with neoadjuvant therapy. J Surg Oncol 2009; 99:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/29\">",
"      Reissfelder C, Rahbari NN, Koch M, et al. Validation of prognostic scoring systems for patients undergoing resection of colorectal cancer liver metastases. Ann Surg Oncol 2009; 16:3279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/30\">",
"      Berri RN, Abdalla EK. Curable metastatic colorectal cancer: recommended paradigms. Curr Oncol Rep 2009; 11:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/31\">",
"      Adam R, de Haas RJ, Wicherts DA, et al. Is hepatic resection justified after chemotherapy in patients with colorectal liver metastases and lymph node involvement? J Clin Oncol 2008; 26:3672.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/33\">",
"      Carpizo DR, Are C, Jarnagin W, et al. Liver resection for metastatic colorectal cancer in patients with concurrent extrahepatic disease: results in 127 patients treated at a single center. Ann Surg Oncol 2009; 16:2138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/34\">",
"      Tanabe KK. Palliative liver resections. J Surg Oncol 2002; 80:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/35\">",
"      Bolton JS, Fuhrman GM. Survival after resection of multiple bilobar hepatic metastases from colorectal carcinoma. Ann Surg 2000; 231:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/36\">",
"      Weber SM, Jarnagin WR, DeMatteo RP, et al. Survival after resection of multiple hepatic colorectal metastases. Ann Surg Oncol 2000; 7:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/37\">",
"      Malik HZ, Hamady ZZ, Adair R, et al. Prognostic influence of multiple hepatic metastases from colorectal cancer. Eur J Surg Oncol 2007; 33:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/38\">",
"      Wicherts DA, Miller R, de Haas RJ, et al. Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases. Ann Surg 2008; 248:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/39\">",
"      Pawlik TM, Abdalla EK, Ellis LM, et al. Debunking dogma: surgery for four or more colorectal liver metastases is justified. J Gastrointest Surg 2006; 10:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/40\">",
"      Kornprat P, Jarnagin WR, Gonen M, et al. Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy. Ann Surg Oncol 2007; 14:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/41\">",
"      de Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg 2009; 250:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/42\">",
"      Brouquet A, Abdalla EK, Kopetz S, et al. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol 2011; 29:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/43\">",
"      Adam R, Laurent A, Azoulay D, et al. Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors. Ann Surg 2000; 232:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/44\">",
"      Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005; 241:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/45\">",
"      Are C, Gonen M, Zazzali K, et al. The impact of margins on outcome after hepatic resection for colorectal metastasis. Ann Surg 2007; 246:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/46\">",
"      Jaeck D, Nakano H, Bachellier P, et al. Significance of hepatic pedicle lymph node involvement in patients with colorectal liver metastases: a prospective study. Ann Surg Oncol 2002; 9:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/47\">",
"      Nordlinger B, Vaillant JC, Guiguet M, et al. Survival benefit of repeat liver resections for recurrent colorectal metastases: 143 cases. Association Francaise de Chirurgie. J Clin Oncol 1994; 12:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/48\">",
"      Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. Oncologist 2008; 13:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/49\">",
"      Pulitan&ograve; C, Bodingbauer M, Aldrighetti L, et al. Colorectal liver metastasis in the setting of lymph node metastasis: defining the benefit of surgical resection. Ann Surg Oncol 2012; 19:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/50\">",
"      Rau C, Blanc B, Ronot M, et al. Neither preoperative computed tomography nor intra-operative examination can predict metastatic lymph node in the hepatic pedicle in patients with colorectal liver metastasis. Ann Surg Oncol 2012; 19:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/51\">",
"      Pulitan&ograve; C, Bodingbauer M, Aldrighetti L, et al. Liver resection for colorectal metastases in presence of extrahepatic disease: results from an international multi-institutional analysis. Ann Surg Oncol 2011; 18:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/52\">",
"      Wiering B, Krabbe PF, Jager GJ, et al. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer 2005; 104:2658.",
"     </a>",
"    </li>",
"    <li>",
"     Wiering B, Oyen W, Van der Sijp J, et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with FDG-PET: a randomized study (abstract). J Clin Oncol 2008; 26:179s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/54\">",
"      Pawlik TM, Assumpcao L, Vossen JA, et al. Trends in nontherapeutic laparotomy rates in patients undergoing surgical therapy for hepatic colorectal metastases. Ann Surg Oncol 2009; 16:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/55\">",
"      Ruers TJ, Langenhoff BS, Neeleman N, et al. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol 2002; 20:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/56\">",
"      Fong Y, Saldinger PF, Akhurst T, et al. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg 1999; 178:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/57\">",
"      Lai DT, Fulham M, Stephen MS, et al. The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch Surg 1996; 131:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/58\">",
"      Valk PE, Abella-Columna E, Haseman MK, et al. Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg 1999; 134:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/59\">",
"      Imdahl A, Reinhardt MJ, Nitzsche EU, et al. Impact of 18F-FDG-positron emission tomography for decision making in colorectal cancer recurrences. Langenbecks Arch Surg 2000; 385:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/60\">",
"      Langenhoff BS, Oyen WJ, Jager GJ, et al. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol 2002; 20:4453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/61\">",
"      Akhurst T, Kates TJ, Mazumdar M, et al. Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol 2005; 23:8713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/62\">",
"      Glazer ES, Beaty K, Abdalla EK, et al. Effectiveness of positron emission tomography for predicting chemotherapy response in colorectal cancer liver metastases. Arch Surg 2010; 145:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/63\">",
"      van Kessel CS, Buckens CF, van den Bosch MA, et al. Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis. Ann Surg Oncol 2012; 19:2805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/64\">",
"      Jarnagin WR, Conlon K, Bodniewicz J, et al. A clinical scoring system predicts the yield of diagnostic laparoscopy in patients with potentially resectable hepatic colorectal metastases. Cancer 2001; 91:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/65\">",
"      Adam R, Wicherts DA, de Haas RJ, et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 2009; 27:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/66\">",
"      Fernandez FG, Ritter J, Goodwin JW, et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005; 200:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/67\">",
"      Parikh AA, Gentner B, Wu TT, et al. Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. J Gastrointest Surg 2003; 7:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/68\">",
"      Kooby DA, Fong Y, Suriawinata A, et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 2003; 7:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/69\">",
"      Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004; 15:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/70\">",
"      Bilchik AJ, Poston G, Curley SA, et al. Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol 2005; 23:9073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/71\">",
"      Tisman G, MacDonald D, Shindell N, et al. Oxaliplatin toxicity masquerading as recurrent colon cancer. J Clin Oncol 2004; 22:3202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/72\">",
"      Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24:2065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/73\">",
"      Aloia T, Sebagh M, Plasse M, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006; 24:4983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/74\">",
"      Hubert C, Sempoux C, Horsmans Y, et al. Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases? Liver Int 2007; 27:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/75\">",
"      Ward J, Guthrie JA, Sheridan MB, et al. Sinusoidal obstructive syndrome diagnosed with superparamagnetic iron oxide-enhanced magnetic resonance imaging in patients with chemotherapy-treated colorectal liver metastases. J Clin Oncol 2008; 26:4304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/76\">",
"      Pawlik TM, Olino K, Gleisner AL, et al. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg 2007; 11:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/77\">",
"      Hubert C, Fervaille C, Sempoux C, et al. Prevalence and clinical relevance of pathological hepatic changes occurring after neoadjuvant chemotherapy for colorectal liver metastases. Surgery 2010; 147:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/78\">",
"      Karoui M, Penna C, Amin-Hashem M, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006; 243:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/79\">",
"      Soubrane O, Brouquet A, Zalinski S, et al. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome. Ann Surg 2010; 251:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/80\">",
"      Robinson SM, Wilson CH, Burt AD, et al. Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann Surg Oncol 2012; 19:4287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/81\">",
"      Nakano H, Oussoultzoglou E, Rosso E, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 2008; 247:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/82\">",
"      Scoggins CR, Campbell ML, Landry CS, et al. Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases. Ann Surg Oncol 2009; 16:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/83\">",
"      Welsh FK, Tilney HS, Tekkis PP, et al. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer 2007; 96:1037.",
"     </a>",
"    </li>",
"    <li>",
"     Zorzi D, Kishi Y, Manu M, et al. Effect of extended preoperative chemotherapy on pathologic response and postoperative liver insufficiency after hepatic resection for colorectal cancer liver metastases (abstract). Data presented at the 2009 ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, January 16, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/85\">",
"      Overman MJ, Maru DM, Charnsangavej C, et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol 2010; 28:2549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/86\">",
"      Gruenberger B, Tamandl D, Schueller J, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008; 26:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/87\">",
"      Okines A, Puerto OD, Cunningham D, et al. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 2009; 101:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/88\">",
"      D'Angelica M, Kornprat P, Gonen M, et al. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol 2007; 14:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/89\">",
"      Reddy SK, Morse MA, Hurwitz HI, et al. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 2008; 206:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/90\">",
"      Kesmodel SB, Ellis LM, Lin E, et al. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 2008; 26:5254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/91\">",
"      Tamandl D, Gruenberger B, Klinger M, et al. Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study. Ann Surg 2010; 252:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/92\">",
"      Wicherts DA, de Haas RJ, Sebagh M, et al. Impact of bevacizumab on functional recovery and histology of the liver after resection of colorectal metastases. Br J Surg 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/93\">",
"      van der Pool AE, Marsman HA, Verheij J, et al. Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases. J Surg Oncol 2012; 106:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/94\">",
"      Wicherts DA, de Haas RJ, Andreani P, et al. Impact of portal vein embolization on long-term survival of patients with primarily unresectable colorectal liver metastases. Br J Surg 2010; 97:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/95\">",
"      Zorzi D, Chun YS, Madoff DC, et al. Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Ann Surg Oncol 2008; 15:2765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/96\">",
"      Aussilhou B, Dokmak S, Faivre S, et al. Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab. Ann Surg Oncol 2009; 16:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/97\">",
"      Wicherts DA, de Haas RJ, Sebagh M, et al. Impact of bevacizumab on functional recovery and histology of the liver after resection of colorectal metastases. Br J Surg 2011; 98:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/98\">",
"      Kozloff M, Yood MU, Berlin J, et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 2009; 14:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/99\">",
"      Ribero D, Wang H, Donadon M, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007; 110:2761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/100\">",
"      Klinger M, Eipeldauer S, Hacker S, et al. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol 2009; 35:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/101\">",
"      Chun YS, Vauthey JN, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009; 302:2338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/102\">",
"      Shindoh J, Loyer EM, Kopetz S, et al. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol 2012; 30:4566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/103\">",
"      Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371:1007.",
"     </a>",
"    </li>",
"    <li>",
"     Nordlinger B,Sorbye H, Glimelius B, et al. EORTC liver metastases intergroup randomized phase III study 40983: Long-term survival results. J Clin Oncol 30, 2012 (suppl; abstr 3508). Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=114&amp;abstractID=99538 (Accessed on June 21, 2012).",
"    </li>",
"    <li>",
"     Petrelli NJ. Plenary program discussion. 43rd annual meeting of the American Society of Clinical Oncology, Chicago, Illinois, June 4, 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/106\">",
"      Alberts SR, Horvath WL, Sternfeld WC, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 2005; 23:9243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/107\">",
"      Delaunoit T, Alberts SR, Sargent DJ, et al. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol 2005; 16:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/108\">",
"      Barone C, Nuzzo G, Cassano A, et al. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer 2007; 97:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/109\">",
"      Ychou M, Viret F, Kramar A, et al. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol 2008; 62:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/110\">",
"      Masi G, Loupakis F, Pollina L, et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 2009; 249:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/111\">",
"      Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/112\">",
"      Wein A, Riedel C, K&ouml;ckerling F, et al. Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid. Ann Oncol 2001; 12:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/113\">",
"      Blazer DG 3rd, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008; 26:5344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/114\">",
"      Adam R, Wicherts DA, de Haas RJ, et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol 2008; 26:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/115\">",
"      Benoist S, Brouquet A, Penna C, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 2006; 24:3939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/116\">",
"      Folprecht G, Grothey A, Alberts S, et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005; 16:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/117\">",
"      Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/118\">",
"      Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/119\">",
"      Adam R, Aloia T, L&eacute;vi F, et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 2007; 25:4593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/120\">",
"      Van Cutsem E, K&ouml;hne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/121\">",
"      Saltz LB, Clarke S, D&iacute;az-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/122\">",
"      Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/123\">",
"      Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/124\">",
"      Lehmann K, Rickenbacher A, Weber A, et al. Chemotherapy before liver resection of colorectal metastases: friend or foe? Ann Surg 2012; 255:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/125\">",
"      Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28:4697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/126\">",
"      Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/127\">",
"      Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009; 27:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/128\">",
"      Kemeny NE, Melendez FD, Capanu M, et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2009; 27:3465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/129\">",
"      Go&eacute;r&eacute; D, Deshaies I, de Baere T, et al. Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg 2010; 251:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/130\">",
"      Reddy SK, Zorzi D, Lum YW, et al. Timing of multimodality therapy for resectable synchronous colorectal liver metastases: a retrospective multi-institutional analysis. Ann Surg Oncol 2009; 16:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/131\">",
"      de Haas RJ, Wicherts DA, Flores E, et al. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann Surg 2008; 248:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/132\">",
"      Vogt P, Raab R, Ringe B, Pichlmayr R. Resection of synchronous liver metastases from colorectal cancer. World J Surg 1991; 15:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/133\">",
"      Lambert LA, Colacchio TA, Barth RJ Jr. Interval hepatic resection of colorectal metastases improves patient selection. Arch Surg 2000; 135:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/134\">",
"      Livraghi T, Solbiati L, Meloni F, et al. Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection: the \"test-of-time approach\". Cancer 2003; 97:3027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/135\">",
"      Martin RC 2nd, Augenstein V, Reuter NP, et al. Simultaneous versus staged resection for synchronous colorectal cancer liver metastases. J Am Coll Surg 2009; 208:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/136\">",
"      Tanaka K, Shimada H, Matsuo K, et al. Outcome after simultaneous colorectal and hepatic resection for colorectal cancer with synchronous metastases. Surgery 2004; 136:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/137\">",
"      Minagawa M, Yamamoto J, Miwa S, et al. Selection criteria for simultaneous resection in patients with synchronous liver metastasis. Arch Surg 2006; 141:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/138\">",
"      de Santiba&ntilde;es E, Lassalle FB, McCormack L, et al. Simultaneous colorectal and hepatic resections for colorectal cancer: postoperative and longterm outcomes. J Am Coll Surg 2002; 195:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/139\">",
"      Martin R, Paty P, Fong Y, et al. Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. J Am Coll Surg 2003; 197:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/140\">",
"      Lyass S, Zamir G, Matot I, et al. Combined colon and hepatic resection for synchronous colorectal liver metastases. J Surg Oncol 2001; 78:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/141\">",
"      Reddy SK, Pawlik TM, Zorzi D, et al. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol 2007; 14:3481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/142\">",
"      Mitry E, Fields AL, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008; 26:4906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/143\">",
"      Portier G, Elias D, Bouche O, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006; 24:4976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/144\">",
"      Ychou M, Hohenberger W, Thezenas S, et al. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol 2009; 20:1964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/145\">",
"      O'Neil BH, Goldberg RM. What is the standard chemotherapy for colorectal cancer patients with resectable liver metastases? Nat Clin Pract Oncol 2009; 6:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/146\">",
"      Lygidakis NJ, Ziras N, Parissis J. Resection versus resection combined with adjuvant pre- and post-operative chemotherapy--immunotherapy for metastatic colorectal liver cancer. A new look at an old problem. Hepatogastroenterology 1995; 42:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/147\">",
"      Asahara T, Kikkawa M, Okajima M, et al. Studies of postoperative transarterial infusion chemotherapy for liver metastasis of colorectal carcinoma after hepatectomy. Hepatogastroenterology 1998; 45:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/148\">",
"      Kemeny MM, Goldberg DA, Browning S, et al. Experience with continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries. A prospective randomized study. Cancer 1985; 55:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/149\">",
"      Lorenz M, M&uuml;ller HH, Schramm H, et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg 1998; 228:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/150\">",
"      Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study. J Clin Oncol 2002; 20:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/151\">",
"      Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341:2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/152\">",
"      Kemeny NE, Gonen M. Hepatic arterial infusion after liver resection. N Engl J Med 2005; 352:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/153\">",
"      House MG, Kemeny NE, G&ouml;nen M, et al. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. Ann Surg 2011; 254:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/154\">",
"      Bolton JS, O'Connell MJ, Mahoney MR, et al. Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52. Clin Colorectal Cancer 2012; 11:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/155\">",
"      Weaver ML, Atkinson D, Zemel R. Hepatic cryosurgery in treating colorectal metastases. Cancer 1995; 76:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/156\">",
"      Faynsod M, Wagman LD, Longmate J, et al. Improved hepatic toxicity profile of portal vein adjuvant hepatic infusional chemotherapy. J Clin Oncol 2005; 23:4876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/157\">",
"      Jones RP, Jackson R, Dunne DF, et al. Systematic review and meta-analysis of follow-up after hepatectomy for colorectal liver metastases. Br J Surg 2012; 99:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/158\">",
"      Verberne CJ, Wiggers T, Vermeulen KM, de Jong KP. Detection of recurrences during follow-up after liver surgery for colorectal metastases: both carcinoembryonic antigen (CEA) and imaging are important. Ann Surg Oncol 2013; 20:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/159\">",
"      Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol 1997; 15:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/160\">",
"      Gomez D, Sangha VK, Morris-Stiff G, et al. Outcomes of intensive surveillance after resection of hepatic colorectal metastases. Br J Surg 2010; 97:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/161\">",
"      Fong Y, Blumgart LH, Cohen A, et al. Repeat hepatic resections for metastatic colorectal cancer. Ann Surg 1994; 220:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/162\">",
"      Fern&aacute;ndez-Trigo V, Shamsa F, Sugarbaker PH. Repeat liver resections from colorectal metastasis. Repeat Hepatic Metastases Registry. Surgery 1995; 117:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/163\">",
"      Adam R, Bismuth H, Castaing D, et al. Repeat hepatectomy for colorectal liver metastases. Ann Surg 1997; 225:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/164\">",
"      Yamamoto J, Kosuge T, Shimada K, et al. Repeat liver resection for recurrent colorectal liver metastases. Am J Surg 1999; 178:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/165\">",
"      Petrowsky H, Gonen M, Jarnagin W, et al. Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann Surg 2002; 235:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/166\">",
"      Nagakura S, Shirai Y, Suda T, Hatakeyama K. Multiple repeat resections of intra- and extrahepatic recurrences in patients undergoing initial hepatectomy for colorectal carcinoma metastases. World J Surg 2002; 26:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/167\">",
"      Tanaka K, Shimada H, Ohta M, et al. Procedures of choice for resection of primary and recurrent liver metastases from colorectal cancer. World J Surg 2004; 28:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/168\">",
"      Pessaux P, Lermite E, Brehant O, et al. Repeat hepatectomy for recurrent colorectal liver metastases. J Surg Oncol 2006; 93:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/169\">",
"      Ishiguro S, Akasu T, Fujimoto Y, et al. Second hepatectomy for recurrent colorectal liver metastasis: analysis of preoperative prognostic factors. Ann Surg Oncol 2006; 13:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/170\">",
"      Yan TD, Sim J, Black D, et al. Systematic review on safety and efficacy of repeat hepatectomy for recurrent liver metastases from colorectal carcinoma. Ann Surg Oncol 2007; 14:2069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/171\">",
"      Sa Cunha A, Laurent C, Rault A, et al. A second liver resection due to recurrent colorectal liver metastases. Arch Surg 2007; 142:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/172\">",
"      Jones NB, McNally ME, Malhotra L, et al. Repeat hepatectomy for metastatic colorectal cancer is safe but marginally effective. Ann Surg Oncol 2012; 19:2224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/173\">",
"      Adair RA, Young AL, Cockbain AJ, et al. Repeat hepatic resection for colorectal liver metastases. Br J Surg 2012; 99:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/55/41850/abstract/174\">",
"      Kopetz S, Vauthey JN. Perioperative chemotherapy for resectable hepatic metastases. Lancet 2008; 371:963.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2483 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-189A616C48-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_55_41850=[""].join("\n");
var outline_f40_55_41850=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BIOPSY CONFIRMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SURGICAL RESECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Patient selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14008291\">",
"      - Number and location of metastases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - PET scans",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14008586\">",
"      - Selecting patients for diagnostic laparoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      NEOADJUVANT CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5842613\">",
"      Chemotherapy-related liver toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5842661\">",
"      Issues related to bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20653035\">",
"      - Toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5842675\">",
"      Response evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5842004\">",
"      Initially resectable disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5844162\">",
"      - Choice of regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Conversion therapy for initially unresectable metastases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Choice of regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Role of hepatic intraarterial (HIA) chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      LOCAL OPTIONS FOR INCOMPLETELY RESECTED METASTATIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TIMING OF HEPATECTOMY IN PATIENTS PRESENTING WITH METASTASES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      THERAPY AFTER RESECTION OF LIVER METASTASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - NCCN recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Regional therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Hepatic intraarterial chemotherapy alone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - HIA plus systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - HIA plus other local approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Portal vein infusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Hepatic radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H650939148\">",
"      SURVEILLANCE AFTER METASTASECTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      REPEAT RESECTION FOR RECURRENT METASTASES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2483\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2483|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/35/13878\" title=\"figure 1\">",
"      Segmental anatomy of liver",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2483|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/60/24524\" title=\"table 1\">",
"      Hepatic resection for metastatic colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/39/5756\" title=\"table 2\">",
"      Mod approach surg CRC mets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/48/42764\" title=\"table 3\">",
"      RECIST response criteria solid tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/20/5454\" title=\"table 4\">",
"      Chemo regimens met CRC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/38/20077\" title=\"table 5\">",
"      Neoadj chemo hepatic mets CRC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/53/17246\" title=\"table 6\">",
"      Modified FOLFOX6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/32/3599\" title=\"table 7\">",
"      FOLFOXIRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/53/21341\" title=\"table 8\">",
"      Postop surv ASCO NCCN rec",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/49/33564\" title=\"table 9\">",
"      Repeat hepatic resection CRC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/30/26087?source=related_link\">",
"      A short primer on cost-effectiveness analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=related_link\">",
"      Adjuvant therapy for resected stage III (node-positive) colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44074?source=related_link\">",
"      Chemotherapy hepatotoxicity and dose modification in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/10/34986?source=related_link\">",
"      Clinical features and diagnosis of primary hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/33/17946?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/63/24569?source=related_link\">",
"      Hepatic resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/29/19930?source=related_link\">",
"      Locoregional methods for management and palliation in patients who present with stage IV colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/14/37095?source=related_link\">",
"      Nodular regenerative hyperplasia of the liver",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/36/28234?source=related_link\">",
"      Nonsurgical local treatment strategies for colorectal cancer liver metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/4/40009?source=related_link\">",
"      Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/0/6148?source=related_link\">",
"      Patient information: Colon and rectal cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/27/19890?source=related_link\">",
"      Patient information: Colon and rectal cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/22/40293?source=related_link\">",
"      Patient information: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13560?source=related_link\">",
"      Surgical resection of pulmonary metastases: Outcomes by histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28634?source=related_link\">",
"      Surveillance after colorectal cancer resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/20/21833?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=related_link\">",
"      Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=related_link\">",
"      Treatment protocols for colorectal cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_55_41851="Abx therapy pyomyositis";
var content_f40_55_41851=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F77419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F77419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Empiric antimicrobial therapy for pyomyositis in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\">",
"        Regimens for beta-hemolytic streptococci and methicillin-susceptible staphylococci",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cefazolin",
"       </td>",
"       <td>",
"        1 g intravenously every 8 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxacillin",
"       </td>",
"       <td>",
"        1-2 g intravenously every 6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nafcillin",
"       </td>",
"       <td>",
"        1-2 g intravenously every 6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\">",
"        <p>",
"         Regimens for beta-hemolytic streptococci and staphylococci",
"        </p>",
"        <p>",
"         (including activity against MRSA)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Preferred therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vancomycin",
"       </td>",
"       <td>",
"        30 mg/kg intravenously every 24 hours in 2 equally divided doses; not to exceed 2 g/24 hours unless concentrations in serum are inappropriately low",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Alternative agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Daptomycin",
"       </td>",
"       <td>",
"        4 mg/kg intravenously once daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Linezolid",
"       </td>",
"       <td>",
"        600 mg intravenously twice daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ceftraoline",
"       </td>",
"       <td>",
"        600 mg intravenously every 12 hours&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tigecycline",
"       </td>",
"       <td>",
"        100 mg intravenously once, thereafter 50 mg intravenously every 12 hours",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    MRSA: Methicillin-resistant Staphylococcus aureus",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_55_41851=[""].join("\n");
var outline_f40_55_41851=null;
var title_f40_55_41852="TNM stage gastric carcinoid";
var content_f40_55_41852=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F65045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F65045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    TNM staging carcinoid tumors of the stomach",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Primary tumor (T)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TX",
"      </td>",
"      <td colspan=\"3\">",
"       Primary tumor cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T0",
"      </td>",
"      <td colspan=\"3\">",
"       No evidence of primary tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tis",
"      </td>",
"      <td colspan=\"3\">",
"       Carcinoma in situ/dysplasia (tumor size less than 0.5 mm), confined to mucosa",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor invades lamina propria or submucosa and 1 cm or less in size",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor invades muscularis propria or more than 1 cm in size",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor penetrates subserosa",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       T4",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor invades visceral peritoneum (serosal) or other organs or adjacent structures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"3\">",
"       For any T, add (m) for multiple tumors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Regional lymph nodes (N)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       NX",
"      </td>",
"      <td colspan=\"3\">",
"       Regional lymph nodes cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N0",
"      </td>",
"      <td colspan=\"3\">",
"       No regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N1",
"      </td>",
"      <td colspan=\"3\">",
"       Regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Distant metastases (M)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M0",
"      </td>",
"      <td colspan=\"3\">",
"       No distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M1",
"      </td>",
"      <td colspan=\"3\">",
"       Distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Anatomic stage/prognostic groups",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage 0",
"      </td>",
"      <td>",
"       Tis",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage I",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IIA",
"      </td>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IIB",
"      </td>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IIIA",
"      </td>",
"      <td>",
"       T4",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IIIB",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IV",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M1",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_55_41852=[""].join("\n");
var outline_f40_55_41852=null;
var title_f40_55_41853="Flow volume loop airway lesions";
var content_f40_55_41853=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Schematic flow-volume loop configuration in a spectrum of airway lesions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 234px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) normal; (B) variable extrathoracic upper airway obstruction; (C) variable intrathoracic upper airway lesions; (D) fixed upper airway obstruction; and (E) lower airways obstruction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_55_41853=[""].join("\n");
var outline_f40_55_41853=null;
var title_f40_55_41854="Digital pitting scars in SSc";
var content_f40_55_41854=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F60308&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F60308&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Digital pitting scars in scleroderma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Digital pitting scars in a patient with limited cutaneous systemic sclerosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD, FRCP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_55_41854=[""].join("\n");
var outline_f40_55_41854=null;
var title_f40_55_41855="Cradle position PI";
var content_f40_55_41855=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F69936&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F69936&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 495px\">",
"   <div class=\"ttl\">",
"    Cradle position for breastfeeding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 475px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The cradle hold can be done while the mother sits in a chair. To feed from the left breast, the infant's head and body are supported by the mother's left forearm. The mother's left hand usually supports the baby's buttocks or upper thighs. Some women use a pillow to support this arm. The baby's stomach should be flat against the mother's chest and the baby's head should be in line with the body (not turned). The mother's free hand (the right hand in this example) supports and guides the breast to the infant's wide open mouth. The thumb on the free hand may be placed on top of the areola and the breast supported with the cupped fingers. Care should be taken to position the hand away from the nipple so that the thumb and fingers do not interfere with latching.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_55_41855=[""].join("\n");
var outline_f40_55_41855=null;
